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ABSTRACT
A commonality among cancer types is the high frequency of mutations that inhibit or alter
signaling of the p53 and pRb (Retinoblastoma) tumor suppressors.

These genes regulate

processes vital for cancer suppression such as apoptosis, senescence, and cell cycle arrest among
others. Loss of both p53 and pRb promotes processes that support cancer progression and is
associated with decreased patient survival and increased rates of tumor reoccurrence. Although
data points to the ability of p53 and pRb to collaborate and to inhibit tumorigenesis, it remains
unclear how p53 and pRb cooperate toward this task. Using RNA expression profiling, 179 p53
and pRb cross-talk candidates were identified in normal lung fibroblasts (WI38) cells
exogenously coexpressing p53 and pRb. Regulator of G protein signaling 16 (RGS16) was
among the p53 and pRb cross-talk candidates and reports suggest it inhibits the activation of
several oncogenic pathways associated with proliferation, migration, and invasion of cancer
cells.
RGS16 is downregulated in pancreatic cancer patients with metastases compared to patients
without metastasized pancreatic cancer.

The role of RGS16 in cancer cell metastasis is

unknown; therefore I tested the hypothesis that RGS16 inhibits pancreatic cancer cell migration
and invasion in vitro. Expression of RGS16 was decreased in the pancreatic cancer cell lines
tested compared to control. Expression of RGS16 inhibited fetal bovine serum (FBS) and
epidermal growth factor (EGF) induced migration of the BxPC-3 and AsPC-1 but not PANC-1
pancreatic cancer cells. It also inhibited EGF induced invasion of BxPC-3 and AsPC-1 cells with
no impact on cell viability. Although RGS16 inhibited cell migration and invasion of BxPC-3
and AsPC-1 cells, there was no change in F-actin polymerization or the amounts of p-AKT, pERK and the epithelial mesenchymal transition (EMT) marker vimentin proteins, but there was a
slight increase in E-cadherin protein expression in BxPC-3 cells.
xiv

Our data suggests the

inhibitory effect of RGS16 on EGF induced pancreatic cancer cell migration is independent of
the PI3K and MAPK pathways. To our knowledge, for the first time, we performed analyses to
identify p53 and pRb cross-talk candidates and demonstrated a role for RGS16 in suppressing
EGF and FBS induced pancreatic cancer migration and invasion.

xv

CHAPTER 1.
INTRODUCTION
SECTION 1.1: p53 AND pRb COLLABORATORS IN THE FIGHT
AGAINST CANCER
Background
The two most commonly mutated signaling pathways in cancer are those associated with
tumor protein 53 (p53) and retinoblastoma protein (pRb). p53 and pRb are the first two tumor
suppressors identified, however, years after identifying and cloning p53 (1979) and pRb (1986)
we are still working to understand their function [1]. p53 and pRb regulate the same processes
(such as; cell arrest, apoptosis, senescence, etc.) using different mechanisms and studies suggests
these two tumor suppressors cooperate to inhibit cancer progression [2-5]. The ability of p53
and pRb to communicate in regulating cellular functions and determining cellular fate could be a
reason mutations in these pathways often occur in cancer. The focus of this section is to give an
overview of p53 and pRb functions and their regulation while presenting evidence and examples
of the p53 and pRb cross-talk.
Brief overview of p53 function and regulation
The function of p53 has been extensively studied; this section will provide a brief
overview of the function and regulation of p53. Originally thought to function as an oncogene,
p53 is now known to induce a variety of processes in cells that inhibit tumorigenesis such as: cell
cycle arrest, apoptosis, DNA repair, and senescence (reviewed in [6-10]). These processes aid in
protecting the integrity of DNA supporting the use of p53’s nickname as “Guardian of the
Genome”[11]. The ability of p53 to regulate a wide variety of processes is due in part to its
functions as either a transcriptional activator or a repressor. p53 forms a tetramer, binds to DNA,
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and recruits co-activators inducing transcription of genes that are involved in DNA repair
(p53R2, MLH1, XPC, PCNA, and DDB2), apoptosis (Bax, Noxa, Bid, APAF-1, DR4, DR5 and
PUMA), senescence (plasminogen activator inhibitor 1: pai-1, p21), G1 (G1: BTG2, p21), and
G2 cell cycle arrest (GADD45, 14-3-3 sigma, and MCG10) [12-15]. The p53 tumor suppressor
promotes differentiation by repressing transcription of factors that promote pluripotency such as
oct4 and nanog and inducing transcription of pRb to initiate myogenesis [16, 17]. In addition to
its transcription regulatory activity, p53 translocates to the mitochondria and interacts with the
outer membrane leading to mitochondria permeabilization by activating the pro-apoptotic Bax
and Bak proteins and inhibiting the pro-survival Bcl-2 and Bcl-xl proteins [13]. These actions
initiate mitochondria membrane permeabilization, the release of cytochrome c, and activation of
caspases that trigger apoptosis (Figure 1.1).
In order to prevent the random induction of apoptosis and other p53-regulated processes,
expression of p53 is normally sustained at low basal levels by the E3 ubiquitin ligase HDM2.
HDM2 a transcriptional target of p53, binds and translocates p53 to the cytoplasm preventing
p53 from binding to DNA and initiating transcription [12, 14]. HDM2 also poly-ubiquitinates
p53 marking it for degradation by the proteasome. Stabilization of p53 occurs due to posttranslational modifications by factors activated when the cell is under stress such as: DNA
damage, hypoxia, loss of normal cell contacts, and activity of oncogenes [12, 14].

Post-

translational modifications such as phosphorylation and acetylation stabilize p53 by preventing
its poly-ubiquitination and degradation [12, 14]. The binding of p14ARF to HDM2 also leads to
the stabilization of p53 preventing its polyubiquitination by HDM2. Figure 1.1 contains a
summary of the function and regulation of p53 demonstrating the complexity of p53 signaling.
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Figure 1.1: Schematic depicting regulation of p53 and downstream transcription
targets. p53 initiates a variety of responses through its ability to regulate transcription of
targets that are involved in DNA repair, apoptosis, cell cycle arrest, senescence, and
differentiation. p53 expression is regulated by its own downstream transcriptional target,
HDM2 which polyubiquitinates p53 marking it for degradation in the proteasomes. p53
expression is stabilized by signals initiated by DNA damaging, hypoxia, or overexpression
of oncogenes. p53 also initiates apoptosis by binding and interacting with mitochondria
outer membrane and proteins located there. Pathway was constructed using Qiagen’s
Ingenuity
pathway
Analysis
(IPA®,
QIAGEN
Redwood
City,
www.qiagen.com/ingenuity) Pathway Designer tools. Adapted from Levine, A. J. et al.
2006
Brief overview of pRb function and regulation
Known for its ability to induce cell cycle arrest at the G1/S checkpoint, pRb also
regulates apoptosis, DNA repair, senescence, and differentiation. pRb is a transcription regulator
that binds to co-factors and either functions as a co-repressor or co-activator of transcription.
Classically, pRb is acknowledged for its role in binding to the cell cycle stimulatory E2F
transcription factors and recruiting histone deacetylases and other transcription repressors and
thereby inhibiting transcription of E2F target genes and initiating cell cycle arrest [18-20].
3

Cyclin-dependent kinases-4 and -6 phosphorylate pRb inhibiting binding of pRb with E2F
resulting in the release of E2F to bind to DNA and its dimerization partner (DP2) resulting in the
initiation of transcription of cell cycle stimulatory proteins [19, 21].

Activation of E2F

transcription results in the expression of cyclin E, which binds to cyclin-dependent kinase 2 and
functions in a negative feedback loop to promote phosphorylation and inactivation of pRb.
Phosphorylation of pRb is inhibited by cyclin-dependent kinase inhibitors among which are the
proteins p27, p16, and p21. Figure 1.2 summarizes the regulation and function of pRb to inhibit
activation of E2F target genes.
The best known or studied function of pRb is its ability to act as a transcriptional
repressor of E2F targets genes. However, pRb can regulate cellular processes or suppress cancer
progression irrespective of its ability to bind to E2F family members.

Studies using pRb

mutants found E2F binding deficient pRb activated transcription and initiated differentiation and
suppressed tumor progression in vitro and in vivo [22, 23]. pRb has been found to bind and
enhance transcription of several transcription factors and nuclear receptors listed in Table 1.1.
Enhanced transcriptional activity by pRb promotes differentiation and regulates hormone
signaling (Table 1.1).

However, there is still not much known regarding pRb’s ability to

function as a transcriptional co-activator indicating the need for more research to understand the
full mechanisms of pRb suppression of cancer progression and promotion of differentiation
processes.
Studies have implicated pRb in having a divergent role in either promoting or inhibiting
apoptosis. pRb, like p53, can interact directly with the mitochondria mediating the induction of
apoptosis triggered by tumor necrosis factor-α [24]. Ianari et al. found that pRb potentiates the
induction of apoptosis triggered by genotoxic or oncogenic stress in proliferating cells [25]. The
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ability of pRb to initiate apoptosis is context dependent, for example; in Ianari’s study, pRb
bound to E2F, enhanced the induction of apoptosis initiated by stress in proliferating cells [25].
However, in another study conducted using breast cancer cells, loss of pRb enhanced the
activation of apoptosis mediated by E2F1 [26]. Furthermore, pRb inhibits induction of apoptosis
by p53 in HeLa overexpressing exogenous p53 and pRb [27].
Table 1.1: Transcription factors that are regulated by pRb
Transcription Factor

Effect

Source

MyoD
C/EBP (CAAT/enhancer-binding protein)
family

Regulates muscle differentiation
Regulates adipocyte and
monocyte differentiation
Regulates keratinocyte
differentiation
Binds and initiates activation of
E-cadherin bcl-2 promoter
Regulates Osteogenic
differentiation
Regulates differentiation

[28]

c-Jun
AP-2
CBFA1 (Runx2)
SP-1
Nuclear receptors (Glucocorticoid receptor;
Androgen receptor; ERα & ERβ (Estrogen
receptor α & β); HNF4 (hepatocyte nuclear
factor-4); SF-1 (steroidogenic factor-1);
and NGF1-B orphan nuclear receptor
family members NGF1-B/Nurr 77/NR4A1,
NOR1, & Nurr1)

Initiates transcription of genes
that regulate hormone signaling
and differentiation
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[29, 30]
[31]
[32] [33]
[34, 35]
[36, 37]

[38-44]

Figure 1.2: Schematic depicting pRb regulation and function as a transcriptional
repressor. Pathway was constructed using Qiagen’s Ingenuity pathway Analysis (IPA®,
QIAGEN Redwood City, www.qiagen.com/ingenuity) Pathway Designer tools.
p53 and pRb cross-talk
Evidence of p53 and pRb Cross-talk
The existence of a p53 and pRb cross-talk pathway is supported by evidence collected
from tumor analyses and in vitro and in vivo experiments. Most tumors, including osteosarcomas
and cancers of the breast, lung (small cell), cervix, and bladder [1, 4, 45, 46], have deficiencies in
either the p53 or pRb pathway. Both p53 and pRb have a high frequency of mutations in
osteosarcomas, lung (non-small cell), breast, and cervical carcinomas [1, 4, 46]. Approximately
60% of osteosarcomas have loss of both functional p53 and pRb, which is vital for osteosarcoma
6

(OS) development [1, 46]. Patients who have mutations in both TP53 and RB1 have increased
tumor recurrence and decreased survival compared to patients with only one inactive tumor
suppressor genes [45, 47]. Deletions or mutations in the p16 locus, and overexpression of
HDM2 or cyclin-D can also interfere with p53 and pRb activity. Table 1.2 describes examples
(small representative) of mutations and alterations that prevent p53 and pRb activation.
Table 1.2: Examples of alterations that can occur in cancers that alter p53 and pRb
signaling
Alteration

p16 deletions/mutations

Overexpression of HDM2

Overexpression of cyclin-D

Cancer
Pancreatic cancer, Head & Neck
Squamous Cell Carcinomas
(HNSCC), Non-Small Cell Lung
Cancers (NSCLC),
Glioblastomas (GBMs)Sarcomas (soft tissue and
osteosarcoma), retinoblastoma, &
esophageal carcinomas
HNSCC, breast cancers,
pancreatic cancers, and prostate
cancers

Sources

[48-51]

[52, 53]

[54-57]

Loss of both p53 and pRb promotes cancer by initiating tumorigenesis and increasing
chromosome instability, and chemoresistance. Binding of DNA tumor virus proteins associated
with adenovirus, certain strains of human papilloma virus (HPV), and simian virus 40 (SV-40) to
p53 and pRb with resultant loss of activity is vital for viral induced transformation [4, 58].
Chromosome instability is associated with cancer initiation, promotion of tumor growth, and
chemoresistance [59, 60]. In cell lines from two different cancer types, loss of both p53 and pRb
synergizes to promote chromosome instability due to chromosome gains and losses during
mitosis [60]. Loss of pRb leads to increased genetic alterations (gains or losses) and the loss of
p53 cooperates to allow the continued proliferation of these cells [60].
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A study examining p53 mediated responses to chemotherapy found a reduction in cellular
response if there was a loss of pRb signaling [61]. Interestingly, inactivation of both p53 and
pRb (through the use of a p53 dominant negative fragment and pRb siRNA) increased sensitivity
of the cancer cells to chemotherapy compared to inactivation in p53 alone [61]. However, this
was not seen in cells where p16 levels were decreased via siRNA, suggesting that p16 and p53
mutations are more advantageous for cancer progression [61]. Another study found loss of both
p53 and pRb can induce multidrug resistance prior to transformation [62]. Accordingly, patients
diagnosed with breast cancer and treated with adjuvant chemotherapy had a better response if
they had functional p53 and pRb [61].
Several mouse models utilize inactivation of p53 and pRb to initiate tumor development
that mimics the human disease. For example, inactivation of both TP53 and RB1 genes in bone
marrow mesenchymal stem cells or dermal connective tissue cells resulted in the development of
osteosarcomas or soft tissue sarcomas respectively [63, 64]. Mutations in both tumor suppressor
genes work synergistically to promote cancer progression. Conditional inactivation of the RB1
and TP53 genes in lung epithelial cells of mice, led to the development of aggressive small cell
lung tumors [65]. Also p53-/- mice that were also RB1+/- developed more tumors than mice with
single mutations; i.e. heterozygous TP53+/- RB1-/- or TP53 null mice [4].

Furthermore,

inactivation of TP53 and RB1 genes in the prostate epithelium of mice led to the development of
aggressive prostate cancers that were highly metastatic resulting in decreased survival compared
to mice with only one in activated gene [5]. Likewise, inactivation of pRb by a fragment of the
SV40 T-Antigen in mammary epithelium results in formation of adenocarcinomas that appear
earlier in mice that are also TP53+/- [66].
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Loss of functional p53 and pRb signaling happens with a high frequency in cancers and
promotes processes involved in tumor progression. Loss of p53 or pRb promotes metastasis and
both tumor suppressors inhibit processes such as migration and invasion needed for the spread of
cancer [67-69, 70{Feakins, 2003 #7786]}. However, there is a lack of studies investigating
whether the concomitant loss of p53 and pRb promotes migration and invasion more than
inactivation of just one pathway. Although p53 and pRb are two of the most studied genes in
cancer, there is a lack of understanding how they synergistically function to inhibit cancer
formation and/or progression.
Examples of p53 and pRb cross-talk
Over the years evidence has accumulated painting a picture of the communication that
exists between the p53 and pRb pathways. Proteins known to be implicated in the p53 and pRb
cross-talk include E2F-1, HDM2, p21, BTG2 and the INK4a locus. Figure 1.3 is a schematic
representing known examples of p53 and pRb cross-talk.

Briefly, through mechanisms of

alternate splicing, the CDKN2A locus codes for two genes, p16/INK4a and p14/ARF [71]. p14
binds to HDM2, inhibits p53 polyubiquitination its subsequent degradation by the proteasomes
[71]. This allows p53 to initiate transcription of downstream target genes including p21, and
BTG2 [72, 73]. The cyclin-dependent kinase inhibitors p16 and p21 together with BTG2 prevent
the phosphorylation and inactivation of pRb and stop cell cycle progression [71-73]. Loss of
pRb bound to E2F-1 due to inactivation of pRb or p16 can trigger p53 dependent apoptosis
through E2F-1 stabilizing p53 by two methods, 1) activating proteins that phosphorylate or
acetylate p53 thereby preventing HDM2 binding or by 2) inducing expression of p14 [74-78].
p53 induces expression of HDM2 which functions in a negative feedback loop to inhibit p53.
However, pRb can bind to HDM2 and p53 complexes leading to the stabilization of p53 [47, 79].
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p53 complexed to HDM2 and pRb is unable to bind to DNA and regulate transcription, however
it can induce apoptosis by directly acting on the mitochondria membrane [47, 79].
The previous examples of p53 and pRb cross-talk mostly highlight the use of proteinprotein interactions to determine cell fate.

However, p53 and pRb also cross-talk using

transcriptional regulatory mechanisms, for example, p21 and BTG-2, both transcribed by p53,
can inhibit inactivation of pRb, illustrating a pathway by which p53 and pRb coordinate cell
cycle arrest. p53 also binds to the RB1 promoter and initiates transcription of pRb triggering
pRb induced muscle differentiation [17]. Furthermore, both p53 and pRb bind to the promoter of
the RNA polymerase III specific transcription factor, TFIIIB and suppress transcription of
TFIIIB providing another example of how these proteins inhibit cell cycle progression [80].
However, management of p53 and pRb controlled processes such as apoptosis, cell cycle arrest
or development may require p53 and pRb to regulate gene expression in an opposing rather than
cooperative manner.

Expression of an embryonic development gene, Placenta-specific 1

(PLAC1) is down-regulated by p53 and up-regulated by pRb demonstrating how p53 and pRb
can play contrasting roles to regulate cellular processes [81].
Although proteins involved in the p53/pRb cross-talk have been identified, there is still a
lack of information regarding how p53 and pRb communicate to regulate cell fate. p53 and pRb
co-regulated genes were investigated to expanding on the current knowledge of the p53 and pRb
cross-talk. We have identified 179 proteins co-regulated by p53 and pRb. Transcriptional
regulation of the same genes by p53 and pRb may function as a failsafe mechanism if one
pathway is inactivated, the other is able to prevent the accumulation of additional mutations that
results in the development of cancer. Unraveling the complex interactions between p53 and pRb
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will contribute to further understanding how p53 and pRb cooperate to prevent tumorigenesis,
while also providing knowledge that can potentially be used to advance current cancer therapy.

Figure 1.3: Schematic depicting proteins known to mediate p53 and pRb cross-talk.
Pathway was constructed using Qiagen’s Ingenuity pathway Analysis (IPA®, QIAGEN
Redwood City, www.qiagen.com/ingenuity) Pathway Designer tools.
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SECTION 1.2. PANCREATIC CANCER
Epidemiology and characterization
Pancreatic ductal adenocarcinoma, also referred to as pancreatic cancer, accounts for
2.8% of all new cancer cases and is the 4th leading cause of cancer related death in the United
States compared to the 8th and 9th cause of mortality for men and women respectively worldwide [82]. The American Cancer Society estimates that approximately 46,420 individuals will
be diagnosed with pancreatic cancer and 39,590 will die from this disease in 2014 [83]. The oneyear survival rate for all stages of pancreatic cancer is 20% and the five-year survival rate is 6%
[83]. The percentage of cases and the five year survival rate are depicted in Table 1.3 for stage
of cancer at time of diagnosis. A majority of patients (53%) present with metastatic disease at
time of diagnosis and have a dismal 5-year survival rate of 2.3%. Only 9% of pancreatic cancer
patients present with localized disease but their 5-year survival rate is still low at 25.8%. Most
patients newly diagnosed with pancreatic cancer present with highly progressed and/or
metastatic cancer that is resistant to treatment [84, 85]. This data reflects the great need for
methods to prevent, and therapeutics to treat advanced pancreatic cancer.

Table 1.3: Percentages of survival and cases based on stage of cancer at time of diagnosis
Stage
Localized
Regional (regional lymph node metastasis)
Distant (metastasized)
Unstaged (unknown)

% of Cases at Diagnosis
9
28
53
11

% Survival
25.8
9.9
2.3
4.4

Information obtained from Howlader N et al.. SEER Cancer Statistics Review, 1975-2011, National Cancer
Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission,
posted to the SEER web site, April 2014.
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Pancreatic cancer has a higher rate of incidence in industrialized areas and predominately
affects individuals later in life with the average age of diagnosis being 71. Smoking, age, and
chronic pancreatitis have been established as risk factors; whereas, obesity, diabetes, and family
history of pancreatic cancer are associated with increased risk [86]. Approximately 5 to 10% of
pancreatic cancer patients have a family history of pancreatic cancer and less than 20% of those
are due to germline mutations [86-89].
Staging
Pancreatic cancers are commonly referred to pancreatic ductal adenocarcinomas (85%)
however; pancreatic cancers can be classified as acinar cell carcinoma, pancreatoblastoma, solid
pseudopapillary neoplasm, serous cystadenoma, and pancreatic endocrine tumors [86]. These
cancers mostly affect the exocrine portion of the pancreas that consists of acinar and duct cells
that are responsible for secretion of digestion enzymes [86]. The head of the pancreas is a
favored location of tumor development and allows rapid infiltration into surrounding tissue [85].
There are four types of preneoplastic pancreatic lesions known as: pancreatic intraepithelial
neoplasia (PanINs), mucinous cystic neoplasm, (MCN) and intraductal papillary mucinous
neoplasm (IPMN) [85, 86]. PanINs are the most common preneoplastic lesion and can exist in
three stages.

Stage III

PanINs develop into pancreatic cancer (pancreatic ductal

adenocarcinomas) [86].
Pancreatic cancers are staged using the American Joint Committee on Cancer tumornode-metastasis (TNM) classification described in Figure 1.4 & Table 1.4 Unknown TNM
tumor classifications are designated with a X, (TX, NX, or MX). Tis designates carcinoma in
situ or preneoplastic lesions.
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Figure 1.4: Describes the American Joint Committee on Cancer Tumor-Node-Metastasis
classification system. Information adapted from the National Institute of Health
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Table 1.4: Pancreatic Cancer Stages
Stage
0
IA
IB
IIA
IIB
III
IV

Tumor
Tis
T1
T2
T3
T1-3
T4
Any T

Node
N0
N0
N0
N0
N0
N0 or N1
N0 or N1

Metastasis
M0
M0
M0
M0
M0
M0
M1

Based on the American Joint Committee on cancer tumor-node-metastasis. Information adapted from the National
Cancer Institute (2014)

Diagnosis and Treatment
Pancreatic cancer is rarely diagnosed during the early stages of carcinogenesis because of
the lack of noticeable and distinct symptoms [85]. Many of the symptoms such as abdominal
pain, nausea, and jaundice are unspecific and can be equated with other illnesses.

Several

imaging technologies including contrast enhanced multi-detector row computed tomography
(MDCT), ultrasonography (US), endoscopic ultrasonography (EUS), and Magnetic resonance
imaging (MRI) are used to diagnose pancreatic cancer [90]. Ultrasonograhy is often the first
imaging modality used once a patient presents with jaundice or abdominal pain [90]. However,
US is not the most reliable method for staging pancreatic cancer and can miss small pancreatic
tumors (Tis and T1) [91]. Multi-detector row computed tomography is the most accurate and
used method for diagnosing and staging pancreatic cancer [85, 90]. Endoscopic ultrasonography
can be used to rule out pancreatic cancer as a diagnosis therefore eliminating the need to use
other diagnostic methods and is often chosen to visualize tissue extraction for diagnosis [90, 91].
Contrast enhanced MRI with magnetic cholangiopancreatography is often a secondary imaging
tool that can more readily diagnose small pancreatic tumors and rule out other pancreatic
abnormalities [90, 91].
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Surgery, chemotherapy, and/or chemoradiation are the therapies used to treat pancreatic
cancer. Due to late stage of diagnosis less than 20% of patients are eligible for the only possible
curative pancreatic resection (tumor staging T1-T3). The presence of metastasis to the lymph
nodes, peritoneal cavity, liver, or other sites is a negative prognostic factor [85, 92]. In fact
patients who undergo surgery have decreased survival if there is presence of lymph node
metastases. Treatments used for pancreatic cancer are based on tumor staging (Table 1.5).
Surgery is the first treatment option for patients with stage I & II pancreatic cancer followed by
chemoradiation therapy. Neoadjuvant therapy is controversial, however a recent study found
that patients who underwent neoadjuvant therapy had increased survival and time to recurrence
than those who underwent surgery first [93]. The majority of patients diagnosed with pancreatic
cancer present with stage III or IV pancreatic cancer that is ineligible for surgery. However, a
portion of patients (8 to 30%) with stage III cancer undergoing neoadjuvant chemoradiation
therapy become eligible for pancreatic resection and have survival rates similar to patients who
first undergo surgery [84]. An analysis of the five-year survival rates for various cancers over a
span of thirty years found that pancreatic cancer had the least improvement from 2% (19751977) to 6% (2003 to 2009) [83]. The aggressive nature of pancreatic cancer, lack of early
diagnosis, and therapy resistance of this deadly disease contribute to the lack of advancement in
enhancing the survival rate [94].
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Table 1.5: Pancreatic cancer treatment broken down based on tumor stage.
Tumor Stage

I & II

III

IV

Treatment
Surgery
Postoperative chemoradiation
(5-fluorouracil (5-FU) chemo and radiation therapy)
Postoperative chemotherapy
(gemcitabine or 5-FU/leucovorin)
Chemoradiation
1. Chemoradiation followed by chemotherapy
2. Chemotherapy followed by chemoradiation
(patients w/o metastasis)
Chemotherapy
(gemcitabine; gemcitabine & erlotinib; gemcitabine and nabpaclitaxel; or 5-FU, leucovorin, irinotecan, & oxaliplatin
(FOLFIRINOX)
Palliative therapy
(pain relieving procedures and supportive care)
Chemotherapy
(gemcitabine; gemcitabine & erlotinib; or (FOLFIRINOX)

Information adapted from National Cancer Institute (2014)
Mutations and altered signaling pathways in pancreatic cancer
Pancreatic cancer is a heterogeneous disease that contains on average 63 genetic
mutations affecting a set core of 12 pathways [95]. At least one of four genes listed in Table 1.6
is commonly mutated in pancreatic cancer and aids in proliferation, survival, migration,
epithelial mesenchymal transition (EMT), and invasion. K-Ras mutations are the most common
genetic alteration and occur early in low grade PanIN 1A lesions. K-Ras is commonly mutated
at codon G12 and with less frequency, codons G13 and Q61. These mutations result in the
constitutive activation of K-Ras [96]. Expression of mutant K-Ras (G12D) in mice induces
PanIns that develop into pancreatic cancer [97]. K-Ras mutations promote pancreatic cancer
proliferation, survival, invasion, migration and metastasis and exerts its cancer promotion via
modulation of the Raf/Mek/Erk, PI3K/AKT, and Ral-A and Ral-B pathways [96]. K-Ras/PI3K
signaling is critical for the initiation, progression, and maintenance of pancreatic cancer in mice
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[98].

Activation of the Raf/ERK MAPK pathway using mice with conditional knock-in

BrafV600e in the pancreas induced PanIns that later developed into pancreatic cancer [99]. K-Ras
activates the Ral guanine nucleotide exchange factor (RalGEFs) leading to the subsequent
activation of Ral-B and Ral-A that are linked to pancreatic cancer growth (Ral-A) and metastasis
(Ral-B) [100].
Inactivating mutations in CDKN2A (affecting predominantly INK4a/p16 and to a lesser
extent, ARF/p14), p53, and Smad4 occur in moderate or advanced PanIns suggesting they are
late events [101]. CDKN2A is the most targeted tumor suppressor gene for mutations in
pancreatic cancer and, as highlighted in section 1.1, it codes for the p16/INK41 and p14ARF
proteins. However, most of the mutations decrease p16 expression, thereby negating its ability to
inhibit proliferation and induce cell cycle arrest through preventing the phosphorylation and
inhibition of pRb. The importance of p16 inactivation in pancreatic cancer can be seen in
genetically modified mice. The conditional concomitant mutation knock-in of mutant K-RasG12D
and knock-out of CDKN2Aflox/flox in the pancreas of mice induces more aggressive and metastatic
pancreatic cancers than K-RasG12D (only) mice models [102]. Mutations in p53 occur at a high
frequency and aid in suppression of apoptosis and cell cycle arrest, while also increasing
metastasis, proliferation and genomic instability [103]. Similar to p16 knock-out mice, knock-in
mutations of mutant p53R172H and K-RasG12D in the pancreas of mice decreases the time for
tumor development and subsequent metastasis compared to mice with only mutant K-RasG12D
[104]. Smad4 is activated by transforming growth factor-β (TGF-β) and mediates some of its
downstream signaling [86, 101]. TGF-β has both tumor promoting and suppressing mechanisms.
Mutations affecting Smad4 expression results in the loss of TGF-β mediated cell cycle arrest and
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cell motility[105]. Loss of Smad4 decreases migration and increases chemoresistance, and
expression of EGFR and VEGF promoting pancreatic cancer progression [105-107].
Other genetic alterations result in the overexpression of the epithelial growth factor
receptor (EGFR), AKT2, and RhoC in pancreatic cancers [108-110]. AKT2 is overexpressed in
10% of pancreatic cancers and promotes growth and invasion that was inhibited by the use of
antisense AKT RNA [109]. RhoC is overexpressed in pancreatic cancers with the highest
expression seen in tumors from patients who had the presence of metastasis [108]. EGFR and its
fellow family member HER2/erbB2 are overexpressed in 85% or 10% respectively, of pancreatic
cancers. EGFR activates a variety of pathways (see following section) that are responsible for
proliferation, EMT, migration and survival.

Table 1.6: Common genetic mutations in pancreatic cancer and incidence
Gene

K-Ras
CDKN2A
(p16/INK4a)
p53
SMAD4/DPC4

Effect of mutation
↑ proliferation; ↓ apoptosis;
↑ migration; ↑ metastasis & evasion of
immune response
↓ cell cycle control; ↑ proliferation;
↓ apoptosis; ↓ cell cycle arrest;
↑ metastasis; ↑ proliferation;
↑ genomic instability
↑ epithelial mesenchymal transition
(EMT); ↑ invasion; ↓cell cycle arrest;
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% Pancreatic
Cancers with
mutation

Source

> 90

[96]

85

[51, 101]

50 to 70

[86, 103, 111]

50

[86, 101, 105,
112]

Epidermal Growth Factor (EGF) Signaling
There are four receptors in the EGF family designated as EGFR/erbB1/HER1,
erbB2/HER2, erbB2/HER3, and erbB4/HER4.

EGFR/erbB1 is overexpressed in pancreatic

cancer and promotes metastasis, proliferation, angiogenesis, and survival [110, 113, 114].
Knockdown of EGFR inhibits the epithelial mesenchymal transition in pancreatic cancer and
EGFR is needed for K-Ras induced pancreatic tumorigenesis [115, 116]. EGFR activity is
stimulated by the binding of its ligands (epidermal growth factor (EGF), transforming growth
factor-α (TGF-α), and amphiregulin), which initiate receptor hetero- or homo- dimerization and
autophosphorylation [110, 113, 114]. As a result of this receptor modification adapter proteins
are recruited, leading to the activation of PI3K/AKT, Ras/MAPK, and phospholipase Cγ (PLC-γ)
pathways [110, 113, 114]. Figure 1.5 depicts four downstream pathways stimulated by EGFR
signaling and the biological effects mediated by these pathways such as metastasis, migration,
invasion, proliferation and chemoresistance [110, 113, 114, 117-122]. Ras pathway can also
activate Rho GTPases and PI3K demonstrating cross-talk between these signaling pathways
[123].
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Figure 1.5: Summary of EGFR signaling and downstream effects upon cancer
progression. Pathway was constructed using Qiagen’s Ingenuity pathway Analysis (IPA®,
QIAGEN Redwood City, www.qiagen.com/ingenuity) Pathway Designer tools. Adapted from
Robert Roskoski Jr. (2014)
Metastasis
Metastasis accounts for 90% of cancer related deaths and involves a series of steps that
can be targeted for cancer therapy [124]. Table 1.7, describes the various steps, processes, and
molecular signals involved for a cancer cell to metastasize. Briefly, a tumor cell needs to
disassociate from the tumor and surrounding environment. Detachment is facilitated by the
epithelial mesenchymal transition (EMT) in which cells adopt a mesenchymal phenotype [106,
125]. EMT results in a change in cell morphology, acquisition of motility and increased
secretion of proteases [126]. A hallmark of EMT is the loss of E-cadherin and an increase in the
expression of the mesenchymal markers N-cadherin, vimentin, fibronection, and αvβ6 integrin
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[106, 125].

N-cadherin forms weaker cell-cell interactions than E-cadherin allowing the

dissociation of the cancer cells [106, 125]. Growth factors [EGF, TGF-β, tumor necrosis factorα (TNF-α), hepatocyte growth factor (HGF), and insulin-like growth factor-1 (IGF-1)] , secreted
by stromal cells in the tumor microenvironment, act on the tumor cells to initiate EMT [125].
After acquisition of a mesenchymal phenotype cancer cells can disassociate, migrate and
invade through surrounding tissues and, intravasate into the lymph or blood system [124].
Intravasation is a complex process mediated by multiple mechanisms including cell migration
and invasion. Proteases are secreted, breaking down the extracellular matrix, creating a path for
cells to migrate [127]. Once in the lymphatic or blood system, cells need to survive stresses that
can induce apoptosis such as shear force, lack of adherence, and hypoxia [128]. Once the cell
has migrated to a distant site, it extravasates out of the lymphatic or blood system. The migrated
cell will divide to form a secondary tumor of up to 2 mm in diameter before initiating
angiogenesis and other processes it needs to colonize the distant location [124, 129].
Angiogenesis provides the micro-metastasis with the nutrients it needs to further grow beyond 2
mm of diameter. Angiogenesis is promoted by the secretion of vascular endothelial growth
factor (VEGF), platelet derived growth factor, (PDGF), chemokines, and cytokines by the tumor
and stromal cells [129, 130].
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Table 1.7 : Steps, processes and molecular signals involved in the metastasis of cancer cells
Steps of metastasis

Process

Molecular signals involved

Disassociation

EMT: cells obtain phenotype of
mesenchymal cells that aids in
metastasis. (↓ E-cadherin, ↑ Ncadherin, ↑ vimentin, ↑ fibronectin, ↑
αvβ6 integrin)

Intravasation
&
Extravasation

Cancer cells migrate and invade
surrounding tissue and intravasate into
lymph or blood vessels and
extravasate into a new site.
Intravasation
and
extravasation
involve the ability of cancer cells to
migrate and invade surrounding tissue
and vessels.

Survival

Cells need to avoid cell death evoked
by loss of cellular attachments and
survive in vasculature

Angiogenesis

Generation of blood vessels to supply
metastasized cell(s) with nutrients
needed to grow

EGF, TGF-β, tumor necrosis
factor-α (TNF-α), hepatocyte
growth factor (HGF), and
insulin-like growth factor-1
(IGF-1)
Migration mediated by activation
of Rho GTPases: RhoA, Cdc-42,
Rac-1 (also associated with
EMT).
Invasion mediated by secretion
of proteases that break down
ECM: Matrix Metalloproteinases
(MMP), urokinase plasminogen
activator
(uPA),
and
plasminogen.
Activation of survival signals
(Ras, AKT, & ERK) inhibition of
apoptotic suppressors (p53, Bim)
and upregulation of apoptosis
inhibitors (BCL-2, BCL-XL)
Secretion of Vascular endothelial
growth factor (VEGF), Platelet
derived growth factor PDGF,
chemokines, and cytokines.

Sources: [106, 124, 125, 127-129, 131]
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SECTION 1.3. RGS16: EXPRESSION, REGULATION, AND FUNCTION
Background
The regulator of G protein coupled receptor (GPCR) signaling (RGS) family is comprised
of 37 RGS proteins that regulate GPCR signaling [132]. GPCRs are the largest family of
receptors, encoded by more than 2% of the genome [133]. GPCRs are overexpressed in cancer
and promote proliferation, migration, metastasis, and angiogenesis [133].

GPCRs mediate

cancer progression through activation and downstream signaling of small G proteins [133]. In
their inactive state small G proteins consist of a heterotrimeric subunit complex (Gαβγ).
Stimulation of GPCRs by ligand binding initiates the exchange of GDP to GTP on Gα by
guanine nucleotide exchange factors (GEFs). Now in its active state, Gα dissociates from the
Gβγ subunits and both Gα and Gβγ activate downstream signaling events. GPCR signaling is
terminated by the hydrolysis of GTP to GDP on the Gα subunit. In the stimulated state the
GTPase activity in G is lower than what is needed to mediate GPCR signals. RGS proteins
function as GTP accelerating proteins (GAPs) by binding to Gα and enhancing the hydrolysis of
GTP to GDP [132, 134]. All RGS proteins contain a ~120 amino acid conserved region called
the RGS box that is responsible for accelerating GTPase activity of Gα proteins [132, 134].
RGS proteins are divided into 8 subfamilies based on homology and function. The R4
subfamily contains the highest number of members and consists of the smallest (molecular
weight) RGS proteins. The R4 proteins contain one RGS box domain and a small number of
amino acids on its N- and C- terminals. With the exception of RGS2 (Gαq only) R4 members
modulate Gαi and Gαq proteins [132, 134]. The other subfamilies contain domains that assist in
the stability, localization, and protein-protein interactions (reviewed [132, 134]). The induction
of p53 levels through DNA damage was used to identify RGS16, an R4 family member, as a
target gene in several cancer cell lines [135]. We have identified RGS16 as a p53 and pRb cross24

talk candidate using RNA expression profiling (Chapter 2) and expression of RGS16 inhibited
the migration and invasion activity in several pancreatic cancer cell lines (Chapter 3). In this
next section we will explore the expression, regulation, and function of RGS16.
RGS16 Expression
RGS16 expression is seen in a wide variety of normal and cancerous tissues as shown in
Table 1. RNA tissue array analysis found RGS16 mRNA to be highly expressed in the kidney,
brain, and lung; moderately expressed in the pancreas, colon, and small intestines, and ovaries;
and weakly expressed in the skeletal muscle, liver, and heart [135]. Animal studies have also
found wide spread expression of this G protein regulator corresponding to expression patterns
seen in human tissue (Table 1.8). Recently aberrant expression of RGS16 has been found in
colon (higher), breast (lower), metastatic pancreatic (lower), Burkitt’s lymphomas and pediatric
high hyperdiploid acute lymphoblastic leukemias (higher) (Table 1.8). Although RGS16 has
been found to be aberrantly expressed in several cancer types, there are few reported studies
focused on the function of RGS16 in cancer progression.
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Table 1.8: Expression of RGS16 in normal and cancer tissue
Tissue with expression of RGS16
Normal tissues
Expressed in: kidney, brain, lung, pancreas, colon, small
intestine, ovary, skeletal muscles, liver, and heart by RNA
tissue array.
Expressed in immune system: T-lymphocytes, auto immune Bcells,
Expressed in Liver: periportal hepatocytes
Expressed in progenitor cells: progenitor pancreatic cells during
development and expression initiated in type I and II diabetes
models and megakaryocytes
Expressed in brain: superchiasmatic nucleus (SCN) and
hypothalmus
Expressed highly in retina
Expressed in the heart myocardial myocytes
Cancer
Central neurocytomas: upregulated
Burkitt’s lymphomas and pediatric high hyperdiploid acute
lymphoblastic leukemias: upregulated
Colorectal cancers: upregulated
Metastatic pancreatic cancer: downregulated
Breast cancers with chromosomal breakpoints, promoter
methylation, and allelic imbalances: downregulated

Species

Sources

Human

[135]

Mouse

[136-138]

Mouse
Mouse (pancreas)
Human
(megakaryocytes)

[139]
[140, 141]

Mouse

[142]

Mouse
Rat

[143]
[144, 145]

Human

[146]

Human

[147]

Human
Human

[148]
[149]

Human

[150]

RGS16 Regulation
RGS16 expression is modulated by GPCR signaling pathways and other stimuli
In the previous section, expression of RGS16 was shown to be widely expressed in
several tissue types.

But what regulates RGS16 expression?

This section will highlight

pathways and stimuli that induce expression of RGS16 and post-translational modifications that
modulate its activity. RGS16 is upregulated by a variety of compounds including doxorubicin,
retinoic acid, fetal bovine serum (FBS) and several ligands and signaling mediators of GPCRs
(Table 1.9).

The binding of Lysophosphatidic acid (LPA), Endothelin-1 (ET-1), and

Sphingosine 1-phosphate (S1P) to their respective GPCRs increases transcription and expression
of RGS16.

Upregulation of RGS16 by ET-1 and SP-1 is dependent on RhoA and Rac-1
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signaling respectively [145]. The transcription regulator Yin Yang inhibits transcription of
RGS16 by induced by FBS, ET-1, and S1P [145].
Upregulation of RGS16 by PKC is hypothesized to induce increase expression of tumor
necrosis factor- α (TNF-α) in an ERK dependent manner. TNF-α then signals through its
receptor and upregulates RGS16.

It is hypothesized that upregulation of RGS16 regulates the

GPCRs responsible for T-cell response during inflammation [151]. Doxorubicin, retinoic acid,
or histone deacetylase inhibitor (Vorinostat) plus lysine-specific demethylase1 (LSD1)
knockdown induce expression of RGS16 in cancer cells. Doxorubicine increases expression of
RGS16 through a p53 dependent mechanism, demonstrating for the first time that RGS16 is a
transcriptional target for p53 [135].
Post translational modification regulate RGS16 activity and localization
RGS16 transcription is up-regulated by a variety of stimuli; however other mechanisms
such as post-translational modification and proteasomal degradation regulate RGS16 activity and
protein half-life. Palmitoylation, the addition of palmitic acid to a cysteine residue in the Nterminal domain of RGS16, is integral to the localization and activity of RGS16. Loss of the Nterminal region inhibits RGS16 localization to the membrane and as a consequence the Gα
GTPase activity [152, 153]. RGS16 contains two palmitoylation sites at cysteines 2 and 12 of
the N-terminus. Mutational studies inhibiting palmitoylation at either site impaired RGS16 GAP
activity and prevented RGS16 localization to lipid rafts [154, 155]. Localization of RGS16 to
lipid rafts promotes the palmitoylation of cysteine 98 in the RGS box by a protein acyltransferase
resulting in the acceleration of RGS16 GAP activity demonstrating the necessity of
palmitoylation for RGS16 function [155, 156].
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RGS16 activity is also regulated by phosphorylation. Prevention of EGFR induced
phosphorylation of Tyr168 in RGS16 diminished its GTPase activity by 30% [157].
Furthermore phosphorylation of RGS16 by Src inhibited RGS16 degradation [158]. However
phosphorylation of RGS16 can also impair its function in regulating GPCRs. Phosphorylation of
mouse RGS16 on Ser 58 and Ser194 subsequent to GPCR stimulation prevented its ability to
accelerate hydrolysis of GTP [159].
RGS16 contains a destabilizing N-terminal residue called N-degron which targets RGS16
for degradation by the N-end rule pathway [160]. The N-end rule was developed to calculate a
protein’s half-life based upon its N-terminal amino acid sequence [161]. Recognition of the Ndegron by the E3 ubiquitin ligases N-recognins marks RGS16 for degradation by the
proteasomes [160, 161]. Degradation of RGS16 by the N-end rule pathway demonstrates another
layer of RGS16 regulation.
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Table 1.9: Regulation of RGS16 transcription
Protein / Stimulus

Effect on RGS16

Sources

Doxorubicin/p53 activation

Increases transcription
Increases expression
(Neuroblastoma cell lines)

[135]

Retinoic acid
Concomitant treatment HDAC
(Vorinostat) inhibitor and LSD1
(lysine-specific demethylase1)
knockdown
Carbachol
Fasting
IL-17
Lysophosphatidic acid (LPA)
Endotoxin (LPS)
FBS
Sphingosine 1-phosphate (S1P)
Endothelin-1 (ET-1)
Yin Yang
Runx2

Increased transcription
(Triple negative breast cancer cells)
Increases transcription
(Mouse fibroblast cells)
Increases RGS16 transcription (in mouse
liver)
Increases transcription
(Mice autoimmune B cells)
Increases RGS16 transcription
(MCF-7 breast cancer cells)
Increases transcription
(Rat myocardial myocytes)
Increases transcription
(Rat myocardial myocytes)
Increases transcription
(Rat myocardial myocytes)
Increases transcription
(Rat myocardial myocytes)
Inhibits transcription induced by FBS, S1P,
and ET-1
(Rat myocardial myocytes)
inhibits transcription
(mouse calvariae progenitors)

[162]

[163]

[135]
[139]
[138]
[164]
[144, 165]
[135, 145]
[145]
[145]
[145]
[166]

RGS16 Function
Pathways regulated by RGS16
There are 16 known Gα proteins that mediate GPCR signaling. The Gα proteins are
broken down into four subfamilies based on function designated as Gαi/o, Gαq, Gα12/13 and Gαs
[167].

RGS16 regulates GPCR signaling mediated by Gαi/o and Gαq/11 proteins by accelerating

GTPase activity [134].

Gαi/o proteins are so named because they inhibit adenyl cyclase

activation preventing generation of cAMP [167]. These proteins activate phospholipase Cβ
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(PLCβ) which hydrolyzes PIP2 (phosphoinositide 4,5-bisphospate) to DAG (diacyl glycerol) and
IP3 (inositol 1,4,5 triphosphate) [167]. DAG and IP3 activation results in activation of PKC-ε
(protein kinase C-ε) and mobilization of Ca2+ respectively [167]. However, the Gβγ complex
also mediates downstream signaling that is deactivated by the hydrolysis of GTP on Gα by
RGS16 [135]. An example of this is the loss of MAPK activation induced by Gβγ of M1 and M2
muscarinic receptors due to RGS16 GAP activity [135].
RGS16, as seen in Table 1.9, is regulated by mitogenic signals and analogous to other
RGS proteins, functions in a negative feedback loop to inhibit GPCRs that induce their
expression. Examples of this negative regulatory process can be seen for the GPCRs of LPA and
ET-1 ligands. Binding of LPA to its receptor (LPA1) increases expression of RGS16 which then
inhibits activation of RhoA and serum response element dependent transcription induced by LPA
[164]. ET-1 was previously shown to induce expression of RGS16, however this increased
expression inhibits activation of PLCβ by ET-1 [145, 165]. Table 1.10 contains on overview of
RGS16 targets and effects on cell signaling.
Table 1.10: Effect of RGS16 on downstream events
Target of RGS16
LPA
ET-1
Platelet Activating Factor
GPR39
Muscarinic receptor
Chemokines
(CxCR4, CCR10, CCR3,
CCR5, and CCR4)
EGF/EGFR

Effect
↓ RhoA activation &
↓ transcription of Serum response element
↓ activation of PLCβ
↓ activation of p38 MAPK
↓ of survival & ↓ pigment epithelium-derived
growth factor (PEDF)
↓ activation of ERK/MAPK

Sources
[164]
[165]
[168]
[169]
[135]

↓ migration in megakaryocytes, B cells,
and T-lymphocytes

[136, 137, 141,
170]

↓ proliferation &
↓ activation of PI3K/AKT pathway

[171]
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Non-canonical functions of RGS16
RGS proteins also have non-canonical functions, ergo, regulation of cell signaling
independent of the RGS box (Reviewed in [172]). Two examples of RGS16 functioning in a
non-canonical fashion are the regulation of LPA induced activation of RhoA and inhibition of
EGF/EGFR phosphorylation and activation of PI3K. LPA, as previously mentioned, stimulates
expression of RGS16, which with a negative feedback loop inhibits LPA induced activation of
RhoA. LPA is a GPCR that mediates its signaling through Gα12/13, which is not a target for
RGS16 regulation.
RGS16 regulates LPA signaling events by binding to Gα13 independently of its RGS box
and sequestering this subunit to the lipid rafts. The exile of Gα13 by RGS16 inhibits Gα13
mediated activation of RhoA and serum response elements [164].
RGS16 can also inhibit EGF/EGFR signaling. Knockdown of RGS16 in breast cancer
cells increased proliferation induced by EGF or FBS and increased expression of RGS16
inhibited EGF and FBS induced proliferation [171]. RGS16 binds to the p85α subunit of PI3K
preventing recruitment of PI3K to adapter proteins attached to EGFR thereby inhibiting PI3K
mediated phosphorylation and activation of AKT [171]. GPCRs can activate tyrosine kinase
receptors such as EGFR and together these two proteins

induce MAPK activation [173].

Regulation of EGFR signaling by RGS16 is another mechanism by which RGS16 inhibits
mitogenic signals initiated by GPCRs.
RGS16 and cell migration
Several studies have shown a role for RGS16 in inhibiting cell migration. Trafficking or
migration of T lymphocytes, B cells, and megakaryocytes induced by chemokine GPCRs are
inhibited by RGS16 [136, 137, 141, 170]. RGS16 inhibits migration of megakaryocytes and
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activation of MAPK and AKT by the SDF-1/CxCR4 chemokine pathway [141]. Expression of
RGS16 in the lymphocytes of a transgenic mice inhibited CxCR4, CCR3, and CCR5 allergen
induced migration to the lung parenchyma [137]. Conversely, in RGS16 knockout mice there
are decreases in T helper type 2 and 17 cell trafficking through regulation of CCR4 and CCR10
chemokine pathways [136]. These studies also show the importance of RGS16 in immune
response and trafficking. Several studies have used knockout mice to delineate the function of
RGS16, but it should be noted that there is no observable phenotype for mice lacking RGS16
[174].
RGS16 and Cancer
RGS16 is aberrantly expressed in some cancer types (Table 1.8). However, the role of
RGS16 in cancer progression remains unclear.

RGS16 is upregulated in colon, central

neurocytomas, Burkitt’s lymphomas, and pediatric high hyperdiploid acute lymphoblastic
leukemia (Table 1.8). Upregulation of RGS16 is due to mitogenic signals. The question remains
whether RGS16 is a reporter for GPCR signaling or does it indeed have a cancer promoting
function in these cancer types? Studies investigating the function of RGS16 in these cancer
types will determine if it promotes cancer progression or if post-translational modifications can
affect its function.

Furthermore post-translational modifications can affect the function of

RGS16 and should also be investigated in these cancer types.
Recent research suggests RGS16 may specifically have tumor suppressor function in
breast and pancreatic cancer. Figure 1.6 depicts the signaling pathways that RGS16 can regulate
demonstrating its potential as a tumor suppressor. As previously mentioned RGS16 inhibited
EGF and FBS induced cell proliferation by blocking the PI3K/AKT pathway. RGS16 knockout
breast cancer cells are more resistant to tyrosine kinase inhibitor treatments [171]. Loss of
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RGS16 occurs in metastatic pancreatic cancer and is associated with decreased patient survival
suggesting RGS16 may inhibit the metastatic process [149]. We have found in our in vitro
studies that RGS16 is co-regulated by p53 and pRb and inhibits pancreatic cancer cell migration
and invasion (Chapters 2 & 3 and [175]). Furthermore, increased expression of RGS16 is
induced by retinoic acid and the down regulation of RGS16 with another retinoic regulated
protein (DUSP6) disrupted retinoid inhibition of neuroblastoma growth [162].

Combined

treatment of triple negative breast cancer cells with a HDAC inhibitor and knockdown of LSD1
induced RGS16 expression that was vital for HDAC induced cytoxicity, downregulation of NFκB, and expression of E-cadherin, ING1, and CDKN1C, all of which have tumor suppressor
function [163].
Several of the GPCRs regulated by RGS16 (Table 1.10) have been implicated in
promoting angiogenesis, proliferation, and metastasis including M1 and M2 muscarinic
receptors, Platelet-activating factor (PAF), LPA, CxCR4, and ET-1 [133, 176, 177]. These
pathways are prime targets for future research regarding the role of RGS16 in cancer and will aid
in identifying possible tumor suppressive functions of RGS16.
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Figure 1.6: Known RGS16 regulation targets and downstream events that promote
cancer progression. These pathways can be activated by a variety of signals including
through EGFR which can also be regulated by RGS16. CxCR4 is a prototypical
representation of a GPCR that is involved in promoting cancer and is regulated by RGS16.
Pathway was constructed using Qiagen’s Ingenuity pathway Analysis (IPA®, QIAGEN
Redwood City, www.qiagen.com/ingenuity) Pathway Designer tools.
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CHAPTER 2.
EXPRESSION PROFILING ANALYSIS OF WI38 NORMAL LUNG
FIBROBLASTS FOLLOWING CO-EXPRESSION OF p53 AND pRb1
SUMMARY
Mutations in p53 or RB1 (Retinoblastoma) genes, their upstream regulators, or
downstream effectors have been found in almost all human malignancies. Evidence suggests
that p53 and pRb cooperate to suppress tumorigenesis, but does not elucidate the extent to which
p53 and pRb cross-communicate to regulate cellular functions. RNA expression profiling was
performed on normal human lung fibroblast WI38 cells following overexpression of p53 and/or
pRb, to identify genes co-regulated and involved in mediating p53 and pRb tumor suppressor
processes. The goals of the analyses were to investigate the cross-talk between p53 and Rb
proteins and to find downstream effectors regulated by these two tumor suppressor genes. This
knowledge might be used in the development of novel anti-cancer treatments. Microarray
analyses performed on WI38 cells overexpressing p53, pRb, or both p53 and pRb identified 294p53, 650-Rb, and 514-p53/Rb differentially regulated transcripts compared to vector control. By
examining the intersecting genes, we generated lists of p53 and pRb cross-talk candidates.
Several of the cross-talk candidates are known to be regulated by p53 and/or pRb.

Five

differentially expressed transcripts were chosen for validation by quantitative Real-Time PCR
(qRT-PCR) in WI38 cells and in the p53 negative and RB1 mutated SAOS-2 cells. Ingenuity
Pathway Analysis (IPA) identified an enrichment of transcripts involved in cellular movement,
development, cellular growth and proliferation among others in the WI38 cells overexpressing

1

A portion of this work has been submitted and accepted for publication in the journal Genes
and Cancer (see Appendix for draft) or [175]..
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p53 and pRb. To our knowledge, this is the first time microarray analyses have been used to
identify putative p53 and pRb cross-talk candidate genes.

The identity of these genes can be

used in future studies on specific cancer types to better understand how p53 and pRb regulate
cellular functions to prevent tumorigenesis. Deeper knowledge of the p53 and pRb cross-talk
pathway may aid in identifying new molecular targets, developing better therapies for cancer,
and providing more information on the coordination of tumor suppressor mechanisms by p53
and pRb.

INTRODUCTION
The p53 and pRb tumor suppressors are two signaling molecules that are frequently
altered during cancer progression. Mutations that disrupt the p53 and pRb function can occur in
the gene sequences or in their upstream regulators and/or downstream effectors [178]. Both
tumor suppressor genes are inactivated in a variety of malignancies including osteosarcoma,
small cell lung, breast, and bladder carcinomas [1, 4, 45, 46]. Furthermore, alterations in
expression or activity of proteins involved in p53 and pRb signaling pathways have been
identified in retinoblastoma and cancers of the pancreas, colon, and head and neck among others
[49, 51, 52, 111]. The large number of cancers that have defects in the p53 and pRb pathways
demonstrates the importance of these signaling modules in preventing cancer development and
progression.
Both p53 and pRb regulate processes vital for the suppression of cancer progression, such
as cell cycle arrest, apoptosis, senescence, and differentiation [4, 73, 179].

Existing data

suggests that p53 and pRb cooperate to prevent tumor progression. Examples of this cooperative
interaction have been shown in various studies using human primary cancer samples and mouse
models.

Patients who have mutations in both p53 and RB1 genes have increased tumor
36

recurrence and decreased survival compared to patients with a mutation in either p53 or RB1 [45,
47, 180]. Studies conducted in primary tumor samples and established cell lines found that
inactivation of both p53 and pRb signaling pathways promotes processes that support cancer
progression such as chromosome instability, chemoresistance, and the Epithelial Mesenchymal
Transition (EMT) [60, 62, 181]. Mice that are p53-/- and also heterozygous for RB1 developed
more tumors than mice with single mutations; i.e. heterozygous p53 or RB1 null or p53 null with
w.t. RB1 [4]. In another study, mice with conditional inactivation of both p53 and RB1 in
prostate epithelium developed highly metastatic tumors and had decreased survival time
compared to mice with single inactivation of either p53 or RB1 [5]. The accumulated evidence
suggests p53 and RB1 gene products have cooperative or synergistic effects for cancer
suppression.
Considering the network of communication that exists within a cell, the rate of mutation
of p53 and RB1, and the cellular processes these two proteins regulate, a natural hypothesis is
that these two genes and respective gene products cross-communicate in order to determine
cellular fate and prevent carcinogenesis. Over the years, data have accumulated that paints a
picture of the communication that exists between the p53 and pRb pathways. The cell cycle
stimulating transcription factor E2F protein provides a prime example of the link between the
p53 and pRb pathways. In its hypophosphorylated form pRb binds to E2F family members
(E2F1, E2F2, or E2F3) and acts as a transcriptional repressor to inhibit the transcription of genes
needed for the continuation of the cell cycle [18-20]. Cyclin-dependent kinases-4 and -6
phosphorylate pRb resulting in the release of E2F from pRb binding thus allowing this factor to
stimulate the transcription of genes encoding cell cycle stimulatory proteins [19, 21]. An
increased amount of unbound E2F due to loss of RB1 or alteration in the pRb pathway can
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trigger a p53-dependent apoptotic response [74, 78]. The interaction between E2F1 and p53 to
initiate apoptosis demonstrates a protective mechanism employed by the cell to prevent cancer
development when pRb regulation is lost. E2F1 is not the only protein known to be involved in
the convergent signaling between the p53 and pRb pathways; other proteins known to be
implicated in p53 and pRb cross-talk are Hdm2, p21, and the INK4a locus (reviewed in [3, 47,
182]). Although several proteins that are involved in the p53 and pRb pathways have been
identified, the full extent in which these two tumor suppressors interact along their pathways to
regulate cellular fate is still unknown. Current data and analyses have only begun to elucidate the
proteins involved between p53 and pRb mediated cancer suppression. The focus of this study
was to identify signaling molecules involved in the p53 and pRb cross-talk pathway and to
provide leads to the nature of downstream effector molecules responsible for inducing p53 and
pRb mediated cancer suppression. Identification of p53 and pRb downstream effectors will
provide new targets for future anti-cancer therapies.

Materials and Methods
Cell culture and virus transductions
The human lung fibroblast WI38 cell line and the osteosarcoma cell line SAOS-2 (p53
null and truncated RB1) were purchased from the American Type Culture Collection (Manassas,
VA, USA).

WI38 cells were grown in Hyclone MEM/EBSS (ThermoFisher Scientific,

Waltham, MA) media supplemented with 10% research grade fetal bovine serum (FBS)
(ThermoFisher Scientific, Waltham, MA) and 1% Penicillin Streptomycin (Corning, Corning,
NY) and SAOS-2 cells were grown in Hyclone High Glucose DMEM (ThermoFisher Scientific,
Waltham, MA) supplemented with 10% FBS and 1% Penicillin Streptomycin.
cultured at 37°C in a humidified 5% CO2 incubator.
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Cells were

Ad.CMV (adenovirus with CMV promoter) and Ad.CMV.p53 (Adenovirus containing
wild-type p53 gene under control of CMV promoter) viral vectors were generated using the
AdEasy system (Carlsbad, CA). The Ad.CMV.pRb (Adenovirus containing RB1 gene cDNA
under control of CMV promoter) vector was provided by Dr. Juan Fueyo (M.D. Anderson
Cancer Center, The University of Texas). Viruses were amplified and tittered as previously
described [183-185].
Microarray expression profiling
For expression profiling, WI38 cells were transduced with each of the following vectors
or vector combination: (1) adenovirus vector with no insert (Adenoviral CMV-vector ctrl), (2)
Ad.CMV.p53, (3) Ad.CMV.pRb, and (4) both Ad.CMV.p53 and Ad.CMV.pRb. Vectors were
added at a multiplicity of infection (MOI) of 50 to confluent WI38 cells (500,000 cells / 100mm
plate) in MEM/EBSS media supplemented with 2% heat-inactivated FBS. Culture media were
replaced with 10% FBS and 1% Penicillin/Streptomycin supplemented MEM/EBSS medium 16
hours after vector addition; cells were collected after 48 hours. Four biological replicates were
performed for each of the four expression studies. Immunoblots were used to verify increased
expression of p53 and/or pRb in the WI38 samples prior to microarray analysis.
Total RNA was isolated from transduced WI38 cells using TRIzol reagent (Invitrogen,
Carlsbad, CA) according the manufacturer’s protocol. Using a universal reference design, two
RNAs (transduced WI38 cells + Agilent (Santa Clara, CA) human universal reference RNA)
were hybridized to Agilent 44K whole human genome expression arrays. Total RNAs were
labeled with either cyanine (Cy)-3-CTP and Cy5-CTP (Perkin Elmer, Waltham, MA) using
Agilent QuickAmp cRNA labeling kits. Following purification, Cy3- and Cy5-labeled cRNAs
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were combined and hybridized for 17 hours at 65ºC in an Agilent hybridization oven.
Microarrays were then washed and scanned using Agilent DNA Microarray Scanner.
Statistical Analysis of Expression Profiling Data
Lowess-normalized feature intensities were extracted from the scanned image using
Feature Extraction (Agilent). These data were exported as tab-delimited files (one file per
sample) to Microsoft Excel® for filtering. For each feature, data were removed if both channels
reported values not well-above background according to default Feature Extraction Criteria. For
each comparison, log base-2 ratios of each sample to universal reference RNA were collated into
a single table. Features for which fewer than 50% of all samples had a present value were
removed from further analysis.
The resulting tables were imported into Multiple Experiment Viewer (MEV) v4.3. Log
base 2 ratios were compared between each of three sample sets (p53 overexpressed samples.
RB1 overexpressed samples and p53 and RB1 overexpressed samples) and the adenovirus vector
control samples by Significance Analysis of Microarrays [186].

We used a conservative

threshold whereby only genes for which MEV reported a false discovery rate of 0% were
considered significantly differentially expressed.
Data extracted using Feature Extraction was uploaded to the NCBI’s Gene Expression
Omnibus (GEO) public database and is available via access number GSE59660.
Ingenuity Pathway Analysis
The functional analyses were generated through the use of QIAGEN’s Ingenuity
Pathway Analysis (IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity). The accession
number and fold change of differentially expressed mRNA identified by RNA expression
profiling were uploaded into Ingenuity Pathway Analysis (IPA) software for functional analysis.
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The gene transcripts identified in the microarray were categorized based on their molecular and
cellular function in order to identify pathways that are being altered or enriched by p53 and pRb
signaling, however, information regarding disease and physiological system development were
also reported (Doc. SI2 or Doc. SI3). Benjamini-Hochberg multiple correction p-values were
computed for the null hypotheses that genes with altered mRNA levels are independent of
molecular and cellular functions, and functions with a corrected p-value less than 0.05 were
considered statistically significant. Pathways examining known relationships between the crosstalk candidates and p53, pRb, and E2F1-3 were generated using IPA Knowledge Base and
Pathway designer tools (grow and connect).
Quantitative Real-time PCR analysis
Total RNA was isolated from cells using TRIzol reagent (Invitrogen, Carlsbad, CA)
according to the manufacturer’s protocol. Total RNA (2ug) was reverse transcribed into cDNA
using the High Capacity cDNA Reverse Transcription kit from Applied Biosystems (Foster City,
CA) according to the manufacturer’s protocol.

Real-Time PCR was performed using the

Applied Biosystems TaqMan Gene Expression Assays in the ABI 7000 detection system (Foster
City, CA). TaqMan probes were purchased from Applied Biosystems (Foster City, CA) IL-6
(HS00197982_m1), BCL2L11 (BCL2L11) (HS00197982_m1), RGS16 (HS00892674_m1),
BTG2 (HS00198887), STAT4 (HS00231372_ml) and GAPDH (HS02758991). The relative fold
change for each marker was calculated using the 2-ΔΔCT analysis according to Livak et.al and
statistical significance was determined using a one way ANOVA with a Dunnett’s post-hoc test,
using Prism V6.0c (GraphPad Software, Inc., La Jolla, CA) [187].
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Western blot analysis
WI38 or Saos-2 cells were lysed in whole cell lysis buffer containing 50mM Tris-HCl
(pH7.4), 5mM EDTA 250mM NaCl, 50mM NaF, 0.1mM Na3VO4, 0.1% Triton X-100 and
protease inhibitors (Pierce Protease inhibitor Tablets 88661; Thermo Scientific, Rockford, IL).
Protein extracts (50ug, measured using Bradford protein assay) were loaded onto 8%
polyacrylamide gels and proteins were separated using sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS-PAGE). Blots were blocked 1 hour in 5% dry non-fat milk diluted in
Tris-buffered saline solution containing 0.1% Tween-20 pH 7.6 (TBS-T). Membranes were
probed overnight at 4°C with mouse anti-p53 (SC-DO1, 1: 1000) or mouse anti-pRb (SC-IF8,
1:500) antibodies from Santa Cruz Biotechnology (Dallas, TX). Following primary antibody
incubation the membranes were washed using TBS-T (three times; 5 minutes) and probed with
Horseradish peroxidase (HRP)-conjugated goat anti-mouse (1:5000) secondary antibodies
(Rockland, Gilbertsville, PA) for 1 hour at room-temperature. Primary and Secondary antibodies
were diluted in TBS-T. Blots were washed 5 minutes in TBS-T three times and Amersham ECL
prime western blotting detection reagent was added in order visualize the protein bands (RPN
2232, GE Life Sciences, Pittsburgh, PA).

Western blot images were captured using

FOTODYNE FOTO/Analyst FX (Hartland, WI) imaging camera. Membranes were normalized
using mouse anti-actin (1:1000).

RESULTS
Identification of p53 and pRb cross-talk candidates in WI38 cells following exogenous
expression of p53 and/or pRb.
Studies have shown that p53 and pRb cooperate to prevent tumorigenesis. Currently, the
molecules that function in the p53 and pRb cross-talk pathway to regulate cellular fate are not
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known thus expression profiling by microarray was performed to find genes co-regulated by p53
and pRb. Normal human lung WI38 fibroblast cells were transduced with adenoviral vectors
expressing the p53 and/or RB1 genes under the control of a cytomegalovirus (CMV) promoter.
The WI38 cell line was used because it is from non-cancerous tissue and lacks mutations or viral
transformations that could disrupt the p53 and pRb pathways. Four experimental conditions were
used in which WI38 cells were transduced with adenovirus vector control (cond. 1, Adenoviral
CMV-vector control, Ad.CMV.p53 (cond. 2), Ad.CMV.pRb (cond. 3), or both Ad.CMV.p53 and
Ad.CMV.pRb (cond. 4). RNA and protein from WI38 cells was collected 48 hours after
adenoviral infection. Immunoblots verified increased expression of p53 (fold change compared
to Ad.CMV control = 2.80, 1.54, and 2.77) and/or hypophosphorylated (active form) pRb
(hypophosphorylated/total pRb fold change compared to Ad.CMV control = 0.94, 5.48, 5.02) in
the WI38 cells treated with adenoviruses containing p53, pRb, or both p53 and pRb respectively
(Figure 2.1A).

Fold change values for p53 and hypophosphorylated pRb coincided with

previously reported results in experiments that activated endogenous p53 and pRb [30, 31].
Microarray data from the adenovirus vector control (empty vector with CMV promoter) was
used as a reference to determine genes that were differentially expressed as a consequence of
p53, pRb, and p53 + pRb expression. Analysis of the microarray data identified 294-p53, 650pRb, and 514-p53 + pRb differentially expressed genes (Figure 2.1B). Of the differentially
expressed genes, 294/294 genes were upregulated in cells with p53 expression, 427/650 genes
were upregulated in cells with pRb expression, and 319/514 genes were up-regulated in cells
with p53 + pRb coexpression (Figure 2.1B). Consistent with protein measurements, increased
expression of p53 and/or RB1 mRNAs were also found in the appropriate groups (data not
shown).
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A Venn diagram shows the number of differentially expressed genes shared between the
experimental groups (Figure 2.1B). By looking at the common genes between the three
experimental groups, we were able to generate two lists of genes that may be involved in the p53
and pRb cross-talk pathway. The first list of cross-talk candidates (designated as the p53 and pRb
common gene set) consisted of 39 genes found to be commonly up-regulated in cells expressing
either p53 or pRb. The second list of possible cross-talk members (designated as the p53 and
pRb interaction gene set) contained 140 genes that were found to be differentially expressed only
when p53 and pRb were overexpressed together (see Addendum for Chapter 2 for p53 and pRb
interaction gene set). Thirty-two of the 39 common gene set cross-talk candidates were found to
be up-regulated in the interaction gene set, while the remaining 7 were commonly up-regulated
in cells that overexpress either p53 or pRb (Table 2.1). By focusing on the common and
interaction gene sets, we were able to remove transcripts that were up- or down-regulated by
only p53 or pRb and focus on candidates that may be involved in the p53 and pRb cross-talk
pathway.
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Figure 2.1: Identification of differentially expressed transcripts in WI38 cells
overexpressing p53 and/or pRb. WI38 cells were transduced with adenoviruses carrying the
transgenes p53, or RB1/p105; a MOI of 50 was used in each case. A) Western blot analysis
was used to test for p53 and pRb expression prior to microarray analysis. B) Fold change of
protein expressions compared to CMV control. C) A Venn diagram shows the differentially
expressed transcripts and intersects identified during the microarray analysis. The numbers in
red denote transcripts that were up-regulated due to p53, pRb, or p53 and pRb expression.
.
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Table 2.1: Fold change of p53 and pRb common gene set cross-talk candidates
Gene Symbol

Name

FC-p53

FC-Rb

FC-p53+Rb

LOC387763
A_24_p775812
RGS16
AREG
CCL3
TNFSF15
IL-1B
OLFM2
NR4A1
POSTN
D4S234e
IL-6
DMN
EPPK1
IQSEC3
PLAC2
L3MBTL2
LHX6
AKR1B10
RRAD
c10orf58
BCL2L11
COL7A1
JUP
VCAN
CRISPLD2
STOX2
BTG-2
P2RY2
TSKU
C4B
RTN4R
STAT4
AK124344
KLHL20
NOTCH3
KSR1
GDF15
LOC654346

hypothetical LOC387763
Unknown
Regulator of G-protein signaling 16
Amphiregulin
Chemokine (c-c motif ligand 3)
Tumor necrosis factor (ligand) superfamily, member 15
Interleukin-1 beta
Olfactomedin 2
Nuclear receptor subfamily 4 group A member 1
Periostin
D4S234e (NSG1; neuron specific gene family member 1)
Interleukin-6
Desmuslin
Epiplakin
IQ motif and Sec7 domain 3
Placenta specific 2
Lethal(3)malignant brain tumor-like protein 2
LIM homeobox 6
Aldo-keto reductase family 1 member B10
Ras associated with diabetes
chromosome 10 open reading frame 58
Bcl2-like 11 (apoptosis facilitator)
Collagen, type VII, alpha 1
Junction plakoglobin
Versican proteoglycan
Cystein-rich secretory protein 11
Storkhead-box 2
B-cell translocation gene 2
purinergic receptor P2Y, G-protein coupled, 2
Tsukusi,small leucine rich proteoglycan
Complement component 4B
Reticulon 4 receptor
Signal transducer and activator of transcription 4
cDNA FLJ42353 fis, clone UTERU2007520
Kelch like 20
Notch homolog 3
Kinase suppressor of RAS
Growth/differentiation factor 15
similar to galectin 9 short isoform (LOC654346)

30.62
15.65
18.84
8.15
3.78
10.68
4.82
10.60
11.56
2.91
21.20
6.04
4.57
32.06
7.29
21.60
18.33
10.11
11.61
5.98
4.86
9.58
5.97
7.60
5.61
10.11
14.48
3.85
2.38
5.28
3.38
8.01
5.98
5.21
4.88
4.68
3.86
3.24
2.81

159.25
199.36
30.82
46.41
8.18
69.61
22.53
37.76
20.73
21.051
7.86
12.37
27.42
8.27
20.37
4.63
11.82
7.11
13.92
7.80
9.20
6.50
10.65
16.61
9.17
5.38
8.70
5.07
19.53
5.42
7.64
6.19
7.80
7.13
4.46
3.96
4.08
3.40
4.77

297.07
252.80
149.75
81.91
56.12
53.34
43.79
27.31
27.08
25.66
22.06
21.99
21.25
20.04
19.95
19.00
16.00
15.15
13.30
12.61
11.74
11.34
10.94
9.92
9.73
9.55
9.33
7.46
6.91
5.97
2.22
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

FC = Fold change
N/A= Fold change not available. Gene was not found to be significantly differentially expressed in WI38 cells overexpressing p53 and
pRb.

46

qRT-PCR validation of microarray data in WI38 and SAOS-2 cells
The ultimate goal in performing the microarray analysis was to determine molecules
involved in the p53 and pRb cross-talk pathway in order to identify and study downstream
effector molecules that can be expressed to induce a p53 and/or pRb tumor suppressive function.
Because of our interest in identifying downstream effector molecules, we chose five mRNA
transcripts (IL-6, BTG-2, STAT4, RGS16, BCL2L11) from the set of 39 commonly up-regulated
transcripts by p53 and pRb for validation via qRT-PCR. IL-6, BTG-2, STAT4, RGS16, and
BCL211 were chosen for validation because of vaying function, known regulation by p53 and
pRb, and fold change values of the expression profiling assay. WI38 cells were plated and
transduced with adenoviral expression vectors via the same methods used for the microarray
analysis. Relative fold change was calculated for IL-6, BTG-2, STAT4, RGS16, and BCL2L11
in WI38 cells expressing p53 and/or pRb as shown in Figure 2.2. Statistically significant upregulation of all transcripts tested except BCL2L11 was found in WI38 cells expressing p53 and
pRb confirming the microarray results. Expression of p53 and pRb in WI38 cells increased
mRNA expression for some of the transcripts (for example, RGS16 and BTG-2) to a greater
extent than single expression of either p53 or pRb. This suggests p53 and pRb are working
together resulting in an additive (i.e. BTG-2) or synergistic (i.e. RGS16) effect on mRNA
expression for some of the transcripts.
To further support the RNA expression profiling results, we repeated the expression of
p53 and pRb in a p53 null, RB1 mutant osteosarcoma cell line (SAOS-2) and performed qRTPCR analysis of IL-6, BTG-2, STAT4, RGS16, and BCL2L11. The expression of all five
transcripts including IL-6 and BCL2L11 were found to be significantly increased by one-way
ANOVA compared to vector control in SAOS-2 cells expressing p53 and/or pRb (Figure 2.3).
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Dunnett’s test for multiple comparison found BCL2L11 expression to be significantly increased
in cells expressing p53, pRb, and both p53 and pRb and IL-6 was found to be significantly
increased in cells expressing pRb and p53+pRb. Expression of IL-6 was not found to be
statistically significant in SAOS-2 cells expressing p53 due to variation between replicates (fold
change= 2.86). All five transcripts were found to be up-regulated when p53 and/or pRb were
expressed in the microarray analysis and qRT-PCR analysis showed similar results in WI38 and
SAOS-2 cells.
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Figure 2.2: Validation of microarray data using qRT-PCR in WI38 cells.
Five transcripts RGS16, BCL2L11, BTG2, IL-6 and STAT4 from the p53 and pRb intersect were
chosen for validation by qRT-PCR in WI38 cells overexpressing p53, pRb, or both p53 and pRb.
The vector control (Ad.CMV) was used to calculate the fold change for each transcript. One-way
ANOVA with Dunnett’s test for multiple comparison were used to test for statistical significance *
p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001, and **** p-value < 0.0001.
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Figure 2.3: Validation of microarray data using qRT-PCR in SAOS-2 cells.
Five transcripts RGS16, BCL2L11, BTG2, IL-6 and STAT4 from the p53 and pRb intersect
were chosen for validation by qRT-PCR in SAOS-2 cells overexpressing p53, pRb, or both p53
and pRb. The vector control (Ad.CMV) was used to calculate the fold change for each
transcript. One-way ANOVA with Dunnett’s test for multiple comparison were used to test for
statistical significance * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001, and **** pvalue < 0.0001.
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Ingenuity Pathway Analysis of differentially expressed transcripts in WI38 cells following
overexpression of p53 and/or pRb.
The web-based Ingenuity Pathway Analysis software (IPA) was used to perform
functional analysis on the WI38 expression profiles. Differentially expressed mRNA transcripts
with known functions are eligible for IPA analysis. Eligible transcripts for each overexpression
were as follows: p53: 263/294, pRb: 533/650, and p53 + pRb: 441/514). These gene sets were
loaded into IPA for global functional analysis to predict biological functions that may be
activated or inhibited due to p53 and pRb signaling. Lists of the significant molecular and
cellular functions found to be statistically overrepresented by p-value (Benjamini-Hochberg
correction after Fisher’s exact test) due to overexpression of p53, pRb, and both p53 and pRb
based on IPA annotations are shown in Figures 2.4-2.6. Cellular development was the top
overrepresented molecular and cellular function in WI38 cells overexpressing p53 followed by
cellular movement and cell-to-cell signaling and interaction (Figure 2.4). Transcripts associated
with cell cycle regulation functions such as cell cycle, cellular assembly and organization, and
DNA replication, recombination, and repair were enriched in WI38 cells overexpressing pRb
(Figure 2.5). WI38 cells overexpressing both p53 and pRb showed enrichment in transcripts
associated with cellular growth and proliferation, cell cycle, cell death and survival, and
development (Figure 2.6). Similar cell and molecular functions were found to be overrepresented
in WI38 cells overexpressing p53, pRb, and p53 + pRb. Transcripts involved in cellular
development, cellular growth and proliferation, cell death and survival, and cellular movement
were found to be differentially expressed in all three experimentally conditions with differences
in order of significance between groups. Genes involved in DNA replication, recombination and
repair biological functions were not found to be significantly differentially expressed in WI38
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cells overexpressing p53 but were significantly enriched in cells overexpressing pRb and p53 +
pRb. There was also enrichment in genes involved in cell cycle regulation in all three
experimental conditions, however, in WI38 cells overexpressing p53, cell cycle was the twelfth
significant biological pathway. The differences in biological functions found to be enriched by
IPA highlights the various pathways regulated by p53 or pRb.
Because of my interest in discovering p53/pRb cross-talk mechanisms, IPA functional
analysis was also performed on IPA-eligible genes from both cross-talk candidate gene subsets
(p53 and pRb common (36/39) and interaction (104/140) gene sets combined and separately)
identified by RNA expression profiling. IPA functional analysis on all cross-talk candidates
(combined cross-talk gene subsets) revealed statistically significant enrichment in functions
involved in cellular growth and proliferation, cellular development, cell death and survival,
cellular movement, and cell cycle (Figure 4.7). Interestingly, when examining the cross-talk gene
sets separately; different functions are significantly enriched between groups. Only annotations
associated with cellular growth and proliferation, cell cycle, and cellular development were
found to be statistically significant in the interaction gene set (Figure 4.8). In the common gene
set, 25 functions were found to be statistically overrepresented including cellular movement,
cellular development, cellular growth and proliferation, cell cycle, and lipid metabolism (Figure
4.9).
Each category of cell and molecular functions is broken down into subcategories.
Analysis of these sub categories in combination with examination of the top annotations
associated with disease in IPA, revealed an enrichment of transcripts involved in immune
response (not a category for cell and molecular function) in cells expressing p53, pRb, and p53 +
pRb.

Interestingly, annotations associated with immune response were among the top

52

statistically significant functions in the IPA analysis of p53 and p53 + pRb common gene sets.
Biological processes associated with inflammation of organ (2.29E-03), development of
leukocytes (2.29E-03), accumulation of leukocytes (2.75E-03), and movement of lymphocytes
(1.10E-02) were found to be statistically significant in WI38 cells that overexpress p53 (Data not
shown). Generation of T lymphocytes (3.04E-04), inflammation of organ (6.41E-04), TH1
immune response (5.36E-03), development of TH17 cells (5.70E-03), and mobilization of
phagocytes (8.25E-03) among others were statistically significant in the p53 and pRb common
gene set (data not shown). Annotations associated with immune response were also statistically
enriched in the other gene sets (WI38 overexpressing pRb, p53 + pRb, collective cross-talk
candidates). These data demonstrate an increase in proteins associated with immune response.
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Figure 2.4: Cell and molecular functions statistically overrepresented in WI38 cells
overexpressing p53.
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Figure 2.5: Cell and molecular functions statistically overrepresented in WI38 cells
overexpressing pRb.
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Figure 2.6: Cell and molecular functions statistically overrepresented in WI38 cells
overexpressing p53 + pRb.
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Figure 2.7: Cell and molecular functions statistically overrepresented in collective p53
and pRb common and interaction cross-talk candidates.
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Figure 2.8: Cell and molecular functions statistically overrepresented in the
interaction gene set p53 and pRb cross-talk candidates
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Figure 2.9: Cell and molecular functions statistically overrepresented in the common
gene set p53 and pRb cross-talk candidates.
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IPA pathway generation of known interactions between p53, pRb, E2F family members
(E2F1-3), and cross-talk candidates identified by RNA expression profiling
By using RNA expression profiling, we were able to identify transcripts that may be coregulated by p53 and pRb and involved in regulating tumor progression. In order to gain more
understanding of p53 and pRb cross-talk, pathways were generated examining known direct and
indirect relationships between the cross-talk candidates and p53, pRb, and E2F1-3 using IPA’s
Ingenuity Knowledge Base (Ingenuity Systems). The p53 and Rb common and interaction crosstalk candidate gene sets were loaded into IPA and pathways were generated using the Ingenuity
Knowledge Base and IPA pathway tools (“Grow, Connect, and Pathway Designer”) to examine
upstream and downstream relationships between p53, pRb, E2F1-3 (E2F family members
regulated by pRb) and the differentially expressed cross-talk gene sets (Figure 2.10-2.12). A
pathway comprised of known interactions between all of the cross talk candidates (designated as
the collective p53 and pRb cross-talk candidate pathway) made using the p53 and pRb common
and interaction gene sets is depicted in Figure 2.12. Separate pathways for each cross-talk gene
set, designated as p53 and pRb common gene set and interaction gene set pathways, respectively,
were also generated (Figures 2.10-2.11). Pathway generation by IPA identified the common
gene set candidates RGS16, D4s234e/NSG1, BTG-2, GDF-15, VCAN, AKR1B10 and AREG
and the interaction gene set candidates: F11R, TNFRSF10C, CERS6, HDM2, SESN1, RBM38
and PMAIPI/NOXA as targets of p53 transcriptional activation (Figures 2.10-2.12).

The

interaction gene set cross-talk candidates BUB1, CDT1, and MCM3 are targets for
transcriptional repression by p53, whereas, VRK1, MCM3, and CDT1 are known to be downregulated by pRb (Figure 2.11-2.12). Interactions between E2F and the cross-talk candidates
were assessed because of regulation of E2F gene expression by pRb. IPA identified FGFR3,
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MCM3, and KRT14 interaction gene set candidates as transcriptional targets of E2F1-3 family
members (Figures 2.11-2.12). Interestingly, IPA’s database identified only 17 out of 39 of the
p53 and pRb common and 26 out of 140 of the interaction cross-talk candidates as having known
up- or down-stream relationships with p53, pRb, or E2F1. The low number of cross-talk
signaling molecules known to have a direct and indirect relationship with p53 and pRb highlights
the need for more research to understand the functions of these tumor suppressors.
Known interactions between the p53 and pRb cross-talk candidates are also depicted.
Connections can be seen between cross-talk members that are centrally located in the IPA
pathway. In the common gene set pathway, IL-1β, IL-6, BCL2L11, STAT4, BTG-2, and
NR4A1 all have multiple connections (4 or more) with p53, pRb, E2Fs, or other cross-talk
candidates (Figure 2.10). Centrally located signaling molecules or nodes are also present in the
p53 and pRb interaction pathway and consist of HDM2, BMP-2, and IL-12A (Figure 2.11).
Furthermore, the same cross-talk candidates (IL-1β, IL-6, BCL2L11, STAT4, BTG-2, NR4A1,
HDM2, BMP-2, and IL-12A) appear to function as signaling nodes in the collective cross-talk
pathway signifying their possible role in mediating p53 and pRb functions.
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Figure 2.10: Known interaction network of common gene set cross-talk candidates
with p53, pRb, and E2F1-3. IPA Ingenuity Knowledge base pathway tools and pathway
designer were used to generate a pathway showing known direct (solid lines) and indirect
(dashed lines) relationships between the p53 and pRb common gene set and p53, pRb, and
E2F1-3. Each shape represents a different type of signaling molecule. Color intensity is
associated with the degree in which the transcripts were up- (red) or down-regulated
(green).
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Figure 2.11: Known interaction network of p53 and pRb interaction gene set cross-talk
candidates with p53, pRb, and E2F1-3. IPA Ingenuity Knowledge base pathway tools and
pathway designer were used to generate a pathway showing known direct (solid lines) and
indirect (dashed lines) relationships between the p53 and pRb interaction gene set cross-talk
candidates and p53, pRb, and E2F1-3. Each shape represents a different type of signaling
molecule. Color intensity is associated with the degree in which the transcripts were up- (red)
or down-regulated (green).
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Figure 2.12: Known interaction network of colectiveollective p53 and pRb crosstalk candidates with p53, pRb, and E2F1-3. IPA Ingenuity Knowledge base
pathway tools and pathway designer were used to generate a pathway showing known
direct (solid lines) and indirect (dashed lines) relationships between all of the p53 and
pRb cross-talk candidates and p53, pRb, and E2F1-3. Each shape represents a different
type of signaling molecule. Color intensity is associated with the degree in which the
transcripts were up- (red) or down-regulated (green).
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DISCUSSION
Significance of investigating p53 and pRb cross-talk
Historically, investigations of p53 and pRb regulated transcription have focused on
identifying the individual downstream targets of p53 and pRb. However, cell fate is not
determined solely by one signaling pathway but by many pathways that communicate through a
network of signaling molecules. Cross-communication between pathways allows the integration
of the exogenous and endogenous signals in a cell to aid in the determination of cell fate. Coexpression of p53 and pRb in cancer cells with compromised p53 and pRb activity inhibited p53
mediated apoptosis and promoted cell cycle arrest suggesting that p53 and pRb cross-talk to
regulate cellular fate [188, 189]. Furthermore, data from previous studies suggests p53 and pRb
may also cooperate to inhibit cancer progression. Patients diagnosed with breast cancer and
treated with adjuvant chemotherapy had a better prognosis to adjuvant chemotherapy if they had
functional p53 and pRb [61].
To our knowledge this is the first study that examined altered gene expression when p53
and pRb are overexpressed together or separately with the purpose of finding genes co-regulated
by both tumor suppressor genes. How p53 and pRb cross-communicate to regulate cellular
functions or cooperate to inhibit cancer progression still remains largely unknown. The p53 and
pRb pathways are commonly altered during tumorigenesis. The study of genes dually regulated
by p53 and pRb will provide a valuable insight into the collaborative cancer preventative
properties of these two tumor suppressor proteins.
Transcriptional regulation may be one method used by p53 and pRb to coordinate cellular
functions. For example, the cyclin kinase inhibitor p21 is a down-stream target gene of p53 that
inhibits phosphorylation and inactivation of pRb [25]. Transactivation of p21 demonstrates a
mechanism by which p53 can coordinate with pRb to initiate cell cycle arrest.
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During

myogenesis, p53 increases the expression of Rb (mRNA and protein), which later leads to pRb
and MyoD initiation of muscle differentiation [17]. This provides an example by which p53
directly enhances pRb expression leading to muscle differentiation. However, this one example
is likely an indicator of large number of interactions that regulate complex cellular programs.
Change in RNA expression profiles of WI38 cells overexpressing both p53 and pRb
compared to expression of p53 or pRb alone and identification of cross-talk candidates.
In this study, we identified genes that may be regulated by p53 and pRb and compiled
two lists of p53 and pRb cross-talk candidates by overexpressing p53 and/or pRb in WI38 cells.
Although p53 has transcriptional repression activity, our microarray analysis did not detect any
down-regulated transcripts in the WI38 cells overexpressing p53 [190, 191]. The deficit of p53
down-regulated transcripts in our microarray analysis compared to previous work, could be due
to our method of p53 activation, cell type, or p53 levels, which have previously been found to
induce a distinct p53 response with a small set of overlapping genes [192, 193]. Our expression
profiling analyses were conducted in normal lung fibroblasts cells instead of cancer epithelial
cells. Lack of p53 down-regulated genes in the p53 overexpressing WI38 cells could also be
attributed to the ability of p53 and pRb to alter each other’s transcriptional activation or
repression functions. Previous studies that discovered p53 down-regulated targets using
expression profiling were done in cancer cells with mutated or null p53 and wild-type RB1 such
as PC-3, HCT116, and H1299 cells [190, 194].
There were 319 upregulated transcripts when p53 and pRb were expressed together
compared to 427 and 295 in the WI38 cells expressing pRb and p53 respectively. The change in
upregulated genes suggests p53 and pRb can alter one another’s ability to regulate gene
expression. Management of p53 and pRb processes may require these transcription factors to
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regulate gene expression in an opposing manner. Expression of an embryonic development gene,
Placenta-specific 1 (PLAC1), has recently been found to be down-regulated by p53 and upregulated by pRb demonstrating how p53 and pRb can play contrasting roles to regulate cellular
processes [81].
pRb is most associated with transcriptional repression of E2F target genes. However,
binding of E2F by pRb is not needed to promote transcription, suppress tumor growth and induce
cellular differentiation or senescence [22, 23]. In fact, pRb acts as a co-activator for several
transcription factors including Sp-1, RUNX-2, MyoD, and several nuclear receptors (including
NR4A1) resulting in cellular differentiation [22, 39]. We found more upregulated transcripts in
WI38 cells overexpressing pRb demonstrating its function as a transcription co-activator. There
is still a lack of information regarding pRb regulation, therefore, this study could contribute to
identifying genes up-regulated by pRb and understanding the function of pRb as a transcriptional
co-activator.
Candidates for the p53 and pRb cross-talk pathway were chosen based on whether (1) the
transcripts were differentially expressed in both WI38-p53 overexpressing cells and WI-38-pRboverexpressing cells (the common gene set), or (2) only in WI38 cells that simultaneously
overexpress p53 and pRb (interaction gene set). By focusing on the p53 and pRb common and
unique genes, we were able to remove from our analysis genes regulated by p53 or pRb alone.
RNA expression profiling validation
Validation of microarray data was performed using qRT-PCR for five (RGS16,
BCL2L11, BTG-2, IL-6 and STAT4) of the p53 and pRb common gene set cross-talk candidates.
Up-regulation of all transcripts tested except BCL2L11 was found to be statistically significant
in WI38 cells overexpressing p53 and pRb confirming the microarray results. The analysis was
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performed using a normal cell line in order to avoid any mutations that could be present up- or
downstream of p53 and pRb that could hinder identification of downstream targets of both genes.
Although p53 and pRb were expressed using adenoviruses in normal cells, the fold change of
p53 and hypophosphorylated pRb proteins compared to CMV control were equivalent to or less
than fold change values in WI38 cells incubated in serum free media to induce quiescence (fold
change p53 after 24 hours in serum free media = 5.5) or MCF7 cells undergoing confluence
induced cell growth arrest (fold change hypophosphorylated pRb/total pRb = 6.00) [195, 196].
This data suggests the concentration of virus used did not induce protein expression exceeding
endogenous protein expression of p53 and the active hypophosphorylated form of pRb. The use
of a normal cell line with wild-type p53 and RB1 could make it difficult to identify cross-talk
molecules due to possible interactions between endogenous and exogenous p53 and pRb.
Expression of RGS16, BCL2L11, BTG-2, IL-6, and STAT4, were measured using qRT-PCR in
the p53 null and pRb mutated osteosarcoma cell line SAOS-2 to investigate if exogenous and
endogenous p53 and pRb interactions could influence expression profiles. Expression of all
transcripts in the p53 and pRb overexpressing SAOS-2 cells was found to be increased with
differences in magnitude of expression similar to the WI38 microarray data and qRT-PCR
results. Differential expression of BCL2L11 was not statistically significant in WI38 cells but
was in SAOS-2 cells overexpressing p53, pRb, or p53 + pRb. Replication of the qRT-PCR
analysis in SAOS-2 cells provided additional information that supports the hypothesis that the
chosen transcripts are involved in the p53 and pRb cross-talk pathway. Interestingly, in the
microarray data, STAT4 was found to be differentially expressed in WI38 cells overexpressing
p53 or pRb but not in cells that overexpressing both genes. However, qRT-PCR analysis found a
statistically significant increase in STAT4 expression in WI38 and SAOS-2 cells overexpressing
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p53 and pRb. The statistical analyses of expression profiling data or the sensitivity of microarray
signal detection could account for the failure to observe differential expression of STAT4 in
WI38 cells overexpressing p53 and pRb.
IPA functional analysis identified enriched cell and molecular functions in p53 and/or pRb
overexpressed WI38 cells
p53, pRb, and p53 + pRb overexpressing cells
Co-expression of p53 and pRb in bladder and cervical cancer cells with mutations or
inactivation of both proteins induced cell cycle arrest and inhibited p53 induced apoptosis [188,
189]. The ability of pRb to inhibit p53-mediated apoptosis suggests co-expression of both genes
can alter gene regulation and ultimately cellular fate. IPA functional analysis was performed on
all three experimental groups plus cross-talk candidate gene sets to determine if co-expression of
p53 and pRb would differentially induce expression of transcripts associated with different
biological functions compared to cells with overexpression of either p53 or pRb. IPA software
cross-references genes and expression changes against Ingenuity Knowledge Base to identify
known connections, diseases, and biological functions associated with a large dataset. The
biological functional analysis information provided by IPA is broken down into molecular and
cellular functions and physiological system development and functions. In the analysis, I was
interested in the biological functional analysis information pertaining to molecular and cellular
functions enriched due to overexpression of p53 and/or pRb. Interestingly, IPA found significant
enrichment in molecular and cellular functions such as cellular development, cellular movement,
cell death and survival, and cellular growth and proliferation in WI38 cells overexpressing p53
and/or pRb with differences in order of significance between groups. Furthermore, cell cycle
regulation and DNA replication recombination and repair did not make the top significant
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molecular cellular functions in cells overexpressing p53 but did in the pRb and p53 + pRb
groups. Also noteworthy, biological functions overrepresented in cells overexpressing p53 + pRb
are a cross between the results obtained from the cells overexpressing p53 or pRb suggesting
activation of both p53 and pRb alters gene expression and cellular fate more than if one tumor
suppressor was activated. This data supports the hypothesis that p53 and pRb coordinate to
regulate cellular functions.
Cross-talk candidate gene sets
Both cross-talk candidate gene sets are differentially expressed when p53 and pRb are
overexpressed together suggesting these candidates could interact with one another. Because of
the possible interaction between the p53 and pRb common and interaction gene sets, we
performed IPA analysis collectively on all of the cross-talk candidate gene sets and separately to
identify enriched cell and molecular functions. Even though it was the larger gene set, IPA
analysis of the interaction gene set, using Benjamini-Hochberg multiple testing correction pvalue, yielded only three IPA annotations significantly enriched (cellular growth and
proliferation, cell cycle, and cellular development) compared to 25 significantly enriched
biological functions in the common gene set.

Collective IPA analysis of all of the cross-talk

candidates increased the amount of cell and molecular functions found to be statistically
significant compared to separate IPA analyses performed on common and interaction gene sets.
In summary IPA identified a significant enrichment in transcripts responsible for development,
cell cycle, apoptosis, and immune response in WI38 cells overexpressing p53 and/or pRb and in
the cross-talk gene sets. Enrichment in similar biological functions in all three experimental
conditions and in the cross-talk gene sets supports the hypothesis that p53 and pRb communicate
to regulate cell outcomes. This study provides information regarding the p53 and pRb cross-talk
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that can be used to better understand how p53 and pRb regulate processes that inhibit cancer
progression and are those vital for organism development.

IPA pathway generation
Identification of known interaction of cross-talk candidates with p53, pRb, and
E2F1-3
IPA pathway tools were used to construct pathways to aid in identifying known up- and
down-stream interactions (i.e. expression, regulation, activation, and protein-protein interaction)
between the cross-talk candidates, p53, pRb, and E2F1-3. These interactions were chosen
because of pRb’s known function as a transcriptional repressor of E2F target genes and the
known involvement of E2F-1 in p53 and pRb cross-talk [18]. From the IPA derived pathways
we were able to 1) determine which cross-talk candidates have previously been found to be
regulated by p53 or pRb, and 2) uncover known interactions between the cross-candidates.
Using IPA software we were able to identify which of the cross-talk candidates were previously
found to be regulated by p53 or pRb, providing a validation of the microarray results [135, 193,
197-205]. Only a few of the downregulated p53 and pRb cross-talk candidates have previously
been found by other studies to be downregulated by p53 (MCM3, BUB1, and CDT1) or pRb
individually (VRK1, MCM3, and CDT1) [190, 206-209]. There are no down-regulated p53 and
pRb commonly expressed cross-talk candidates due to lack of p53 down-regulated transcripts in
the microarray data. Although several of the p53 and pRb cross-talk candidates have previously
been found to be regulated by p53, regulation of these transcripts by pRb has not been reported.
In fact, very few of the p53 and pRb cross-talk candidates have been identified as down-stream
targets of pRb regulation by the IPA database. This lack in knowledge regarding pRb
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transcriptional control can be attributed to lack of studies on the ability of the Rb protein to act as
a transcriptional co-factor. Furthermore, function and regulation of several of the cross-talk
candidates in the common and interaction gene sets remains unknown demonstrating the need for
more research to understand the function of these unknown genes.
Identification of possible signaling nodes in WI38 cells overexpressing p53 and pRb
Also of interest, several cross-talk candidates were found to be centrally located in the
IPA pathways denoting relationships with other cross-talk candidates and the transcription
factors of interest (p53, pRb, or E2F1-3). This observation suggests these candidates may
function as signaling nodes to mediate p53 and pRb downstream effects.

The cross-talk

candidates IL-1β, IL-6, BCL2L11, IL12A, STAT4, BTG-2, NR4A1, HDM2, and BMP-2 were
all found to have a number of interactions between other cross-talk candidates or p53, pRb, or
E2F1-3.

NR4A1, STAT4, and BTG-2 all have transcription regulation activities and are

involved in controlling processes such as differentiation, immune response, and cell cycle arrest
[72, 210, 211].
Several of the signaling nodes (IL12A, IL-1β, and IL-6) are known to play a role in
regulation of immune responses and have been linked to cancer [212, 213]. Contrary to the
expression profiling and qRT-PCR findings, the cytokine IL-6 is transcriptionally repressed by
p53 and pRb in HeLa cells and is usually associated with aiding cancer progression [214].
Despite its role in cancer promotion, IL-6 has also been found to inhibit phosphorylation of pRb
and to aid in cell cycle arrest in growth-sensitive hematopoietic cells [215]. Furthermore, RB1
negative murine fibroblasts have decreased expression of chemokines and cytokines including
IL-6 [216]. With these functions in mind, the role of IL-6 in cells overexpressing p53 and/or
pRb is unclear. Expression of IL-6 and other immune associated factors could be due to p53 and
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pRb induced senescence [217]. Senescence induced by these two tumor suppressors causes an
immune response through secretion of factors collectively referred to as the senescence
associated secretory phenotype (SASP) [218, 219]. In fact several of the immune regulatory p53
and pRb cross-talk candidates upregulated in the microarray data (IL-6, IL-1β, CCL3, and
AREG) are associated with SASP and their expression could be due to the increased levels of
p53 and pRb. [217].

CONCLUSIONS
p53 and pRb are two of the most studied tumor suppressors and function to regulate
many of the same processes. Therefore, it is not surprising similar cell and molecular functions
are enriched in cells overexpressing p53 and pRb. The different order of significance when both
genes are overexpressed suggests that the combination of p53 and pRb alters outcome of the cell
compared to activation of only one tumor suppressor.
By utilizing microarray expression profiling, p53 and pRb regulated candidates or genes
involved in coordinating cancer suppression processes and determining cell fate were identified.
p53 and pRb are not the only pathways involved in cancer suppression and determination of cell
fate, but they are currently the most targeted for mutations in cancer. The investigation of p53
and pRb cross-talk focused on transcriptional regulation as a mechanism for p53 and pRb to
coordinate cell functions and provides a frame work to study the cooperation between p53 and
pRb in determining cell fate. Further studies are required to identify new molecular targets that in
turn could lead to the development of more effective anti-cancer therapies.
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Addendum for Chapter 2
p53 and pRb Interaction Significant Differentially Expressed Gene Set
Systematic
Name

Gene Name

AI911302

AI911302

NM_002632

PGF

NM_018965
A_24_P878366

TREM2
A_24_P878366

NM_198173

GRHL3

NM_017565

FAM20A

THC2668267

THC2668267

THC2565393

THC2565393

A_32_P168727

A_32_P168727

BC073976

BC073976

NM_002590

PCDH8

CD511705

CD511705

NM_138344

C14orf152

Description
AI911302 wd14e10.x1
Soares_NFL_T_GBC_S1 Homo sapiens
cDNA clone IMAGE:2328138 3', mRNA
sequence [AI911302]
Homo sapiens placental growth factor,
vascular endothelial growth factor-related
protein (PGF), mRNA [NM_002632]
CYP4F2
Unknown
Homo sapiens grainyhead-like 3
(Drosophila) (GRHL3), transcript variant 2,
mRNA [NM_198173]
Homo sapiens family with sequence
similarity 20, member A (FAM20A),
mRNA [NM_017565]
Q3MAK1_ANAVT (Q3MAK1)
Phosphoglucomutase/phosphomannomutase
partial (4%) [THC2668267]
Q5VT28_HUMAN (Q5VT28) Family with
sequence similarity 27, member B (Family
with sequence similarity 27, member A)
(Family with sequence similarity 27,
member C), partial (81%) [THC2565393]
Unknown
Homo sapiens cDNA clone IMAGE:
6018774, partial cds. [BC073976]
Homo sapiens protocadherin 8 (PCDH8),
transcript variant 1, mRNA [NM_002590]
AGENCOURT_14360862 NIH_MGC_187
Homo sapiens cDNA clone
IMAGE:30405414 5', mRNA sequence
[CD511705]
Homo sapiens chromosome 14 open
reading frame 152 (C14orf152), mRNA
[NM_138344]
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Average
Fold
Change
86.74

46.762
24.856
21.512
21.126

20.308

19.498

19.246

17.802
17.16
16.226

16.062

15.977

NM_001080468

SYCN

NM_021571

ICEBERG

NM_001082

CYP4F2

NM_000729

CCK

NM_001200

BMP2

NM_133177

PTPRU

THC2642537

THC2642537

NM_023067

FOXL2

NM_003991

EDNRB

NM_004428

EFNA1

NM_004387

NKX2-5

NM_000526

KRT14

NM_003841

TNFRSF10C

NM_000142

FGFR3

NM_152404

UGT3A1

Homo sapiens syncollin (SYCN), mRNA
[NM_001080468]
Homo sapiens ICEBERG caspase-1
inhibitor (ICEBERG), mRNA
[NM_021571]
Homo sapiens cytochrome P450, family 4,
subfamily F, polypeptide 2 (CYP4F2),
mRNA [NM_001082]
Homo sapiens cholecystokinin (CCK),
mRNA [NM_000729]
Homo sapiens bone morphogenetic protein
2 (BMP2), mRNA [NM_001200]
Homo sapiens protein tyrosine phosphatase,
receptor type, U (PTPRU), transcript
variant 2, mRNA [NM_133177]
Q2Q5T5_MOUSE (Q2Q5T5) Embryonic
stem cell-and germ cell-specific protein
ESGP, complete [THC2642537]
Homo sapiens forkhead box L2 (FOXL2),
mRNA [NM_023067]
Homo sapiens endothelin receptor type B
(EDNRB), transcript variant 2, mRNA
[NM_003991]
Homo sapiens ephrin-A1 (EFNA1),
transcript variant 1, mRNA [NM_004428]
Homo sapiens NK2 transcription factor
related, locus 5 (Drosophila) (NKX2-5),
mRNA [NM_004387]
Homo sapiens keratin 14 (epidermolysis
bullosa simplex, Dowling-Meara, Koebner)
(KRT14), mRNA [NM_000526]
Homo sapiens tumor necrosis factor
receptor superfamily, member 10c, decoy
without an intracellular domain
(TNFRSF10C), mRNA [NM_003841]
Homo sapiens fibroblast growth factor
receptor 3 (achondroplasia, thanatophoric
dwarfism) (FGFR3), transcript variant 1,
mRNA [NM_000142]
Homo sapiens UDP glycosyltransferase 3
family, polypeptide A1 (UGT3A1), mRNA
[NM_152404]
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15.905
14.305

12.569
12.407
11.436
11.168

10.941
10.62
10.585
10.517
10.47

10.436

10.17

10.133

10.083

NM_152670

C2orf51

NM_005268

GJB5

NM_000422

KRT17

NM_033120

NKD2

BC063385

TRAα

NM_015879

ST8SIA3

NM_005523

HOXA11

NM_024989

PGAP1

NM_018558

GABRQ

AK125985

AK125985

CB852325

CB852325

NM_002392

MDM2

ENST000003775
25

ENST00000377
525

NM_004755

RPS6KA5

NM_015404

DFNB31

Homo sapiens chromosome 2 open reading
frame 51 (C2orf51), mRNA [NM_152670]
Homo sapiens gap junction protein, beta 5
(GJB5), mRNA [NM_005268]
Homo sapiens keratin 17 (KRT17), mRNA
[NM_000422]
Homo sapiens naked cuticle homolog 2
(Drosophila) (NKD2), mRNA
[NM_033120]
Homo sapiens T cell receptor alpha locus,
mRNA (cDNA clone MGC:71411
IMAGE:4853814), complete cds.
[BC063385]
Homo sapiens ST8 alpha-N-acetylneuraminide alpha-2,8-sialyltransferase 3
(ST8SIA3), mRNA [NM_015879]
Homo sapiens homeobox A11 (HOXA11),
mRNA [NM_005523]
Homo sapiens GPI deacylase (PGAP1),
mRNA [NM_024989]
Homo sapiens gamma-aminobutyric acid
(GABA) receptor, theta (GABRQ), mRNA
[NM_018558]
Homo sapiens cDNA FLJ43997 fis, clone
TESTI4021456. [AK125985]
UI-CF-FN0-afp-n-21-0-UI.s1 UI-CF-FN0
Homo sapiens cDNA clone UI-CF-FN0afp-n-21-0-UI 3', mRNA sequence
[CB852325]
Homo sapiens Mdm2, transformed 3T3 cell
double minute 2, p53 binding protein
(mouse) (MDM2), transcript variant
MDM2, mRNA [NM_002392]
Protein FAM27E1.
[Source:Uniprot/SWISSPROT;Acc:Q5T7N
7] [ENST00000377525]
Homo sapiens ribosomal protein S6 kinase,
90kDa, polypeptide 5 (RPS6KA5),
transcript variant 1, mRNA [NM_004755]
Homo sapiens deafness, autosomal
recessive 31 (DFNB31), mRNA
[NM_015404]
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9.5914
9.5447
9.5142
8.9252

8.706

8.6842
8.521
8.3487
8.2783
8.1169

7.8293

7.8157

7.7762

7.7329

7.657

NM_153268

PLCXD2

AF334945

FKSG43

NM_005755

EBI3

NM_014759

PHYHIP

NM_017495

RBM38

NM_002581

PAPPA

THC2532504

THC2532504

BC085019

GDF5OS

AF140675

ADAMTS7

NM_004097

EMX1

NM_033393

KIAA1727

NM_014872

ZBTB5

ENST000003270
26

ENST00000327
026

NM_017434

DUOX1

NM_007021

C10orf10

NM_144503

F11R

Homo sapiens phosphatidylinositol-specific
phospholipase C, X domain containing 2
(PLCXD2), mRNA [NM_153268]
Homo sapiens FKSG43 (FKSG43) mRNA,
complete cds. [AF334945]
Homo sapiens Epstein-Barr virus induced
gene 3 (EBI3), mRNA [NM_005755]
Homo sapiens phytanoyl-CoA 2hydroxylase interacting protein (PHYHIP),
mRNA [NM_014759]
Homo sapiens RNA binding motif protein
38 (RBM38), transcript variant 1, mRNA
[NM_017495]
Homo sapiens pregnancy-associated plasma
protein A, pappalysin 1 (PAPPA), mRNA
[NM_002581]
Q9BX12_HUMAN (Q9BX12) GTP
binding protein 2 (Fragment), partial (26%)
[THC2532504]
Homo sapiens hypothetical LOC554250,
mRNA (cDNA clone MGC:99835
IMAGE:6650156), complete cds.
[BC085019]
Homo sapiens zinc metalloprotease
ADAMTS7 (ADAMTS7) mRNA, complete
cds. [AF140675]
Homo sapiens empty spiracles homeobox 1
(EMX1), transcript variant 1, mRNA
[NM_004097]
Homo sapiens KIAA1727 protein
(KIAA1727), mRNA [NM_033393]
Homo sapiens zinc finger and BTB domain
containing 5 (ZBTB5), mRNA
[NM_014872]
coiled-coil domain containing 57
[Source:RefSeq_peptide;Acc:NP_932348]
[ENST00000327026]
Homo sapiens dual oxidase 1 (DUOX1),
transcript variant 1, mRNA [NM_017434]
Homo sapiens chromosome 10 open
reading frame 10 (C10orf10), mRNA
[NM_007021]
Homo sapiens F11 receptor (F11R),
transcript variant 4, mRNA [NM_144503]
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7.6269
7.4397
7.3997
7.3405

7.3358

7.2992

7.0938

6.7892

6.4441

6.4091
6.2283
6.0517

6.0306
5.9386
5.8409
5.7322

NM_182608

ANKRD33

NM_152361

EID2B

NM_021176

G6PC2

NM_018897

DNAH7

NM_014454

SESN1

NM_080647

TBX1

NM_203463

LASS6

BU602485

BU602485

NM_148959

HUS1B

NM_006290

TNFAIP3

NM_203286

PVRL1

NM_002283

KRT85

ENST000002927
29

USP41

BP871540

BP871540

A_24_P767699

A_24_P767699

Homo sapiens ankyrin repeat domain 33
(ANKRD33), mRNA [NM_182608]
Homo sapiens EP300 interacting inhibitor
of differentiation 2B (EID2B), mRNA
[NM_152361]
Homo sapiens glucose-6-phosphatase,
catalytic, 2 (G6PC2), transcript variant 1,
mRNA [NM_021176]
Homo sapiens dynein, axonemal, heavy
chain 7 (DNAH7), mRNA [NM_018897]
Homo sapiens sestrin 1 (SESN1), mRNA
[NM_014454]
Homo sapiens T-box 1 (TBX1), transcript
variant C, mRNA [NM_080647]
Homo sapiens LAG1 homolog, ceramide
synthase 6 (S. cerevisiae) (LASS6), mRNA
[NM_203463]
AGENCOURT_10015118 NIH_MGC_142
Homo sapiens cDNA clone
IMAGE:6496567 5', mRNA sequence
[BU602485]
Homo sapiens HUS1 checkpoint homolog b
(S. pombe) (HUS1B), mRNA
[NM_148959]
Homo sapiens tumor necrosis factor, alphainduced protein 3 (TNFAIP3), mRNA
[NM_006290]
Homo sapiens poliovirus receptor-related 1
(herpesvirus entry mediator C; nectin)
(PVRL1), transcript variant 3, mRNA
[NM_203286]
Homo sapiens keratin 85 (KRT85), mRNA
[NM_002283]
Ubiquitin carboxyl-terminal hydrolase 41
(EC 3.1.2.15) (Ubiquitin thioesterase 41)
(Ubiquitin-specific-processing protease 41)
(Deubiquitinating enzyme 41) (Fragment).
[Source:Uniprot/SPTREMBL;Acc:Q3LFD5
] [ENST00000292729]
BP871540 Sugano cDNA library,
embryonal kidney Homo sapiens cDNA
clone HKR00303, mRNA sequence
[BP871540]
Unknown
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5.7262
5.7078

5.7053
5.6555
5.5047
5.4698
5.4147

5.2332

5.2101

5.1853

5.0026

4.9741

4.8886

4.6823
4.5259

NM_004443

EPHB3

NM_021127

PMAIP1

THC2660977

THC2660977

NM_017654

SAMD9

NM_139067

SMARCC2

NM_001280

CIRBP

NM_182616

C15orf38

NM_004627

WRB

NM_020422

TMEM159

NM_022071

SH2D4A

NM_004759

MAPKAPK2

THC2586959

THC2586959

NM_033219

TRIM14

NM_003130

SRI

NM_007203

PALM2AKAP2

NM_181719

TMCO4

Homo sapiens EPH receptor B3 (EPHB3),
mRNA [NM_004443]
Homo sapiens phorbol-12-myristate-13acetate-induced protein 1 (PMAIP1),
mRNA [NM_021127]
Unknown
Homo sapiens sterile alpha motif domain
containing 9 (SAMD9), mRNA
[NM_017654]
Homo sapiens SWI/SNF related, matrix
associated, actin dependent regulator of
chromatin, subfamily c, member 2
(SMARCC2), transcript variant 2, mRNA
[NM_139067]
Homo sapiens cold inducible RNA binding
protein (CIRBP), mRNA [NM_001280]
Homo sapiens chromosome 15 open
reading frame 38 (C15orf38), mRNA
[NM_182616]
Homo sapiens tryptophan rich basic protein
(WRB), mRNA [NM_004627]
Homo sapiens transmembrane protein 159
(TMEM159), mRNA [NM_020422]
Homo sapiens SH2 domain containing 4A
(SH2D4A), mRNA [NM_022071]
Homo sapiens mitogen-activated protein
kinase-activated protein kinase 2
(MAPKAPK2), transcript variant 1, mRNA
[NM_004759]
1PK0_D Chain D, Crystal Structure Of The
Ef3-Cam Complexed With Pmeapp. {Homo
sapiens} (exp=-1; wgp=0; cg=0), partial
(70%) [THC2586959]
Homo sapiens tripartite motif-containing 14
(TRIM14), transcript variant 2, mRNA
[NM_033219]
Homo sapiens sorcin (SRI), transcript
variant 1, mRNA [NM_003130]
Homo sapiens PALM2-AKAP2 protein
(PALM2-AKAP2), transcript variant 1,
mRNA [NM_007203]
Homo sapiens transmembrane and coiledcoil domains 4 (TMCO4), mRNA
[NM_181719]
79

4.03
3.9596
3.9263
0.2496

0.232

0.2308
0.2277
0.2273
0.2263
0.2172

0.2136

0.212

0.211
0.21
0.2083

0.2044

THC2638360

THC2638360

AF256215

ARNTL2

NM_030928

CDT1

NM_001008224

UACA

A_24_P927230

A_24_P927230

NM_020964

KIAA1632

NM_024808

C13orf34

NM_003384

VRK1

NM_002388

MCM3

AB040957

KIAA1524

AK055915

AK055915

NM_203284

RBPJ

NM_014857

RABGAP1L

NM_004695

SLC16A5

NM_004494

HDGF

NM_198969

AES

Q6STG2_HUMAN (Q6STG2) DNA
polymerase-transactivated protein 3, partial
(13%) [THC2638360]
Homo sapiens cycle-like factor CLIF
mRNA, complete cds. [AF256215]
Homo sapiens chromatin licensing and
DNA replication factor 1 (CDT1), mRNA
[NM_030928]
Homo sapiens uveal autoantigen with
coiled-coil domains and ankyrin repeats
(UACA), transcript variant 2, mRNA
[NM_001008224]
Unknown
Homo sapiens KIAA1632 (KIAA1632),
mRNA [NM_020964]
Homo sapiens chromosome 13 open
reading frame 34 (C13orf34), mRNA
[NM_024808]
Homo sapiens vaccinia related kinase 1
(VRK1), mRNA [NM_003384]
Homo sapiens MCM3 minichromosome
maintenance deficient 3 (S. cerevisiae)
(MCM3), mRNA [NM_002388]
Homo sapiens mRNA for KIAA1524
protein, partial cds. [AB040957]
Homo sapiens cDNA FLJ31353 fis, clone
MESAN2000264. [AK055915]
Homo sapiens recombination signal binding
protein for immunoglobulin kappa J region
(RBPJ), transcript variant 4, mRNA
[NM_203284]
Homo sapiens RAB GTPase activating
protein 1-like (RABGAP1L), transcript
variant 1, mRNA [NM_014857]
Homo sapiens solute carrier family 16,
member 5 (monocarboxylic acid transporter
6) (SLC16A5), mRNA [NM_004695]
Homo sapiens hepatoma-derived growth
factor (high-mobility group protein 1-like)
(HDGF), mRNA [NM_004494]
Homo sapiens amino-terminal enhancer of
split (AES), transcript variant 1, mRNA
[NM_198969]
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0.2044
0.2043
0.2038

0.2023
0.2015
0.1988
0.1938
0.1937
0.1906
0.1875
0.1793

0.1661

0.1656

0.1612

0.1605

0.1605

NM_032294

CAMKK1

AK090664

AK090664

NM_012140

SLC25A10

NM_052853

ADCK2

NM_003243

TGFBR3

AK021837

AK021837

NM_016052

RRP15

ENST000003076
62

SYNPO

D14041

RBPJ

NM_173636

WDR62

ENST000003592
36

FLJ20674

NM_018199

EXDL2

THC2607337

THC2607337

ENST000003748
51

C9orf125

NM_175709

CBX7

NM_000916

OXTR

A_32_P171043

A_32_P171043

NM_024827

HDAC11

Homo sapiens calcium/calmodulindependent protein kinase kinase 1, alpha
(CAMKK1), transcript variant 1, mRNA
[NM_032294]
Homo sapiens cDNA FLJ33345 fis, clone
BRACE2003713. [AK090664]
Homo sapiens solute carrier family 25
(mitochondrial carrier; dicarboxylate
transporter), member 10 (SLC25A10),
mRNA [NM_012140]
Homo sapiens aarF domain containing
kinase 2 (ADCK2), mRNA [NM_052853]
Homo sapiens transforming growth factor,
beta receptor III (TGFBR3), mRNA
[NM_003243]
Homo sapiens cDNA FLJ11775 fis, clone
HEMBA1005891. [AK021837]
Homo sapiens ribosomal RNA processing
15 homolog (S. cerevisiae) (RRP15),
mRNA [NM_016052]
Synaptopodin.
[Source:Uniprot/SWISSPROT;Acc:Q8N3V
7] [ENST00000307662]
Homo sapiens mRNA for H-2K binding
factor-2, complete cds. [D14041]
Homo sapiens WD repeat domain 62
(WDR62), mRNA [NM_173636]
CDNA FLJ20674 fis, clone KAIA4450.
[Source:Uniprot/SPTREMBL;Acc:Q9NWQ
7] [ENST00000359236]
Homo sapiens exonuclease 3'-5' domainlike 2 (EXDL2), mRNA [NM_018199]
Unknown
Uncharacterized protein C9orf125.
[Source:Uniprot/SWISSPROT;Acc:Q9BRR
3] [ENST00000374851]
Homo sapiens chromobox homolog 7
(CBX7), mRNA [NM_175709]
Homo sapiens oxytocin receptor (OXTR),
mRNA [NM_000916]
Unknown
Homo sapiens histone deacetylase 11
(HDAC11), mRNA [NM_024827]
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0.1596

0.1593

0.1588

0.1581
0.1574
0.156
0.1462

0.144
0.1431
0.1393
0.1383
0.1366
0.1354
0.1276
0.1259
0.1242
0.1202
0.1186

A_32_P36709

A_32_P36709

NM_024693

ECHDC3

AK125077

AK125077

NM_007331

WHSC1

NM_152913

TMEM130

NM_017915

C12orf48

THC2677783

THC2677783

NM_005498

AP1M2

NM_024490

ATP10A

NM_133468

BMPER

NM_145251

STYX

NM_000882

IL12A

BC047636

BC047636

NM_000891

KCNJ2

NM_016448

DTL

NM_004336

BUB1

Unknown
Homo sapiens enoyl Coenzyme A
hydratase domain containing 3 (ECHDC3),
mRNA [NM_024693]
Homo sapiens cDNA FLJ43087 fis, clone
BRTHA3019105. [AK125077]
Homo sapiens Wolf-Hirschhorn syndrome
candidate 1 (WHSC1), transcript variant 8,
mRNA [NM_007331]
Homo sapiens transmembrane protein 130
(TMEM130), mRNA [NM_152913]
Homo sapiens chromosome 12 open
reading frame 48 (C12orf48), mRNA
[NM_017915]
Unknown
Homo sapiens adaptor-related protein
complex 1, mu 2 subunit (AP1M2), mRNA
[NM_005498]
Homo sapiens ATPase, Class V, type 10A
(ATP10A), mRNA [NM_024490]
Homo sapiens BMP binding endothelial
regulator (BMPER), mRNA [NM_133468]
Homo sapiens serine/threonine/tyrosine
interacting protein (STYX), mRNA
[NM_145251]
Homo sapiens interleukin 12A (natural
killer cell stimulatory factor 1, cytotoxic
lymphocyte maturation factor 1, p35)
(IL12A), mRNA [NM_000882]
Homo sapiens cDNA clone
IMAGE:4822429. [BC047636]
Homo sapiens potassium inwardlyrectifying channel, subfamily J, member 2
(KCNJ2), mRNA [NM_000891]
Homo sapiens denticleless homolog
(Drosophila) (DTL), mRNA [NM_016448]
Homo sapiens BUB1 budding uninhibited
by benzimidazoles 1 homolog (yeast)
(BUB1), mRNA [NM_004336]
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0.1158
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CHAPTER 3.
IDENTIFYING THE ROLE OF RGS16 IN PANCREATIC CANCER CELL
MIGRATION AND INVASION2
SUMMARY
Pancreatic cancer is ranked as the fourth highest cause of cancer-related deaths in the United
States with a five-year survival rate <5%. Pancreatic cancer is associated with early systemic
dissemination resulting in the majority of newly diagnosed patients having aggressive nonlocalized cancer and non-eligibility for curative treatments. New therapies are needed to inhibit
and treat metastatic pancreatic cancer. A study aimed at identifying markers for pancreatic
cancer metastasis found that Regulator of G protein Signaling 16 (RGS16) is downregulated in
patients with lymph node metastases compared to patients with non-lymph node metastasized
pancreatic cancer. RGS16 belongs to a large family of proteins that play a role in swiftly
shutting down G protein-coupled receptor pathways and is implicated in turning off signaling of
several oncogene pathways that are involved in proliferation, migration, and invasion of cancer
cells. Currently, the role of RGS16 in pancreatic cancer is unknown.
We found that the expression of RGS16 mRNA was downregulated in established pancreatic
cancer cell lines compared to mRNA extracted from normal human pancreatic tissue. We
exogenously expressed RGS16 and/or GFP (control) using adenoviral vectors in established
pancreatic cancer cell lines (BxPC-3, PANC-1, or AsPC-1) and measured the impact of RGS16
expression on cell migration, invasion and cell viability. Expression of RGS16 inhibited
migration and invasion of BxPC-3 and AsPC-1 cells but did not modify PANC-1 cell migration.

2

A portion of this work has been submitted and accepted for publication in the journal Genes
and Cancer (see Appendix for draft) or [175].
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RGS16 expression did not alter BxPC-3, PANC-1, or AsPC-1 cell growth stimulated by FBS or
EGF (epidermal growth factor). Experiments investigating the mechanism behind RGS16
suppression of migration and invasion found no change in the levels of phosphorylated AKT and
ERK suggesting RGS16 inhibits pancreatic migration and invasion independent of the
PI3K/AKT and MAPK pathways.
For the first time we have shown that RGS16 inhibits EGF induced migration and invasion of
pancreatic cancer cells. Further studies are needed to elucidate the mechanism(s) used by
RGS16 to inhibit pancreatic cancer cell migration and invasion.

INTRODUCTION
In 2014, the American Cancer Society estimates that approximately 46,420 individuals will
be diagnosed with pancreatic cancer and 39,590 will die from this disease [83]. The one-year
survival rate for all stages of pancreatic cancer is 20% and the five-year survival rate is 6% [83].
An analysis looking at the five-year survival rates of various cancers over a span of thirty years
found that pancreatic cancer had the least improvement from 2% (1975-1977) to 6% (2003 to
2009) [83]. The majority of patients newly diagnosed with pancreatic cancer present with highly
progressed and/or metastatic cancer that is resistant to treatment [84, 85]. Due to the late stage
of diagnosis and the aggressive nature of this disease, less than 20% of pancreatic cancer patients
are eligible for the potentially curative surgery [85, 220]. Therefore, there is a great need for
more effective drugs aimed at treating or preventing metastatic pancreatic cancer.
The presence of lymph-node metastases is regarded as a negative prognostic factor for
patients who have undergone pancreatic surgery [85, 92]. In order to find biomarkers for lymph
node metastasis to aid in patient prognosis, cDNA microarrays were used to analyze gene
expression in local vs. lymph-node metastasized pancreatic cancer [149]. Microarray analysis
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revealed decreased expression of Regulator of G-protein signaling 16 (RGS16) in pancreatic
tumors with lymph-node metastases compared to non-metastasized pancreatic cancer [149].
Immunohistological analysis revealed only 5.7% (1 out of 17) of the pancreatic tumors with
lymph-node metastases had expression of the Regulator of G-protein signaling 16 (RGS16)
compared to 70.6% (12 out of 17) of pancreatic tumors with non-metastasized pancreatic cancer
[149]. Furthermore, decreased expression of RGS16 was associated with poor pancreatic cancer
patient survival indicating the potential of RGS16 as a pancreatic cancer prognostic marker
[149].
RGS16, a signaling molecule we identified as a p53 and pRb cross-talk candidate belongs to
a large family of proteins that play a role in swiftly shutting down G protein-coupled receptor
(GPCR) signaling pathways [134, 135]. RGS16 is a GTPase activating protein (GAP) that
enhances GTPase activity of the α-subunit of G proteins associated with G-protein coupled
receptors (GPCR). RGS16 has been implicated in negatively regulating the MAPK, AKT/PI3K,
RhoA, and SDF-1/CxCR4 oncogene pathways in normal or cancer cell lines [135, 141, 164,
171]. These oncogene pathways have been implicated in cancer progression processes (such as:
proliferation, survival, chemoresistance, migration, invasion, and metastasis) in a variety of
malignancies including pancreatic cancer [221-225].
Few reports have been published that describe the impact of RGS16 on cancer cell signaling
and progression.

Among these are: increased expression of RGS16 in pediatric high

hyperdiploid acute lymphoblastic leukemia (ALL) and colon cancer; however, functional
analysis has not been performed to identify any oncogenic function of RGS16 in these cancers
[147-149]. Functional and expression analysis of RGS16 has been performed in breast cancers.
The RGS16 promoter is located at a site that is vulnerable to allelic imbalances that can result in
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promoter methylation of RGS16 in 10% of breast cancers with these genomic instabilities [150].
Liang et al. (2009) found that RGS16 overexpression in breast cancer cell lines decreased EGF
induced proliferation and AKT activation by binding to the p85-alpha subunit of PI3K
preventing the phosphorylation of AKT [171]. RGS16 has also been associated with the antiproliferative effect of retinoic acid in neuroblastoma cells and the cytotoxity effect of the histone
deacetylase inhibitor Vorinostat and lysine-specific demethylase 1 knock-down in triple negative
breast cancers [162, 163]. The current data suggest RGS16 plays a role in cancer signaling,
however, more research is needed to delineate the function of RGS16 in cancer cells.
Due to pre-existing data on RGS16 expression and function, we hypothesized that exogenous
expression of RGS16 would inhibit migration and proliferation of pancreatic cancer cells in
vitro. We chose to focus our investigations on EGF induced migration and invasion because 1)
RGS16 inhibits EGF signaling in breast cancer cells, and 2) the epidermal growth factor receptor
(EGFR/ERBB-1) is overexpressed in ~85% of pancreatic cancers, and is linked with
development, invasion, and decreased survival in this deadly disease [110, 115, 226, 227].
Currently, RGS16 has not been linked with inhibition of cancer cell metastasis nor has its
function been investigated to understand the consequences of its downregulation in metastasized
pancreatic cancer.
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MATERIALS AND METHODS
Cell culture and virus transductions
The pancreatic cancer cell lines BxPC-3, AsPC-1, MIA PaCa-2, and PANC-1 (described in
Table 4.1) were purchased from the American Type Culture Collection (Manassas, VA, USA).
BxPC-3, AsPC-1, MIA PaCa-2 and PANC-1 cells were grown in complete media (RPMI
supplemented with 10% fetal bovine serum (FBS) (PAA Laboratories, Dartmouth, MA) and 1%
Penicillin Streptomycin (P/S) (Mediatech, Inc. A Corning Subsidiary, Manassas, VA), RPMI
supplemented with 15% FBS and 1% P/S or DMEM with 10% FBS and 1% P/S respectively).
All cell lines were cultured at 37°C in a humidified 5% CO2 incubator.
Ad.GFP (adenovirus containing GFP) and Ad.GFP.RGS16 (Adenovirus containing
RGS16 and reporter gene GFP) viruses were purchased from Vector Biolabs (Philadelphia, PA).
Viruses were amplified and tittered as previously described [183-185]. For each type of virus,
concentration of 50 MOI (multiplicity of infection) were added to pancreatic cancer cells in
media supplemented with 2% heat-inactivated Hyclone FBS (GE Healthcare Life Sciences,
Pittsburgh, PA).
Quantitative Real-time PCR analysis
Total RNA was isolated from cells using TRIzol reagent (Invitrogen, Carlsbad, CA)
according to the manufacturer’s protocol. Total RNA (2ug) was reverse transcribed into cDNA
using the High Capacity cDNA Reverse Transcription kit from Applied Biosystems (Foster City,
CA) according to the manufacturer’s protocol.

Real-Time PCR was performed using the

Applied Biosystems TaqMan Gene Expression Assays in the ABI 7000 detection system.
TaqMan probes were purchased from Applied Biosystems [RGS16 (HS00892674_m1), and
GAPDH (HS02758991)]. The relative fold change for each marker was calculated using the 2ΔΔCT

analysis according to Livak et.al and statistical significance was determined using a one
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way ANOVA with a Tukey’s post-hoc test using Prism V6.0c (GraphPad Software, Inc., La
Jolla, CA) [187].
Wound Healing Assay
Pancreatic cancer cells (BxPC-3, AsPC-1 and PANC-1) were placed in a 6 well plate at
approximately 70% confluency. The following day, 50 Multiplicity of Infection (MOIs) of
Ad.GFP (control) or Ad.GFP.RGS16 were added to the cells in media containing 2% heatinactivated FBS and incubated for 24 hours. The media was then changed to complete media
(10% FBS for BxPC-3 and PANC-1 or 15% for AsPC-1) and cells incubated for 24hrs. Forty
eight hours after the addition of the virus the media was changed from complete media to media
supplemented with 0.5% FBS and 1% P/S and the cells incubated for additional 24-hours. The
media was replaced with PBS and three wounds or scratches were made per well using a p200
pipette. The cells were washed three times with PBS and incubated for 16-24 hours in complete
media or media supplemented with 100ng/ml of EGF. EGF was added to induce cell migration
at a concentration previously described in [228-230]. Wound widths were measured and images
taken at 0, 16, or 24 hrs after addition of media supplemented with FBS or EGF at 100x
magnification using an Olympus DP71 microscope (Center Valley, PA). Efficacy of virus
transduction was confirmed using fluorescent microscopy to examine GFP expression prior to
the start of the experiment. Percent wound healing was determined using the following equation;
% wound-healing = ([initial scratch width

–

final scratch width]/ initial scratch width) X 100.

Three independent replicates were performed for each cell line.
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MTT Assay
BxPC-3, AsPC-1, and PANC-1 cells (5,000) were plated in quadruplicate in a 96 well
tissue culture dish and incubated for 24 hours at 37֯C. The pancreatic cancer cells were treated as
described in the wound healing assay section. After the cells were serum starved (media
supplement with 0.5% FBS and 1% P/S) for 24-hours complete media or media supplemented
with 100ng/ml of EGF were added to the cells. A 1:10 dilution of MTT (thiazolyl blue
tetrazolium bromide; MP Biomedicals; Santa Ana, CA) stock solution (5mg/ml diluted in PBS),
was added to the media of the cells followed by a 2 hour incubation at 37֯C. The media was
removed and DMSO was added to the cells to solubilize the purple formazan crystals.
Absorbance (560nm) was determined at 0, 24, 48, and 72 hours after addition of supplemented
media using the SpectraMax M2e Molecular Devices (Sunnyvale, CA). Cell viability fold change
was calculated using the average absorbance for each treatment group at 24, 48, or 72 hours
divided by the initial absorbance at time zero. Percent viability was calculated using the average
absorbance for each treatment divided by the average absorbance for the cells not treated with
virus and multiplied by 100. Statistical significance was assessed using Student’s t-test by Prism
V6.0c. The experiment was repeated 3 independent times.
Invasion Assay
BD Bio Coat Matrigel coated polycarbonate invasion chambers (Bedford, MA)
containing membranes with 8um pores were used to assess the ability of RGS16 to inhibit
pancreatic cancer cell migration and invasion. BxPC-3 cells were plated into 6-well dish at 70%
confluency, 24 hours later 50 MOIs of Ad.GFP or Ad.GFP.RGS16 virus were added to the cells
followed by 24 hour incubation in complete media and 24 hours in low-serum media as
described in the wound-healing section. Chambers were re-hydrated in RPMI containing 1% P/S
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and 0.1 % Bovine serum albumin (BSA, Fisher Scientific, Waltham, MA) for 2 hours at 37°C.
BxPC-3 and AsPC-1 cells were collected and 25 x 104 cells were added to the top of the
chambers in RPMI supplemented with 1% P/S and 0.1% BSA. RPMI supplemented with
100ng/ml EGF, 1% P/S, 0.1% BSA was added to lower portion and the chambers were incubated
for 18- (AsPC-1) or 20- (BxPC-3) -hours at 37°C. Time points were determined by literature
and previous preliminary experiments to optimize conditions of the assay. The non-migrating
cells were removed using a cotton swab and the invaded cells were fixed using 100% methanol
(MeOH) for 5 minutes and stained using 0.5% crystal violet plus 20% MeOH (10-15 mins).
Invaded cells were counted using 200x magnification with 12 different views. Percentage of
invasion compared to GFP control was calculated for each cell line [(# of invaded cellstreated / # of
invaded cellcontrol) x 100]. Three replicates were performed for each cell line.
Western Blot Analysis
AsPC-1 and BxPC-3 cells were treated to express GFP and/or RGS16 using adenoviruses
as described in the wound healing assay section. Cells were collected after 0 min, 15 mins, 1
hour and 24 hours after addition of EGF. Cells were lysed in RIPA (Radioimmunoprecipitation
assay) buffer plus protease inhibitors (Pierce Protease inhibitor Tablets 88661; Thermo
Scientific, Rockford, IL).

Protein extracts (35-60ug) were loaded onto 10% or 12%

polyacrylamide gels and proteins were separated using sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE). Blots probed with mouse anti-panAKT (40D4, 1:2000), rabbit
anti-phospho-AKT (p-AKT, S473 D9E, 1:2000), rabbit anti-phospho-p44/42 MAPK (p-ERK1/2,
Thr202, Tyr204, D13.14.4E, 1:2000), rabbit anti-p44/42 MAPK (total-ERK1/2, 137F5, 1:1000)
antibodies from Cell Signaling Technology (Danvers, MA) were blocked in 5% BSA in Trisbuffered saline solution pH 7.6 containing 0.1% Tween-20 (TBS-T).
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Blots probed in rabbit

anti-E-cadherin (Santa Cruz Technologies, Dallas, TX, 1:1000), rabbit anti-RGS16 (Proteintech,
Chicago, IL, 1:250-1:500, band detected at 23kDa) mouse anti-GAPDH (Chemicon
International, Temecula, CA, 1:1000) or mouse anti-vimentin (AF-14b, 1:500) were blocked an
hour in 5% dry non-fat milk diluted in TBS-T. The anti-vimentin (AMF14b), monoclonal
antibody developed by Fulton, A.B. was obtained from the Developmental Studies Hybridoma
Bank, created by the NICHD of the NIH and maintained at The University of Iowa, Department
of Biology, Iowa City, IA 52242. Membranes were probed in primary antibody overnight at 4°C
on a rocker. Following primary antibody incubation the membranes were washed and probed
with Horseradish peroxidase (HRP)-conjugated goat anti-mouse (1:5000) or goat anti-rabbit
(1:10000) secondary antibodies (Rockland, Gilbertsville, PA) for 1 hour at room-temperature.
Primary and Secondary antibodies were diluted in TBS-T. Amersham ECL prime western
blotting detection reagent was added to visualize the protein bands (RPN 2232, GE Life
Sciences, Pittsburgh, PA).

Western blot images were captured using a FOTODYNE

FOTO/Analyst FX (Hartland, WI) imaging camera.

Densitometry was performed using

TotalLab Quant software (TotalLab Ltd, UK).
Phalloidin F-actin staining
BxPC-3 and AsPC-1 cells were plated into a six well dish at 70% confluency for
adenovirus treatment and after 24 hours the cells were treated with 50 MOIs of Ad.GFP or
Ad.RGS16 for 24 hours. Cells were washed with PBS and plated into a Lab-TekII chamber slide
system (Thermo Fisher Scientific, Waltham, MA) with a concentration of 50,000 cells/well and
incubated for 24 hours in complete media. Cells were then incubated in low serum (0.5% FBS)
supplemented media for 24 hours. Media supplemented with EGF (100ng/ml) was added to the
cells for 15 min (BxPC-3) or 30 min (AsPC-1) to induce cytoskeleton rearrangement. Time
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points were determined by literature and previous preliminary experiments to optimize
conditions of the assay. Cells were fixed in 4% paraformaldehyde in PBS (Fisher Scientific) for
15 min and permeabilized using 0.1% Triton X-100 in PBS containing 1% BSA at room
temperature. Cells were blocked for 30 min in PBS containing 1% BSA at room temperature
followed by 30 min incubation of a final concentration of 50nM of Acti-stain 555 Fluorescent
Phalloidin (Cytoskeleton, Inc., Denvir, CO) at room-temperature in a dark humid chamber. Cells
were washed 3x in PBS + 1% BSA for 5 minutes and the nuclei were stained with 300nM DAPI
for 2 min and the cells washed 3x in PBS + 1% BSA for 5 minutes. F-actin was visualized at
400x and 1000x using an Olympus DP71 microscope with a mercury fluorescent light source ULH100HG (Center Valley, PA). The staining for phalloidin was performed three independent
times in the AsPC-1 cells.
Statistical Analysis
All data were expressed as the mean ± SEM and represented using Graph Pad Prism
V6.0c software (GraphPad Software, Inc., La Jolla, CA). Differences between control and
treated samples for the MTT (viability fold change), wound healing and invasion assay were
analyzed by using Student’s t-test (Graph PadPrism V6.0c). Differences for percent viability
determined by MTT assay was analyzed by two-way ANOVA with Dunnet’s post-hoc test for
multiple comparisons. Data from real-time PCR were analyzed by one-way ANOVA followed
by Tukey post-hoc test. Additional statistical analysis used for qRT-PCR analyses are listed in
the respective section. Data was considered significant when the p value was less than 0.05.
Statistical Analysis tests used for qRT-PCR analyses are listed in the respective section.
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Table 3.1: Characterization of pancreatic cancer cell lines [51, 111, 231, 232]
p53

p16

Ras

EGFR

mt
del
wt
high
BxPC-3
mt
del
mt
high
PANC-1
mt
mt
mt
high
AsPC-1
del
mt
low
MiaPaCa-2 mt
mt = mutant, del = deleted, wt = wild-type

Differentiation

Origin

Metastasis

moderate
poor
poor
poor

primary
primary
metastatic (ascites)
primary

no
yes
yes
no

RESULTS
mRNA expression of RGS16 is decreased in pancreatic cancer cell lines.
We first investigated the relative expression of RGS16 mRNA in the BxPC-3, MiaPaCa2, PANC-1, and AsPC-1 pancreatic cancer (pancreatic ductal adenocarcinomas) cell lines in
order to characterize the endogenous expression of RGS16. Expression of RGS16 was measured
by qRT-PCR analysis and the relative RGS16 mRNA fold change was calculated in the four
pancreatic cancer cell lines compared to total RNA from normal human pancreatic tissue.
Expression of RGS16 was decreased in all four pancreatic cancer cell lines compared to control
with BxPC-3 having the highest expression of RGS16 mRNA (Figure 3.1). Expression of
RGS16 varied between the four pancreatic cancer cell lines with BxPC-3 and MIA PaCa-2
having significantly higher expression of RGS16 than PANC-1 and the metastatic derived AsPC1 cells. Higher RGS16 expression was found in the more differentiated and less aggressive cell
line, while less RGS16 expression correlated with the more aggressive and/or metastatic cell
lines (Table 3.1).
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Figure 3.1: Decreased expression of RGS16 mRNA relative to total RNA extracted from
normal human pancreatic tissue. Expression of RGS16 was measured using qRT-PCR in
BxPC-3, MiaPaCa-2, PANC-1, and AsPC-1 cells. Relative fold change was measured using total
RNA extracted from normal human pancreatic tissue as the control. One-way ANOVA with
Tukey’s test for multiple comparison were used to test for statistical significance between the cell
lines and control * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001, and **** p-value <
0.0001.
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Expression of RGS16 inhibited migration of BxPC-3 and AsPC-1 pancreatic cancer cells
but not PANC-1.
To test the hypothesis that RGS16 inhibits pancreatic cancer cell migration, we
exogenously expressed RGS16 in BxPC-3, PANC-1, and AsPC-1 cells with an adenoviral vector
and used wound-healing assays to measure cell migration. We chose BxPC-3, PANC-1, and
AsPC-1 because these three cell lines are derived from tumors with varying expression of
RGS16, differentiation status, mutations, presence of metastases, and expression of Epidermal
Growth Factor Receptor (Table 3.1). EGF was used to stimulate cell migration therefore; we did
not use the MiaPaCa-2 cell line because of the lower levels of EGFR (Table 3.1). We RGS16
was expressed using Adenoviruses that contain RGS16 plus a GFP reporter (Ad.GFP.RGS16).
An Adenovirus expressing GFP (Ad.GFP) was used as the vector control. Expression of RGS16
protein correlated with GFP expression in cells treated with Ad.GFP.RGS16 (Figure 3.2).
Fluorescent microscopy was used to determine viral transductions prior to experiment (Figures
3.3a, 3.4a, and 3.5a). Overexpression of RGS16 significantly inhibited FBS and EGF induced
migration of BxPC-3 cells and FBS induced migration of AsPC-1 cells, but had no effect on FBS
and EGF induced migration of PANC-1 cells (Figures 3.3-3.5). Interestingly, expression of
RGS16 in BxPC-3 cells incubated in media supplemented with EGF caused an increase in
wound width compared to control 16 hours after the start of the experiment.
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Figure 3.2: Fluorescence of GFP associated with RGS16 protein expression in cells
treated with Ad.GFP.RGS16. Cells were plated and received the following treatment: 1)
untreated cells, 2) Ad.GFP and 3) Ad.GFP.RGS16 treated cells. Cells were incubated in
complete and low serum media 24 hours each. A) Images of GFP fluorescence were taken
72 hours after treatment and B) protein expression for RGS16 and GAPDH was assessed by
western blot analysis.
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Figure 3.3: Expression of RGS16 inhibited migration of BxPC-3 cells.
BxPC-3 cells were transduced with 50 MOI of Ad.GFP (CTRL) or Ad.GFP.RGS16. A)
Virus transduction was verified by fluorescent microscopy. B) Images (100x) and
measurements of wounds were taken prior and 16 hours after addition of media
supplemented with FBS (10%) or EGF (100ng/ml). The dashed lines represent size of
scratch at time 0. C) Mean Percentage of wound healing ± SEM of three separate
experiments (three scratches/well) was determined. Student’s t-test was used to determine
statistical significance compared to control * p-value < 0.05, ** p-value < 0.01.

97

Figure 3.4: Expression of RGS16 did not inhibit migration of PANC-1 cells.
Wound healing assays were performed as described in Figure 3.3 A) Fluorescent microscopy
was used to verify virus transductions: B) Images (100X) were taken and C) percentages of
wound healing were calculated at 24 hrs after the addition of media supplemented with FBS or
EGF.
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Figure 3.5: Expression of RGS16 inhibited migration of AsPC-1 cells.
Wound healing assays were performed as described in Figure 3.3. A) Fluorescent microscopy was
used to verify virus transductions: B) Images (100X) were taken and C) percentages of wound
healing were calculated at 24 hrs after the addition of media supplemented with FBS or EGF, * pvalue < 0.05.
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Expression of RGS16 inhibited EGF induced invasion of BxPC-3 and AsPC-1 cells.
Since RGS16 inhibited EGF induced migration of BxPC-3 and AsPC-1 cells, matrigel
invasion chambers were used to investigate whether RGS16 could also inhibit EGF induced
invasion of these pancreatic cancer cells. Media supplemented with EGF was used as the
chemoattractant to induce migration and invasion of BxPC-3 and AsPC-1 cells expressing GFP
and or RGS16. Compared to control cells. RGS16 expression significantly inhibited EGF
induced invasion of the BxPC-3 and AsPC-1 cells by 35.73% and 66% respectively(Figure 3.7).

Figure 3.6: Expression of RGS16 inhibited invasion of BxPC-3 and AsPC-1 cells.
Matrigel invasion chambers were used to measure cell migration and invasion of GFP and/or
RGS16 expressing BxPC-3 (A & B) and AsPC-1 (C & D) cells using EGF as a
chemoattractant. Migrated cells were stained with Crystal Violet and counted at 200x
magnification (A &C). Percent invasion was calculated for each cell line (B & D) * p-value <
0.05.
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Expression of RGS16 using adenoviruses did not modify cell viability
The results from the wound healing assays demonstrated an increase in the wound width
of BxPC-3 cells treated with Ad.GFP.RGS16 and incubated in media supplemented with EGF.
This effect could be due to a decrease in the number of viable cells caused by expression of
RGS16 or by a cytolytic effect of adenoviruses.

MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-

diphenyltetrazolium bromide) assays were used to determine if expression of RGS16 or infection
with the adenoviruses affects the viability of the pancreatic cancer cell lines. The cells were
serum starved for 24 hours to remove any pre-existing growth factors. Complete media
containing FBS (10 or 15%) or EGF (100 ng/ml) was added to induce growth of the pancreatic
cancer cells. Absorbance was measured at 0, 24, 48, and 72 hours following the addition of FBS
or EGF. The fold change of viable cells after 24, 48, and 72 hours compared to initial viable cell
number was calculated for BxPC-3, AsPC-1, and PANC-1 cells treated with Ad.GFP or
Ad.GFP.RGS16. Expression of RGS16 did not alter the number of viable BxPC-3, PANC-1 or
AsPC-1 cells stimulated with FBS or EGF (Figure 3.7A – 3.7C). The percentage of viable
BxPC-3 and AsPC-1 cells treated with Ad.GFP or Ad.RGS16 was not significantly different
compared to no virus treated controls (NV FBS or NV EGF) for any of the time points (Figure
3.7D and 3.7E). There was a significant 20-25% mean drop in cell viability for PANC-1 cells
treated with Ad.GFP or Ad.GFP.RGS16 48 and 72 hours after the addition of FBS to serum
starved cells (Figure 3.7F). However, all migration and invasion experiments were completed at
a time in which there was no significant change in the percentage of viable cells (experiment
completion ≤ 24 hours). The results from the MTT assays suggest that RGS16 expression does
not have an impact on BxPC-3, PANC-1, and AsPC-1 cell viability and the concentration of
virus used to transduce RGS16 was tolerated by the pancreatic cancer cells.
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Figure 3.7: Expression of RGS16 did not alter number of viable cells and concentration
of Adenoviruses used was tolerated by BxPC-3, PANC-1, and AsPC-1 pancreatic cancer
cells. A-C) The fold change of viable cells was calculated by comparing the initial
absorbance (0HR) compared to absorbance for 24, 48, and 72 hours after the addition of
complete media or media supplemented with 100ng/ml of EGF (mean fold change of viable
cells +/- SEM of three separate experiments) Statistical significance was tested using paired
Student’s t-test. D-F) Effect of Adenoviruses on number of viable pancreatic cancer cells was
determined by calculating the % viability by comparing the number of viable cells treated
with Ad.GFP or Ad.GFP.RGS16 to cells that were not treated with viruses. Data represents
mean % of viable cells +/- SEM of three separate experiments. Statistical significance was
tested using two-way ANOVA with Dunnet’s post-hoc test for multiple comparisons.
*P<0.05, # P<0.01 (NV = No virus)
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Expression of RGS16 did not alter EGF induced expression of p-AKT (phosphorylated
AKT), p-ERK (phosphorylated ERK).
Our next step was the investigation of the mechanism(s) employed by RGS16 to regulate
EGF induced cell migration and invasion. Activation of EGFR by EGF initiates a signaling
cascade that is most commonly associated with activation of the PI3K/AKT and mitogen
activated protein kinase (MAPK) pathways [110, 114]. Phosphorylation and activation of AKT
or ERK1/2 (MAPK) are both known to phosphorylate downstream signaling molecules and
transcription factors that are responsible for promoting cell migration and invasion [119, 233235]. Protein expression of p-AKT and p-ERK in BxPC-3 and AsPC-1 cells treated with EGF
were determined in order to delineate if one or both of these pathways is regulated by RGS16.
Resulting in the inhibition of EGF induced migration and invasion. There was no change
detected in the protein levels of p-AKT or p-ERK following 15 minutes of EGF treatment of
BxPC-3 or AsPC-1 cells expressing RGS16 compared to GFP controls (Figure 3.8). This data
suggests RGS16 inhibits migration and invasion of the pancreatic cancer cells independently of
AKT and ERK activity.
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Figure 3.8: RGS16 did not alter expression of phosphorylated AKT (p-AKT) or
phosphorylated ERK (p-ERK). Western blot analyses were used to examine levels of
phosphorylated AKT and ERK in BxPC-3 and AsPC-1 cells expressing GFP and/or RGS16
treated with or without EGF for 15 min (A). The mean fold change +/- SEM of p-AKT/total AKT
(t-AKT) and p-ERK/total ERK (t-ERK) was calculated using densitometry analysis (B & C).
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Investigation of RGS16’s Efect on epithelial mesenchymal transition markers and
cytoskeleton rearrangement
Next we examined if expression of RGS16 inhibits cell migration and invasion by
preventing epithelial mesenchymal transition (EMT) in BxPC-3 and AsPC-1 cells. EGF
promotes EMT by decreasing the expression of the epithelial cell-cell adhesion molecule Ecadherin and increasing the expression of mesenchymal phenotype markers such as vimentin,
fibronectin, and n-cadherin; these mesenchymal proteins allow cell migration and invasion [116,
126]. Using western blot analysis, we examined the expression of vimentin and E-cadherin 1
hour and 24 hours following EGF treatment. Expression of RGS16 up-regulated E-cadherin
protein levels in BxPC-3 but not in the metastatic AsPC-1 cells (Figure 4.10). Furthermore,
vimentin expression did not change in either BxPC-3 or AsPC-1 cells expressing RGS16
compared to the GFP control (Figure 3.9).
Rearrangement of the actin cytoskeleton is an integral part of cancer cell migration and
invasion and it is regulated by members of the Rho GTPase family.

Activation of the

EGF/EGFR pathway initiates actin cytoskeleton rearrangement through activation of Rho
GTPases (Cdc42, RhoA, Rac1) that aide in the migration of cancer cells [121, 122, 236]. We
treated serum starved cells expressing GFP and or RGS16 with EGF for 15- (BxPC-3) or 30(AsPC-1) minutes and stained the F-actin of the cells using phalloidin. There was no obvious
difference in the arrangement of the F-actin in BxPC-3 and AsPC-1 cells expressing RGS16
compared to GFP controls (Figure 3.10). Both cell lines contain a heterogeneous population
making it difficult to quantify a difference in the actin organization between cells expressing
GFP and/or RGS16.
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Figure 3.9: RGS16 increased expression of E-cadherin in BxPC-3 cells but not AsPC-1 and
did not alter vimentin expression in either cell line. Western blots were used to determine Ecadherin and Vimentin expression in BxPC-3 and AsPC-1 expressing GFP and/or RGS16 (A &
C) and treat with EGF for 24h. Mean fold change +/- SEM of EMT markers was calculated
using densitometry analysis for both EMT markers (B & D). * p-value < 0.05
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Figure 3.10: F-actin of BxPC-3 and AsPC-1 cells did not show obvious
reorganization in cells expressing GFP and/or RGS16. BxPC-3 and AsPC-1 cells
expressing GFP and/or RGS16 were treated with EGF for 15(BxPC-3) or 30 (AsPC-1) minutes,
fixed, and stained using Phalloidin conjugated to rhodamine and Dapi cells were imaged at (A &
B) 400x or (C) 1000x
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DISCUSSION
Pancreatic cancer and RGS16 significance
A large portion of patients newly diagnosed with pancreatic cancer present with metastatic or
locally advanced disease resulting in their ineligibility for curative pancreatic surgical resection
[237]. Early dissemination and aggressiveness of this disease contributes to the dismal survival
rates of pancreatic cancer [237, 238]. Loss of RGS16 has been identified as a possible marker
for lymph node metastasis in pancreatic cancer; however, the function of RGS16 is unknown
[149]. We, for the first time, showed that RGS16 expression inhibits pancreatic cancer cell
migration and invasion suggesting that loss of RGS16 could be important in the metastatic
process.
New treatments are needed to prevent or treat advanced or metastatic cancer. However, in
order to develop new treatments we need a better understanding of the molecular changes that
occur in pancreatic cancer. We identified RGS16 as a p53 and pRb cross-talk candidate (Chapter
2). RGS16 has been of interest to further our studies for two reasons: 1) RGS16 regulates
GPCRs, which are common targets for deregulation in cancer and 2) RGS16 has been linked to
regulating the MAPK/RAS, PI3K/AKT, RhoA, and SDF-1/CxCR4 oncogene pathways [133,
135, 141, 164, 171]. Investigations have found that oncogene pathways can feed into one
another and bypass or overcome the inhibitory effects of monoclonal antibodies or other targeted
inhibitors. For example, in melanoma, increased production of VEGF or increased expression or
activation of the platelet-derived growth factor receptor-β or insulin-like growth factor-1 receptor
is associated with resistance to BRAF inhibitors, demonstrating mechanisms cancer cells use to
overcome single target modalities [239]. Therefore investigation of RGS16, a protein known to
modulate several oncogene pathways will aid in understanding mechanisms by which cells alter
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multiple signaling pathways to prevent carcinogenesis. This information could then be used for
future drug development.
RGS16 and cell migration and invasion
RGS16 has been linked with inhibition of cell migration in canonical (through regulation
of GPCR signaling) and non-canonical pathways in normal cells. RGS16 inhibits
megakaryocytes and T lymphocyte migration by regulating the activation of the GPCR CxCR4
and decreasing T helper type 2 and 17 cell trafficking through regulation of CCR4 and CCR10
chemokine pathways representing the canonical form of RGS signaling [136, 137, 141]. The
activation of RhoA, a small GTPase involved in reorganizing actin cytoskeleton and mediating
EGF induced pancreatic cell invasion is inhibited in MCF-7 cells by RGS16 preventing the
relocation of Gα13 to the plasma membrane thus blocking Gα13 mediated activation of RhoA
[164, 240]. The regulation of RhoA activation by RGS16 is an example of a non-canonical, nonGPCR-mediated mechanism.

There are no published reports demonstrating inhibition or

activation of cell invasion by RGS16. However, another member of the R4 subfamily of RGS
proteins, RGS4, suppresses breast cancer migration and invasion in vitro and in vivo by
regulating PAR-1, CxCR4 signaling, and RAC-1 lamellipodia formation [241].
Ours is the first report demonstrating a role of RGS16 in inhibiting EGF induced cell
migration and invasion. The GPCR CxCR4 is aberrantly expressed in malignant and cancer
stem cells and contributes to pancreatic cancer progression by aiding in gemcitabine resistance,
cell migration, and invasion [173, 222, 242, 243]. Although our studies focused on EGF induced
cell migration and invasion, RGS16 may be able to inhibit other pathways that mediate cell
migration and invasion such as CxCR4.

109

EGF and pancreatic cancer signaling
RGS16 and EGF induced activation of the PI3K and AKT pathways
Pancreatic carcinomas have overexpression or amplification of the tyrosine kinase
receptors EGFR/erbB1 (~85%) or HER2/erbB2 (2%) [110, 244]. Activation of EGFR by its
ligands EGF or TGFα induces or enhances activation of a variety of signaling pathways
including PI3K/AKT, MAPK, SRC, PLC, and the small Rho GTPases (Rac1,RhoA, RhoC, and
Cdc42) [114, 121, 122]. These pathways are involved in activating processes that enhance cell
proliferation, migration, invasion, EMT, and metastasis in pancreatic cancer [119, 126, 233]. For
example, both AKT and ERK can aid in cell migration and invasion through regulating
production of matrix metalloproteinase 9 [233, 245]. Mutations downstream of EGFR resulting
in AKT2 amplification or constitutive activation of K-Ras (MAPK pathway) also occur in
pancreatic cancer, making EGFR and its downstream components popular targets for pancreatic
cancer treatments [96, 109].

We investigated whether RGS16 can inhibit EGF induced

migration and invasion via regulation of AKT and ERK (MAPK). A study conducted using
breast cancer cells found that RGS16 knockdown resulted in an increase rate of EGF induced
proliferation in these cells due to increase in p-AKT [171], suggesting that RGS16 may regulate
proliferation by preventing the phosphorylation and activation of AKT. In our studies, RGS16
had no effect on the number of viable pancreatic cancer cells and did not decrease the protein
levels of p-AKT compared to control. Our conflicting results could be due to two possibilities,
1) RGS16 targets different signaling pathways in pancreatic cancer compared to breast cancer or
2) mutations in pancreatic cancer (for example K-Ras or AKT2) overcome the inhibitory effect
of RGS16 on pancreatic cancer viability or activation of AKT.
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RGS16 can inhibit MAPK activation via regulation of G proteins associated with GPCRs
[135]. However, other RGS molecules are known to directly interact and regulate localization
and activity of members in the MAPK cascade. We examined the expression of phosphorylated
ERK and found no change in BxPC-3 and AsPC-1 cells expressing RGS16 relative to the GFP
controls. Our data suggests RGS16 inhibits EGF induced migration and invasion independently
of the PI3K/AKT and MAPK pathways.
RGS16 and EGF induced activation of EMT and F-actin rearrangement
Cancer cells can adapt a mesenchymal phenotype aiding in their dissociation and migration
to a distant site [126].

EGF can induce EMT in a variety of cancer cells by decreasing

expression or localization of E-cadherin and increasing the expression of EMT markers such as
N-cadherin, vimentin, and fibronectin [116, 246]. Knockdown of EGFR in the pancreatic cancer
cell line PANC-1 inhibited EMT and decreased cell migration and invasion [116]. RGS16 may
play a role in regulating E-cadherin. Triple negative breast cancer cells that were knocked-down
for lysine-specific demethylase1 (LSD1) and treated with the histone deacetylase inhibitor
(SAHA) had increased expression of RGS16 that was vital for growth suppression and increased
expression of E-cadherin [163]. Our studies showed increased expression of E-cadherin in
BxPC-3 cells expressing RGS16 compared to GFP control. We did not see a change in the
expression of E-cadherin in the metastatic cell line AsPC-1. This could be due to the differences
in the status of K-Ras in AsPC-1 (mutant) vs. BxPC-3 (wild-type) cells. Studies in prostate
cancer cells overexpressing K-Ras found that increased hypermethylation of E-cadherin
promoter mediated by K-Ras prevented E-cadherin expression [247]. Promoter methylation or
other processes regulated by mutated K-Ras could be responsible for prevention of E-cadherin
expression in AsPC-1. Our data suggests RGS16 may have a role in regulating E-cadherin
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expression, however, further studies are needed to determine if increased expression of Ecadherin aids in the inhibition of BxPC-3 cell migration and invasion. We did not find a change
in vimentin expression. However in addition to the amount of this protein, phosphorylation of
vimentin regulates its organization, localization, and function [248, 249]. We did not examine
the localization or phosphorylation status of vimentin following RGS16 expression, and this is
something to consider for future studies.
EGF can also lead to the activation of RhoA, Rac1 and other Rho GTPases that are also
associated with EMT and initiate rearrangement of filamentous actin (F-actin) [121, 122]. Rac1,
RhoA and Cdc42 are activated by oncogenic Ras and activation of these proteins is vital for Ras
transformation and/or cell motility [250, 251]. Activation of Rac1, RhoA, and Cdc42 results in
reorganization of the actin cytoskeleton causing lamellipodia, stress fiber, or filopodia formation
respectively that aids in different aspects of cell migration [126, 131]. Activation of Rho
GTPases contributes to cell motility, invasion, and metastasis [131]. RhoA and RhoC have both
been shown to be important signaling molecules required for migration, invasion, and metastasis
of pancreatic cancer. Quantitative in vivo fluorescence lifetime imaging of mice with p53 and
K-Ras mutant pancreatic cancer found increased RhoA activity in certain subcellular locations
that are important for invasion [252]. Fukumoto and colleagues found that the Rho GTPase
RhoC is overexpressed in human pancreatic cancer and is associated with metastases and
decreased survival [108]. Inhibition of EGF induced activation of RhoA alone or in combination
with inhibition of RhoB and RhoC by p190 RhoGap (converts active RhoGTP to inactive
RhoGTP) in pancreatic cancer cells repressed EGF induced invasion and metastasis [240, 253].
RGS16 can inhibit activation of RhoA by binding and preventing the small G protein, Gα13
from mediating the activation of RhoA in MCF-7 cells [164]. Although commonly associated
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with GPCR signaling, Gα13 was identified as a mediator of growth factor induced migration and
was found to bind and aid in the localization of active Rac1 to sites of lamellipodia formation
[254]. The significance of Gα13 binding to Rac1 following growth factor stimulation in unclear,
but this interaction may aid in the deactivation of Rac1 resulting in the turnover of actin to be
used for formation of stress fibers or lamellipodia in the cytoskeleton [254]. Rac1 and RhoA
work in an antagonistic fashion and prolonged activation of Rac1 may inhibit RhoA induced
formation of stress fibers needed for cell motility [255, 256].
Although only RGS16 has been directly linked to regulation of RhoA, based on literature
reports other Rho GTPases could be targets for RGS16 regulation.

We examined F-actin

organization in BxPC-3 and AsPC-1 cells expressing GFP and/or RGs16 in order to 1) determine
if there is a change in cytoskeleton, and 2) narrow down possible targets for future study. We
were unable to detect any significant change between cells treated with Ad.GFP or
Ad.GFP.RGS16. This was due in part to the heterogeneity of the cell population making it
difficult to quantify differences between control and RGS16 expressing cells. Also any changes
to the organization of the cytoskeleton could be subtle and not detectable using phalloidin
staining. Measurement of Rho GTPases’ activation state will be required to test the hypothesis
that RGS16 is regulating cytoskeleton rearrangement through modulation of RhoA, RhoC, Rac1,
or Cdc42.

FUTURE STUDIES AND CONCLUSIONS
RGS16 is downregulated in metastatic pancreatic cancer and for the first time we have
delineated a function of RGS16 in inhibiting EGF induced pancreatic cancer cell migration and
invasion in vitro. Phosphorylation is an important mechanism that regulates RGS16 GTPase,
accelerating its activity and stability [157-159]. Tyrosine 168 is located in the RGS box and its
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phosphorylation by EGF/EGFR enhances the GTPase activity of RGS16.
phosphorylation by Src slowed degradation of RGS16 [157, 158].

In contrast,

Our data suggests the

enhancement of RGS16 activity by EGF/EGFR functions in a negative feedback loop to inhibit
pancreatic cancer migration and invasion.

Our study focused on examining migration and

invasion mediated by the EGF/EGFR pathway. However, a single RGS protein can interact and
regulate signaling of multiple pathways ([134, 172]). Future studies are needed to determine if
RGS16 can inhibit cell migration and invasion through other pathways such as the SDF1/CxCR4 pathway. The mechanism behind RGS16 inhibition of migration and invasion still
remains unclear, however, our studies show it is independent of the PI3K/Akt and MAPK
pathways.

More experiments are needed to determine the mechanism governing RGS16

inhibition of EGF induced migration and invasion. Examination of E-cadherin activity in BxPC3 cells and activation of Rho GTPases in cells expressing RGS16 will help narrow down possible
mechanisms.

Our study did not directly investigate whether RGS16 inhibits invasion by

preventing the secretion of factors (such as matrix metalloproteinases) involved in the
breakdown of the extracellular matrix and basement membrane required for the infiltration of
cancer cell into the vasculature. However, this is the first report to our knowledge demonstrating
a relationship between an RGS protein and invasion. Further studies examining the expression
and activity of matrix metalloproteinases (MMPs) could determine whether RGS16 may inhibit
invasion by decreasing the amount, activity or secretion of MMPs.
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CHAPTER 4.
DISCUSSION
Conclusions
The objectives of our research were twofold: first to identify p53 and pRb cross-talk
candidates by examining p53 and pRb co-regulated genes; and second to characterize the
function of a p53 and pRb cross-talk candidate genes in cancer development. As described in
Chapter 1, p53 and pRb are vital for cancer suppression and studies suggest p53 and pRb crosstalk to regulate cellular fate and prevent cancer progression. By utilizing microarray expression
profiling, we have identified 179 p53 and pRb regulated cross-talk candidates that may be
involved in coordinating cancer suppression processes and determining cell fate (Chapter 2).
Ingenuity Pathway Analysis (IPA) identified molecular and cellular functions that could be
modulated by the cross-talk candidate genes and in cells exogenously expressing p53, pRb, and
both p53 and pRb (Chapter 2). This IPA analysis will be useful for generating future hypotheses
aimed at identifying mechanisms employed by p53 and pRb to regulate cellular processes. We
chose to further study RGS16 a common gene set cross-talk candidate because of its known
regulation of several oncogene pathways that are depicted in Figure 1.4 and its ability to regulate
GPCR pathways that are commonly deregulated in cancer.

Loss of RGS16 in metastatic

pancreatic cancer suggests it functions to inhibit processes that aid in metastasis. Our results
support our hypothesis that RGS16 inhibits pancreatic cancer cell migration and invasion in vitro
and suggests that loss of RGS16 may provide to pancreatic cancer a metastatic advantage.
Although it is known that RGS16 is regulated by p53, we are the first to report the regulation
of RGS16 by pRb and its ability to inhibit EGF induced migration and invasion with no impact
on cell viability (Chapter 2 & 3). The findings from our study suggest RGS16 is regulated by p53
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and pRb and functions to inhibit pancreatic cancer cell migration and invasion, however this
effect was cell line dependent. Although not commonly associated with p53 and pRb signaling,
regulation of cellular migration and invasion by both tumor suppressors has become evident over
the course of the past several years. p53 regulates cell polarization and migration of cells
predominately by inhibiting Rho signaling [257] and also inhibits cancer cell invasion by
suppressing the activity or expression of matrix metalloproteinases (MMPs) [258-261]. pRb’s
role in cell migration has recently come to light. pRb has been implicated as an important factor
in regulating neuronal cell migration and was recently found to inhibit CD44 induced collective
cell migration of breast cancer cells [68, 262]. pRb is linked to regulating invasion through its
ability to bind and inhibit E2F induced transcriptional activation of the matrix metalloproteinases
(MMPs) 9, 14, and 15 [67]. Knock-down of E2F1 and E2F3 inhibited migration and invasion of
non-small cell lung cancer cells [67]. RGS16 may be another mechanism employed to regulate
cell migration and invasion by p53 and pRb. However, future studies are needed to verify if
RGS16 regulation by p53 and pRb mediates suppression of cancer cell migration and invasion.
While the exact mechanisms employed by RGS16 to regulate pancreatic cancer cell
migration and invasion remains unknown,, our studies suggests RGS16 regulation is independent
of the PI3K/AKT, and MAPK pathways and increases RGS16 in Ras wild-type cells. Critique of
the data and future directions will be explored below in the following sections outlining the next
steps that can be taken to understand the role of RGS16 in pancreatic cancer.
Critique and Data analysis
Expression profiling analysis was used to identify p53 and pRb cross-talk candidates using
normal lung fibroblast cells (WI38) expressing p53, pRb, or p53 + pRb. Our studies focused on
transcriptional regulation as a cross-talk mechanism employed by p53 and pRb. However,

116

downstream protein-protein interactions are another mechanism of communication and were not
investigated in our study. To avoid mutations that can alter p53 and pRb signaling pathways,
normal WI38 cells were used to study p53 and pRb cross-talk. Our experimental design used an
exogenous system to express p53 and pRb in cells that already express both tumor suppressors.
This method does raise the concern that the total expression of p53 and pRb (exogenous +
endogenous) exceeds normal activation levels of these tumor suppressors inducing irregular
responses in the WI38 cells.

This is a valid concern, however using western blot and

densitometry analysis (Figure 2.1), we found that the fold change in p53 and
hypophosphorylated pRb (active form) to total pRb was equivalent to those seen endogenously
in cells undergoing quiescence or cell cycle arrest respectively [195, 196]. Pathways that tightly
control p53 and pRb expression and activity (highlighted in Chapter 1) are present in WI38 cells
and regulate the expression of these two proteins.
p53 and pRb activity is tightly controlled, so in order to study their transcriptional regulation
functions, we had to induce their expression and/or activity. We used adenoviruses to induce
expression of p53 and pRb overcoming regulatory pathways and activating p53 and pRb
transcriptional responses. There are alternate methods that could have been used to induce p53
and pRb transcriptional activity and will be briefly discussed. p53 and pRb can both be activated
by a variety of compounds or stimuli that induce DNA damage such as doxorubicin, cisplatin, or
UV [263-265] . However, it is hard to isolate activation of just p53 and/or pRb using chemicals
or other stimuli that induce DNA damage. Mouse embryonic fibroblasts (MEF) negative for p53
or pRb were also considered for studying p53 and pRb cross-talk. However, we were unable to
find p53-/- and pRb-/- MEFs. Furthermore both p53 and pRb induce cell cycle arrest and initiate
DNA repair. Loss of both p53 and pRb would make the cells vulnerable to mutations that could
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alter the p53 and pRb signaling pathways hindering identification of valid cross-talk candidate
genes. siRNA knockdown of p53 and/or pRb could have also been employed. Levels of p53 are
kept at low levels in normal cells by MDM2, and depending on the stage of the cell cycle pRb
could be in its inactive form. Additional stimuli to siRNA treated samples may have been
required to initiate p53 and pRb transcriptional activity to compare changes in gene expression
between controls and siRNA treated cells. We chose to use adenoviruses to express p53 and pRb
because it offered a simple method to induce one or both of these tumor suppressor genes
without initiating other cellular pathways.
We identified 179 cross-talk candidate genes that were broken down into two gene sets; the
common (39) and interaction (140) cross-talk candidates (Figure 2.1).

Our interest in the

common set cross-talk candidate RGS16 was first peaked when qRT-PCR analysis revealed p53
and pRb combined expression in WI38 cells synergistically increased RGS16 mRNA. Analysis
of the literature demonstrated that RGS16 not only regulated GPCR receptor signaling but is also
associated with regulating oncogene pathways that are altered in cancer signaling. RGS16 has
been shown to regulate pathways that are associated with cell migration and invasion. However,
no studies have investigated whether RGS16 can inhibit migration and invasion.

Primary

pancreatic tumors from patients with lymph node metastasis had decreased expression of RGS16
that was associated with decreased survival. Since a majority of pancreatic cancer patients
present with metastases at time of diagnosis, we used pancreatic cancer as a model to study
RGS16 migration and invasion.
When we began the migration and invasion studies, we chose to use adenoviruses to express
RGS16 because of the decreased expression of RGS16 in clinical data. Western blot analysis
later showed a faint endogenous band in the BxPC-3 cells (highest expression of RGS16 mRNA)
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(chapter 3) further supporting our decision to express RGS16. However, repeating the migration
and invasion studies using RGS16 siRNA would complement our data and further support our
hypothesis, however due to low basal levels of RGS16, it would be difficult to detect RGS16
knockdown.
We saw decreased EGF induced migration of BxPC-3 and AsPC-1 but not in the PANC-1
cells. The difference in behavior between cell lines could be due to alternate mutations that are
preventing inhibition of PANC-1 cell migration by RGS16. However, this does not mean that
RGS16 could still not inhibit migration of these cells. We examined the ability of RGS16 to
inhibit EGF induced migration and invasion; however, RGS proteins canonically regulate GPCR
signaling [134]. The RGS16 targeted GPCR CxCR4 is expressed in pancreatic cancer and
promotes migration and invasion of the PANC-1 cells [141, 222, 242].
We explored the mechanism behind RGS16 suppression of migration and invasion.
EGF/EGFR activates a variety of pathways that can contribute to cell migration and invasion
including PI3K/AKT, Ras/MAPK, and Rho GTPases. We did not see a change in expression of
phosphorylated AKT or ERK suggesting RGS16 does not modulate EGF induced migration and
invasion through the PI3K/AKT or MAPK pathways. Examinations of EMT markers E-cadherin
and vimentin were inconclusive. We did find an increase in E-cadherin expression in the K-Ras
wild-type BxPC-3 cells but there was no change in vimentin for either BxPC-3 or AsPC-1 cells.
Although there was an increase in E-cadherin expression in BxPC-3 cells by RGS16, we did not
test the activity of E-cadherin in these cells.

Induced upregulation of RGS16 increased

expression of E-cadherin in triple negative breast cancer cells [163]. E-cadherin, often referred
to as the master regulator of EMT, is important for the formation of tight cell-cell contact [125].
RGS16 may regulate E-cadherin in a Ras wild-type dependent manner. K-Ras mutations in
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prostate cancer inhibit E-cadherin expression by promoting methylation of the E-cadherin
promoter [247]. Future studies are needed to test the hypothesis that K-Ras mutations inhibit
increased expression of E-cadherin by RGS16.
Phosphorylation of vimentin regulates its activity and localization. Our studies only focused
on mechanisms that regulate vimentin by increasing or decreasing its expression. Investigation
of the phosphorylation state and localization of vimentin will determine if RGS16 regulates cell
migration and invasion by regulating the post-translational modifications of vimentin. We
cannot say definitively if RGS16 regulates EMT due to the use of only two EMT markers and
differences seen between the two cell lines.

Examination of other EMT markers such as

fibronectin and N-cadherin will provide a more complete picture that will aid in forming more
conclusive results regarding RGS16 and EMT.
Activation of Rho GTPases is also associated with EMT and aids in cell migration and
invasion [126]. Although RGS16 is only directly linked with inhibiting activation of RhoA in
MCF-7 cells there are other Rho GTPases that are involved in the reorganization of the
cytoskeleton and that are integral to motility [164]. We used phalloidin to stain and visualize Factin in BxPC-3 and AsPC-1 cells. We were expecting that phalloidin staining would identify
distinct changes in the organization of F-actin that would pinpoint alterations in signaling to a
Rho GTPase.

We could not distinguish changes quantitatively in the F-actin that forms

lamellipodia, filopodia, or stress fibers; this is likekly due in part to the heterogenous population
of cells. Furthermore phalloidin staining is not a very good quantitative assay and changes in Factin may be subtle in these cells. Activation kits examining RhoA, RhoC Rac1, Cdc42 would
provide more quantifiable assays that would help determine whether RGS16 causes changes to
expression of activated Rho GTPases.
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Our mechanistic investigations concentrated on pathways that are predominately known to
mediate cell migration.

However, both AKT and ERK (MAPK) can aid cell invasion by

increasing expression of MMP-9 [233, 245]. Activation of Rho GTPases does stimulates cell
invasion in vitro and in vivo, however, this is predominately linked with rearrangement of the
actin cytoskeleton, changes in cell-cell contact, and cell adhesion dynamics that mediate cell
movement [126]. Remodeling of the extracellular matrix is an important step for invasion and is
mediated by extracellular proteases such as matrix metalloproteases (MMPs). The mesenchymal
phenotype adopted by cancer cells that underwent EMT is associated with an increase in the
secretion of MMP 2 & 9 [125]. We did not examine the activity or expression of MMPs, but
since we are found an inhibition of invasion, it is possib inhibits the activity or expression of
MMPs.
Future studies
Our studies have only begun to uncover the function and role of RGS16 in pancreatic cancer
progression. There are still several questions that remain unanswered. These questions will be
explored along with future studies that can be performed to fill in the gaps.
How does RGS16 inhibit pancreatic cancer cell migration and invasion in vitro?
We were unable to identify the mechanism used by RGS16 to inhibit pancreatic cancer cell
migration and invasion. However there are several steps that can be taken to further understand
the function of RGS16 in pancreatic cancer that are outlined in Table 4.1.

All proposed

experiments are for BxPC-3 and AsPC-1 cells expressing GFP and/or RGS16 and treated with
EGF following previous protocols as described in Materials and Methods of Chapter 3.
E-cadherin binds to β-catenin and other proteins to form a complex that connects cell-cell
adhesion complexes with the F-actin [126, 266]. Loss of E-cadherin liberates β-catenin that can
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be stabilized by the Wnt signaling pathway in the cytosol leading to the translocation of βcatenin to the nucleus where it can initiate transcription of factors that promote proliferation,
migration, and invasion [126]. Examination of β-catenin expression in the nucleus will determine
if the increased expression of E-cadherin in BxPC-3 translates to increased expression of Ecadherin at the membrane.
The second proposed experiment is the investigation of the localization and phosphorylation
of vimentin.

The post-translational modification of vimentin regulates its organization,

localization, and function [248, 249]. Although the role of phosphorylated vimentin is not well
known it appears to aid in cell migration [249, 267]

Phoshorylation of vimentin causes

disassembly of the intermediate filament resulting in increase of soluble vimentin. Investigation
of vimentin localization (still in filamentous fibers) and phosphorylation will show whether
RGS16 regulates this protein through post-translational modifications.
The Third experiment will test the hypothesis that mutant K-Ras prevents the upregulation of
E-cadherin by mediating the promoter methylation of its gene.

A demethylating agent

(decitabine and azacitidine) will be used in cells with or without adenoviruses expressing GFP
and/or RGS16. The hypothesis will be supported if the data shows increased expression of Ecadherin in cells expressing RGS16 and treated with the demethylating agent.
The last three proposed experiments focus on examining expression or activation of other
EMT markers, MMPs, and Rho GTPases. These proteins can be examined using western blots
or PCR arrays to obtain a more global view of cellular changes due to RGS16 expression.
Completion of these experiments will provide data demonstrating whether RGS16 inhibits
expression of EMT markers, activation of Rho GTPases involved in cytoskeleton rearrangement,
or activation of MMPs.
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Table 4.1: Proposed future in vitro studies to examine mechanisms governing RGS16
inhibition of pancreatic cancer cell migration and invasion.
Experiment Type

1. E-cadherin
activity

Method/hypothesized outcome
Examine β-catenin localization in nucleus (western blots or
immunofluorescence / ↑ E-cadherin activity ↓ localization of β-catenin in
the nucleus

2. Vimentin
localization and
phosphorylation

Examine localization (immunofluorescence) & phosphorylation (western
blot using anti-phosphorylated vimentin and/or extract soluble and
filamentous proteins followed by western blot using anti-vimentin /
determine if localization or spread of vimentin changes (for example,
change in amount of filamentous fibers) and if vimentin is phosphorylated
(phosphorylated vimentin can break down and become soluble)

3. Test if RGS16
induced
expression of Ecadherin is
dependent on
wild-type K-Ras

Treat cells with a DNA demethylating agent with or without concomitant
treatment with adenoviruses expressing GFP and/or RGS16. Measure Ecadherin expression / determine if K-Ras mutations inhibit up-regulation of
E-cadherin by methylation and inhibition of E-cadherin promoter.

4. Examine
expression of
other EMT
markers
5. Activation of
RhoGTPases
6. Matrix
Metalloproteinase
(MMPs) activity

Examine expression of other EMT markers such as N-cadherin,
fibronectin, αvβ6 integrin, or E-cadherin transcriptional repressors (Snail,
slug, ZEB1, or twist (by western blot or PCR array) / more conclusively
show if RGS16 regulates EMT.
Rho GTPase activation kits (immunoprecipitation followed by western blot
analysis) for RhoA, RhoC, Rac1, and Cdc42 / determine if RGS16 inhibits
activation of select Rho GTPases
Examine Matrix metalloproteinase activity using fluorometric activation
kit / determine if and which MMPs are active

Does RGS16 inhibit cell migration and invasion induced by other factors?
A single RGS protein can interact and regulate signaling of multiple pathways [134, 172].
While our studies focused on EGF induced migration and invasion, RGS16 may inhibit
migration and invasion induced by other factors such as CxCR4. Repeating the migration and
invasion experiments using other factors to stimulate cell migration and invasion will show if
RGS16 can regulate multiple mechanism of pancreatic cancer cell migration and invasion.
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These experiments can be completed by two methods: the first, is to use single ligands to induce
activation of certain signaling pathways (for example SDF-1 ligand for CxCR4). The second
option is to use fibroblast conditioned media that contains multiple factors providing a partial
mimic of the microenvironment that cancer cells are exposed to in vivo. Identification of
mechanisms will be easier to identify using single ligands to induce migration and invasion.
However, using fibroblast conditioned media is more representative of the growth factors and
ligands that a cancer cell is exposed to in the microenvironment.
Does RGS16 inhibit pancreatic cancer cell metastasis in vivo?
Pancreatic cancer has a low survival rate that is due in part to the highly metastatic nature of
this disease. By understanding the underlying mechanisms of pancreatic cancer progression, we
will be able to better prevent or treat advanced and metastatic pancreatic cancer. Although
RGS16 was found to inhibit pancreatic cancer cell migration and invasion in vitro (Chapter 3)
this does not guarantee that RGS16 can inhibit pancreatic cancer metastasis. The process of
metastasis is dynamic and complex involving multiple interactions between the tumor and the
surrounding microenvironment that can be better studied using in vivo. There are several mouse
models that can be employed to test the hypothesis that RGS16 inhibits pancreatic cancer cell
metastasis such as genetically engineered mouse (GEM) and mice xenograft models. There are
multiple advantages of GEM over xenograft or carcinogen induced pancreatic cancer models: 1)
GEM models more closely mimic human pancreatic cancer, 2) can be used to study pancreatic
cancer progression from initiation to metastasis, 3) and allows investigation of any interactions
between the tumor and immune response [268, 269]. Using GEM models we can induce
targeted knock-out of RGS16 in the pancreas of mice with knock-in of mutant KRasG12D and
mutant p53R172H (Pdx1-Cre;LSL-KRasG12D/+;LSL-p53R172H/+) or mice with knock-in of mutant
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KRasG12D and knock-out of Ink4a/ARF (Pdx1-Cre;LSL-KRasG12D/+;Ink4a/Arflox/lox ). Both the
Pdx1-Cre;LSL-KRasG12D/+;LSL-p53R172H/+

and

Pdx1-Cre;LSL-KRasG12D/+;Ink4a/Arflox/lox

models develop pancreatic intraepithelial neoplasias (PANINs) that later progress to pancreatic
cancer with the presence of metastases [102, 104]. By combining RGS16 knock-out with well
characterized pancreatic cancer GEM models, we can determine if loss of RGS16 increases
metastases.
There are a couple of disadvantages to using GEM models; one, is expense and the second, is
that the signaling molecules in mice may not have the same mechanisms or effect as in humans.
Wilkie and colleagues (2010) using RGS16::GFP BAC transgenic mice found that RGS16 is
expressed in pancreatic progenitor cells during development [140].

However, after birth,

expression of RGS16::GFP remained in pancreatic cells associated with ducts and veins for 3-4
weeks but was lost in adult mice. In an abstract published earlier this year, the authors found
expression of GFP tagged RGS16 throughout the different stages of tumorigenesis in mice with
pancreatic cancer induced by knock-in mutant KRas and knock-out p16 and p19 targeted to
pancreatic acinar cells (p48CRE;LSL-KRasG12D;CDKN2Af/f ) [270]. In our studies, we found that
the expression of RGS16 mRNA was lower in established pancreatic cancer cells compared to
normal human pancreatic RNA (Chapter 3).

Immunohistochemical analysis of RGS16 in

primary samples showed a decrease in RGS16 staining in tumors extracted from patients with
lymph-node metastases [149].

This data suggests RGS16 expression is present in human

pancreas tissue and expression is lost during progression of pancreatic cancer contradicting the
findings of the mice studies. Human and mouse RGS16 share 85% homology, however, that
15% difference could be sufficient to elicit different functions of RGS16 in the pancreas of these
two species [154]. The function of RGS16 in mice with pancreatic cancer has not yet been
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investigated and experiments using RGS16 knock-out mice will increase our understanding of
the role of RGS16 in mouse pancreatic cancer.
A xenograft orthotopic pancreatic tumor mouse model can used to determine if expression of
RGS16 inhibits pancreatic cancer cell metastasis. In orthotopic models the pancreatic cancer
cells are injected directly into the pancreas of an immunodeficient (nude) mouse and up to 65%
of mice develop metastases [271]. This model can only be used to study the endpoint of
metastasis (in our case) as opposed to GEM models that can be used to study the different stages
of tumorigenesis or metastasis. Using this model, pancreatic cancer cells (AsPC-1) will be
injected into the pancreas of a nude mouse. Mice will be treated with adenoviruses expressing
GFP and/or RGS16 encapsulated in microbubbles for targeted delivery to the tumor site.
Ultrasound will be used to target the delivery of the bubble to the pancreas of the mouse.
Metastasis and tumor growth will be measured. Orthotopic models are invasive and rely on
imaging modalities to measure size of the tumor [272]. However, ultrasound guided tumor
injection protocols for pancreatic cancer has been developed to limit injury to the mice [273].
Use of xenograft mice prevents endogenous investigation of RGS16 function on pancreatic
cancer development and progression. However, this model may bypass problems associated
with RGS16 having different functions in mice vs. humans.
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Abstract
Data collected since the discovery of p53 and pRb/RB1 suggests these tumor suppressors
cooperate to inhibit tumor progression. Patients who have mutations in both p53 and RB1 genes
have increased tumor reoccurrence and decreased survival compared to patients with only one
tumor suppressor gene inactivated. It remains unclear how p53 and pRb cooperate toward
inhibiting tumorigenesis. Using RNA expression profiling we identified 179 p53 and pRb crosstalk candidates in normal lung fibroblasts (WI38) cells exogenously coexpressing p53 and pRb.
Regulator of G protein signaling 16 (RGS16) was among the p53 and pRb cross-talk candidates
and has been implicated in inhibiting activation of several oncogenic pathways associated with
proliferation, migration, and invasion of cancer cells.
RGS16 has been found to be downregulated in pancreatic cancer patients with metastases
compared to patients without metastasis. Expression of RGS16 mRNA was decreased in the
pancreatic cancer cell lines tested compared to control. Expression of RGS16 inhibited migration
of the BxPC-3 and AsPC-1 but not PANC-1 cells and inhibited invasion of BxPC-3 and AsPC-1
cells with no impact on cell viability. We have identified for the first time p53 and pRb cross-talk
candidates and a role for RGS16 to inhibit pancreatic cancer migration and invasion.
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Introduction
The p53 and pRb tumor suppressors are two signaling pathways that are frequently altered
during cancer progression. Mutations that disrupt the p53 and pRb pathways can occur in the
gene sequences or in their upstream regulators and/or downstream effectors. Results of studies
have found that both tumor suppressor genes are inactivated in a variety of malignancies
including osteosarcoma, small cell lung, breast, and bladder carcinomas [1, 4, 45, 46].
Furthermore, alterations in expression or activity of proteins involved in p53 and pRb signaling
pathways have been identified in retinoblastoma and cancers of the pancreas, colon, and head
and neck among others [49, 51, 52, 111]. The large number of cancers that have defects in the
p53 and pRb pathways demonstrates the importance of these genes in preventing cancer
development and progression.
Existing data suggests that p53 and pRb cooperate to prevent tumor progression. Examples
of this cooperative interaction have been shown by various studies using human primary cancer
samples and mouse models. Patients who have mutations in both p53 and RB1 genes have
increased tumor recurrence and decreased survival compared to patients with a mutation in either
p53 or RB1 [45, 47, 180]. A study conducted in mice found that p53 null mice who were also
heterozygous for RB1 were susceptible to developing more tumors than mice with single
mutations; i.e. heterozygous p53 or RB1 null or p53 null mice [4]. In another study, mice with
conditional inactivation of both p53 and RB1 in prostate epithelium developed highly metastatic
tumors and had decreased survival time compared to mice with single p53 or RB1 inactivation
[5]. The accumulated evidence suggests p53 and RB1 gene products have cooperative or
synergistic effects for cancer suppression.
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Considering the network of communication that exists within a cell, the rate of mutation of
p53 and RB1, and the cellular processes these two proteins regulate, a natural hypothesis is that
these two genes and respective gene products cross-communicate in order to determine cellular
fate and prevent carcinogenesis. In fact, there are known examples of genes and proteins that are
involved in the convergent signaling between the p53 and pRb pathways; such as Hdm2, p21,
E2F-1 and the INK4a locus (reviewed in [3, 47, 74, 182]). Although several proteins that are
involved in the p53 and pRb pathways have been identified, the full extent in which these two
tumor suppressors interact along their pathway to regulate cellular fate is still unknown. To
identify downstream targets of both p53 and pRb regulation and to elucidate mechanisms of p53
and pRb cross-talk, we coexpressed p53 and pRb in normal human lung fibroblasts cells (WI38)
and used RNA expression profiling to identify up- or down-regulated genes. We identified
Regulator of G protein Signaling 16 (RGS16) as a p53 and pRb cross-talk candidate.
RGS16, previously found to be induced by doxorubicin in cells expressing wild-type p53,
belongs to a large family of proteins that plays a role in swiftly shutting down G protein-coupled
receptor (GPCR) signaling pathways [134, 135]. RGS16 is a GTPase activating protein (GAP)
that aids GTPase activity of the α-subunit of G proteins associated with G-protein coupled
receptors (GPCR). RGS16 has been implicated in negatively regulating the MAPK, AKT/PI3K,
RhoA, and SDF-1/CXCR4 oncogene pathways in normal or cancer cell lines [135, 141, 164,
171]. These oncogene pathways have been implicated in cancer progression processes (such as
proliferation, survival, chemoresistance, migration, invasion, and metastasis in a variety of
malignancies including pancreatic cancer [221-225]. Recently, evidence has demonstrated a role
of RGS16 in cancer signaling. RGS16 locus is a site of genomic instability in (50% of 222)
primary breast tumors and knockdown of RGS16 in breast cancer cell lines increases Epidermal
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Growth Factor (EGF) and Fetal Bovine Serum (FBS) initiated proliferation [150, 171]. A
previous report using tissue microarray analysis revealed decreased expression of Regulator of
G-protein signaling 16 (RGS16) in pancreatic tumors with lymph-node metastases compared to
non-metastasized pancreatic cancer and this loss was associated with decreased patient survival
[149]. Based upon the link of RGS16 regulating several oncogenic pathways and the decreased
expression of RGS16 in metastasized pancreatic cancer, we chose to further study the function of
RGS16 in pancreatic cancer in order to identify the role it has in the p53 and pRb signaling
pathways. Currently, RGS16 has not been linked with inhibition of cancer cell metastasis nor
has its function been investigated to understand it’s downregulation in metastasized pancreatic
cancer. The majority of patients newly diagnosed with pancreatic cancer present with highly
progressed and/or metastatic cancer that is resistant to treatment [84, 85]. Due to the late stage
of diagnosis and the aggressive nature of this disease, less than 20% of pancreatic cancer patients
are eligible for the potentially curative surgery [85, 220]. Therefore, there is a great need for
more effective drugs aimed at treating or preventing metastatic pancreatic cancer. Pancreatic
cancer is associated with p53 mutations and p16 (pRb activator) deletions resulting in the
crippling of both the p53 and pRb pathways. By investigating the p53 and pRb cross-talk and the
role of RGS16 in pancreatic cancer cell migration, we have uncovered a novel regulator of
metastasis processes that could be a future target in developing treatments for metastatic
pancreatic cancer.

Results
Identification of p53 and pRb cross-talk candidates in WI38 cells following coexpression of
p53 and/or pRb.
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Studies have shown that p53 and pRb cooperate to prevent tumorigenesis. Currently, the
molecules that function in the p53 and pRb cross-talk pathway to regulate cellular fate are not
known thus expression profiling by microarray was performed to find genes co-regulated by p53
and pRb. Normal human lung WI38 fibroblast cells were transduced with adenoviral vectors
expressing the p53 and/or RB1 genes under the control of a cytomegalovirus (CMV) promoter.
The WI38 cell line was used because it is from non-cancerous tissue and lacks mutations or viral
transformations that could disrupt the p53 and pRb pathways. Four experimental conditions were
used in which WI38 cells were transduced with adenovirus vector control (cond. 1, Adenoviral
CMV-vector control, Ad.CMV.p53 (cond. 2), Ad.CMV.pRb (cond. 3), or both Ad.CMV.p53 and
Ad.CMV.pRb (cond. 4). RNA and protein from WI38 cells was collected 48 hours after
adenoviral infection. Immunoblots verified increased expression of p53 (fold change compared
to Ad.CMV control = 2.80, 1.54, and 2.77) and/or hypophosphorylated (active form) pRb
(hypophosphorylated/total pRb fold change compared to Ad.CMV control = 0.94, 5.48, 5.02) in
the WI38 cells treated with adenoviruses containing p53, pRb, or both p53 and pRb respectively
(Figure 1A and 1B). Fold change values for p53 and hypophosphorylated pRb coincided with
previously reported results in experiments that activated endogenous p53 and pRb [195, 196].
Microarray data from the adenovirus vector control (empty vector with CMV promoter) was
used as a reference to determine genes that were differentially expressed as a consequence of
p53, pRb, and p53 + pRb expression. Analysis of the microarray data identified 294-p53, 650pRb, and 514-p53 + pRb differentially expressed genes (Figure 1C; see Supplementary
Document 1) for full list of differentially expressed genes. Of the differentially expressed genes,
294/294 genes were upregulated in cells with p53 expression, 427/650 genes were upregulated in
cells with pRb expression, and 319/514 genes were up-regulated in cells with p53 + pRb
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coexpression (Figure 1C). Consistent with protein measurements, increased expression of p53
and/or RB1 mRNAs were also found in the appropriate groups (Supplementary Document 1).
A Venn diagram shows the number of differentially expressed genes shared between the
experimental groups (Figure 1C). By looking at the common genes between the three
experimental groups, we were able to generate two lists of genes that may be involved in the p53
and pRb cross-talk pathway. The first list of cross-talk candidates (designated as the p53 and pRb
common gene set) consisted of 39 genes found to be commonly up-regulated in cells expressing
either p53 or pRb. The second list of possible cross-talk members (designated as the p53 and
pRb interaction gene set) contained 140 genes that were found to be differentially expressed only
when p53 and pRb were overexpressed together (see Supplementary Document 1). Thirty-two
of the 39 common gene set cross-talk candidates were found to be up-regulated in the interaction
gene set, while the remaining 7 were commonly up-regulated in cells that overexpress either p53
or pRb (Table 1). By focusing on the common and interaction gene sets, we were able to remove
transcripts that were up- or down-regulated by only p53 or pRb and focus on candidates that may
be involved in the p53 and pRb cross-talk pathway.

qRT-PCR validation of microarray data in WI38 and SAOS-2 cells.
Our ultimate goal in performing the microarray analysis was to determine molecules
involved in the p53 and pRb cross-talk pathway in order to identify and study downstream
effector molecules that can be expressed to induce a p53 and/or pRb tumor suppressive function.
Because of our interest in identifying downstream effector molecules, we chose five mRNA
transcripts (IL-6, BTG-2, STAT4, RGS16, BCL2L11) from the set of 39 commonly up-regulated
transcripts by p53 and pRb for validation via qRT-PCR. IL-6, BTG-2, STAT4, RGS16, and
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BCL2L11 were chosen for validation because of varying function, known regulation by p53 and
pRb, and fold change values expression profiling assay. WI38 cells were plated and transduced
with adenoviral expression vectors via the same methods used for the microarray analysis.
Relative fold change was calculated for IL-6, BTG-2, STAT4, RGS16, and BCL2L11 in WI38
cells expressing p53 and/or pRb as shown in Figure 2. Statistically significant up-regulation of
all transcripts tested except BCL2L11 was found in WI38 cells expressing p53 and pRb
confirming the microarray results. Expression of p53 and pRb in WI38 cells increased mRNA
expression for some of the transcripts (for example, RGS16 and BTG-2) to a greater extent than
single expression of either p53 or pRb. This suggests p53 and pRb are working together resulting
in an additive (i.e. BTG-2) or synergistic (i.e. RGS16) effect on mRNA expression for some of
the transcripts.
To further support the RNA expression profiling results, we repeated the expression of
p53 and pRb in a p53 null, RB1 mutant osteosarcoma cell line (SAOS-2) and performed qRTPCR analysis of IL-6, BTG-2, STAT4, RGS16, and BCL2L11. The expression of all five
transcripts including IL-6 and BCL2L11 were found to be significantly increased by one-way
ANOVA compared to vector control in SAOS-2 cells expressing p53 and/or pRb (Figure 3).
Dunnett’s test for multiple comparison found BCL2L11 expression to be significantly increased
in cells expressing p53, pRb, and both p53 and pRb and IL-6 was found to be significantly
increased in cells expressing pRb and p53+pRb. Expression of IL-6 was not found to be
statistically significant in SAOS-2 cells expressing p53 due to variation between replicates (fold
change= 2.86). All five transcripts were found to be up-regulated when p53 and/or pRb were
expressed in the microarray analysis and qRT-PCR analysis showed similar results in WI38 and
SAOS-2 cells.
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mRNA expression of RGS16 is decreased in pancreatic cancer cell lines.
RGS16 was identified as a p53 and pRb cross-talk candidate in our expression profiling
analysis that was validated by qRT-PCR. We chose to study the role of RGS16 in pancreatic
cancer cell migration due in part to its down-regulation in patients with metastasized pancreatic
cancer and the high rate of p53 mutations (50-70%) and p16 deletions (85%) affecting both the
p53 and pRb pathways in this disease

[51, 111, 149]. We first investigated the relative

expression of RGS16 mRNA in four pancreatic cancer cell lines (BxPC-3, MIA PaCa-2, PANC1, and AsPC-1) in order to characterize the endogenous expression of RGS16. Expression of
RGS16 was measured by qRT-PCR analysis and the relative RGS16 mRNA fold change was
calculated in the four cell lines compared to total RNA from normal human pancreatic tissue.
Expression of RGS16 was decreased in all four lines compared to control with BxPC-3 having
the highest expression of RGS16 mRNA (Figure 4). Expression of RGS16 varied between the
four lines with BxPC-3 and MIA PaCa-2 having significantly higher expression of RGS16 than
PANC-1 and the metastatic derived AsPC-1 cells. RGS16 expression corresponded with the
more differentiated and less aggressive cell lines having higher levels of RGS16 than the more
aggressive and/or metastatic cell lines (Table 2).

RGS16 inhibited migration of BxPC-3 and AsPC-1 pancreatic cancer cells but not PANC1.
To test the hypothesis that RGS16 inhibits pancreatic cancer cell migration, we exogenously
expressed RGS16 in BxPC-3, PANC-1, and AsPC-1 cells with an adenoviral vector and used
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wound healing assays to measure cell migration. We chose BxPC-3, PANC-1, and AsPC-1
because these three cell lines are derived from tumors with varying expression of RGS16,
differentiation status, mutations, presence of metastases, and expression of Epidermal Growth
Factor Receptor (EGRF, Table 2). We expressed RGS16 using adenoviral vector that contains
RGS16 plus a GFP reporter (Ad.GFP.RGS16) and used a vector expressing only GFP (Ad.GFP)
as the control. Expression of RGS16 protein correlated with GFP expression in cells treated with
Ad.GFP.RGS16 (Supplementary Figure 1). Fluorescent microscopy was used to determine viral
transduction prior to experiment (Figures 5a, 6a, and 7a). EGF was used to stimulate cell
migration because EGFR is overexpressed in pancreatic cancer and is linked with development,
invasion, and decreased survival in pancreatic cancer [115, 226, 227]. RGS16 significantly
inhibited FBS- and EGF-induced migration of BxPC-3 cells and FBS-induced migration of
AsPC-1 cells, but had no effect on FBS and EGF induced migration of PANC-1 cells (Figures 57).
Interestingly, expression of RGS16 in BxPC-3 cells incubated in media supplemented with
EGF caused an increase in wound width compared to control 16 hours after the start of the
experiment. However, MTT assay revealed that there was no statistically significant change in
cell viability of FBS or EGF treated BxPC-3, PANC-1 or AsPC-1 following expression of
RGS16 compared to control cells expressing GFP (Supplementary Figure 2).
Expression of RGS16 inhibited EGF induced invasion of BxPC-3 and AsPC-1 cells.
RGS16 inhibited EGF induced migration of BxPC-3 and AsPC-1 cells, we further
investigated if RGS16 can inhibit EGF induced invasion of these pancreatic cancer cells using
matrigel invasion chambers. Media supplemented with EGF was used as the chemoattractant to
induce migration and invasion of BxPC-3 and AsPC-1 cells expressing GFP and or RGS16.
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Expression of RGS16 significantly inhibited EGF induced invasion of the BxPC-3 and AsPC-1
cells by 35.73% and 66% respectively, compared to control (Ad.GFP) (Figure 8).
Discussion
Significance of investigating p53 and pRb cross-talk
Historically, investigations of p53 and pRb regulated transcription have focused on
identifying the individual downstream targets of p53 and pRb. However, cell fate is not
determined solely by one signaling pathway but by many pathways that communicate through a
network of signaling molecules. Cross-communication between pathways allows the integration
of the exogenous and endogenous signals in a cell to aid in the determination of cell fate.
Previous studies have found that co-expression of p53 and pRb in cancer cells with compromised
p53 and pRb activity inhibited p53 mediated apoptosis and promoted cell cycle arrest suggesting
p53 and pRb cross-talk to regulate cellular fate [188, 189]. Furthermore, data from previous
studies suggests p53 and pRb may also cooperate to inhibit cancer progression. Patients
diagnosed with breast cancer and treated with adjuvant chemotherapy had a better prognosis to
adjuvant chemotherapy if they had functional p53 and pRb [61].
To our knowledge this is the first study that examines altered gene expression when p53 and
pRb are expressed together or separately with the purpose of finding genes co-regulated by both
tumor suppressor genes. How p53 and pRb cross-communicate to regulate cellular functions or
cooperate to inhibit cancer progression still remains largely unknown. The p53 and pRb
pathways are commonly altered during tumorigenesis. Due to the dynamic properties of cell
signaling, the study of genes dually regulated by p53 and pRb will provide a valuable insight into
the collaborative cancer preventative properties of these two tumor suppressor proteins.
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Transcriptional regulation may be one method used by p53 and pRb to coordinate cellular
functions. For example, the cyclin kinase inhibitor p21 is a down-stream target gene of p53 that
inhibits phosphorylation and inactivation of pRb [25]. Transactivation of p21 demonstrates a
mechanism by which p53 can coordinate with pRb to initiate cell cycle arrest. However, this
only begins our understanding of the complex regulation of cellular programs.

Change in RNA expression profiles of WI38 cells expressing both p53 and pRb compared
to expression of p53 and pRb alone, identification of cross-talk candidates, and validation
by qRT-PCR
In this study, we identified genes that may be regulated by p53 and pRb and compiled two
lists of p53 and pRb cross-talk candidates by expressing p53 and/or pRb in WI38 cells.
Although p53 has transcriptional repression activity, our microarray analysis did not detect any
down-regulated transcripts in the WI38 cells expressing p53 [190, 191]. The deficit of p53
down-regulated transcripts in our microarray analysis compared to previous studies could be due
to our method of p53 activation, cell type, or p53 levels, which have previously been found to
induce a distinct p53 response with a small set of overlapping genes [192, 193]. Our expression
profiling analyses were conducted in normal lung fibroblasts cells instead of cancer epithelial
cells. Absence of p53 down-regulated genes in the p53 expressing WI38 cells could also be
attributed to the ability of p53 and pRb to alter each other’s transcriptional activation or
repression functions in normal cells that contain intact pathways. Previous studies that
discovered p53 down-regulated targets using expression profiling were done in cancer cells with
mutated or null p53 and wild-type RB1 such as PC-3, HCT116, and H1299 cells [190, 194].
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There were 319 upregulated transcripts when p53 and pRb were expressed together
compared to 427 and 295 in the WI38 cells expressing pRb and p53 respectively. The change in
upregulated genes suggests p53 and pRb can alter one another’s ability to regulate gene
expression. Management of p53 and pRb processes may require p53 and pRb to regulate gene
expression in an opposing manner. Expression of an embryonic development gene, Placentaspecific 1 (PLAC1), has recently been found to be down-regulated by p53 and up-regulated by
pRb demonstrating how p53 and pRb can play contrasting roles to regulate cellular processes
[81].
pRb is most associated with transcriptional repression of E2F target genes preventing
transcription of genes needed for the continuation of the cell cycle [18-20]. However, binding of
E2F by pRb is not needed to promote transcription, suppress tumor growth and induce cellular
differentiation or senescence [22, 23]. In fact, pRb has been found to act as a co-activator for
several transcription factors including Sp-1, RUNX-2, MyoD, and several nuclear receptors
(including NR4A1) resulting in cellular differentiation [22, 39]. We found more transcripts that
were up-regulated in WI38 cells expressing pRb than downregulated demonstrating its function
as a transcription co-activator. There is still a lot not known about pRb regulation, therefore, this
study could contribute to the identification of genes up-regulated by pRb and understanding of
the function of pRb as a transcriptional co-activator.
Candidates for the p53 and pRb cross-talk pathway were chosen based on whether (1) the
transcripts were differentially expressed in both WI38-p53 and WI38-pRb-expressing cells (the
common gene set), or (2) only in WI38 cells that simultaneously expressed p53 and pRb
(interaction gene set). By focusing on the p53 and pRb common and unique genes, we were able
to remove from our analysis genes regulated by p53 or pRb alone. Several of the p53 and pRb
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common gene set (RGS16, BTG-2, GDF15, VCAN, D4s234e/NSG1, AKR1B10 and AREG)
and interaction gene set

(F11R, TNFRSF10C, CERS6, HDM2, SESN1, RBM38 and

PMAIP1/NOXA) cross-talk candidates have been previously found to be up-regulated by p53,
and this data is in agreement with our microarray results [135, 193, 197-205]. Only a few of the
downregulated p53 and pRb cross-talk candidates have previously been found by other studies to
be downregulated by p53 (MCM3, BUB1, and CDT1) or pRb individually (VRK1, MCM3, and
CDT1) [190, 206-209].

Although several of our p53 and pRb cross-talk candidates have

previously been found regulated by p53, regulation of these transcripts by pRb is not known.
Our expression profiling analysis was performed using a normal cell line in order to avoid
any mutations that could be present up- or downstream of p53 and pRb that could hinder
identification of downstream targets of both genes. Although we expressed p53 and pRb using
adenoviruses in normal cells, the fold change of p53 and hypophosphorylated pRb proteins
compared to CMV control were equivalent to or less than fold change values in WI38 cells
incubated in serum free media to induce quiescence (fold change p53 after 24 hours in serum
free media = 5.5) or MCF7 cells undergoing confluence induced cell growth arrest (fold change
hypophosphorylated pRb/total pRb = 6.00) [195, 196]. This data suggests the concentration of
virus used did not exceed endogenous protein expression of p53 and the active
hypophosphorylated form of pRb. However, the use of a normal cell line with wild-type p53 and
RB1 could make it difficult to identify cross-talk molecules due to possible interactions between
endogenous and exogenous p53 and pRb. To investigate if exogenous and endogenous p53 and
pRb interactions could influence expression profiles expression of RGS16, BCL2L11, BTG-2,
IL-6, and STAT4, were measured using qRT-PCR in the p53 null and pRb mutated osteosarcoma
cell line SAOS-2. Expression of all transcripts in the p53 and pRb expressing SAOS-2 cells were
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found increased with differences in magnitude of expression as they did in our WI38 microarray
data and qRT-PCR results. Interestingly, in the microarray data, STAT4 was found to be
differentially expressed in WI38 cells expressing p53 and pRb but not in cells expressing both
genes.

However qRT-PCR analysis found a statistically significant increase in STAT4

expression in WI38 and SAOS-2 cells expressing p53 and pRb. The statistical analyses of
expression profiling data or the sensitivity of microarray signal detection could account for the
failure to observe differential expression of STAT4 in WI38 cells expressing p53 and pRb.

RGS16 significance and signaling in cancer
RGS16 was of interest to our study for two reasons: 1) RGS16 regulates GPCRs, which are
common targets for deregulation in cancer and 2) RGS16 has been linked to regulating the
MAPK/RAS, PI3K/AKT, RhoA, and SDF-1/CxCR4 oncogene pathways [133, 135, 141, 164,
171]. Investigations have found that oncogene pathways can feed into one another and bypass or
overcome the inhibitory effects of monoclonal antibodies or other targeted inhibitors. For
example, in melanoma, increased production of VEGF or increased expression or activation of
the platelet-derived growth factor receptor β or insulin like growth factor 1 receptor is associated
with resistance to BRAF inhibitors demonstrating mechanisms cancer cells use to overcome
single target modalities [239]. Therefore investigation of RGS16, a protein known to modulate
several oncogene pathways will aid in understanding mechanisms by which cells alter multiple
signaling pathways to prevent carcinogenesis that could be used for future drug development.
We chose to study the function of RGS16 in pancreatic cancer because only 5.7% (1 out of
17) of pancreatic tumors with lymph-node metastases had expression of RGS16 compared to
70.6% (12 out of 17) of pancreatic tumors with non-metastasized pancreatic cancer [149].

160

Furthermore, decreased expression of RGS16 was associated with poor pancreatic cancer patient
survival indicating the potential of RGS16 as a pancreatic cancer prognostic marker [149].
Few reports have been published that describe the impact of RGS16 on cancer cell signaling
and progression. Although increased expression of RGS16 has been found in pediatric high
hyperdiploid acute lymphoblastic leukemia (ALL) and colon cancer, functional analysis of
RGS16 has not been performed to identify any oncogenic function in these cancers [147-149].
Functional and expression analysis of RGS16 has been performed in breast cancers. The RGS16
promoter is located at a site that is vulnerable to allelic imbalances in a subset of breast cancers
that can result in promoter methylation of RGS16 in 10% of these cancers [150]. Liang et al.
(2009) found that RGS16 overexpression in breast cancer cell lines decreased EGF induced
proliferation and AKT activation by binding to the p85-alpha subunit of PI3K preventing the
phosphorylation of AKT [171]. RGS16 has also been associated in the anti-proliferative effect of
retinoic acid in neuroblastoma cells and the cytotoxic effect of histone deacetylase inhibitor
Vorinostat in triple negative breast cancers [162, 163]. The current data suggests RGS16 plays a
role in cancer signaling, however, more research is needed to delineate the function of RGS16 in
cancer cells.

RGS16 and cell migration
RGS16 has been linked with inhibition of cell migration in a canonical (through regulation of
GPCR signaling) and non-canonical pathways in normal cells. RGS16 inhibits megakaryocytes
and T lymphocyte migration by regulating the activation of the GPCR CxCR4 and decreases T
helper type 2 and 17 cell trafficking through regulation of CCR4 and CCR10 chemokine
pathways representing the canonical form of RGS signaling [136, 137, 141]. The activation of
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RhoA, a small GTPase involved in reorganizing actin cytoskeleton and a mediator of EGF
induced invasion of pancreatic cancer cell lines is inhibited in MCF-7 cells by the relocation of
Gα13 to the plasma membrane by RGS16 preventing Gα13 mediated activation of RhoA [164,
240].

The regulation of RhoA activation by RGS16 is an example of a non-canonical

mechanism used to regulate signaling. These studies show mechanisms by which RGS16 can
regulate cell migration. To date, this is the first report demonstrating RGS16 induced inhibition
of cancer cell invasion.
The findings from our study suggest RGS16 is regulated by p53 and pRb and functions to
inhibit pancreatic cancer cell migration and invasion; however this effect was cell line
dependent. PANC-1 cell migration induced by FBS or EGF was not inhibited by RGS16, this
could be due to different mutations in PANC-1 compared to the other cell lines that prevent
RGS16 inhibition of FBS or EGF induced cell migration. Although not commonly associated
with p53 and pRb signaling, regulation of cellular migration and invasion by both tumor
suppressors has become evident over the course of the past several years. p53 has been found to
regulate cell polarization and migration of cells predominately by inhibiting Rho signaling [257].
p53 also inhibits cancer cell invasion by inhibiting activity or expression of matrix
metalloproteinases (MMPs) [258-261]. pRb’s role in cell migration has recently come to light.
pRb has been implicated as an important factor in regulating neuronal cell migration and was
recently found to inhibit CD44 induced collective cell migration of breast cancer cells [68, 262].
pRb is linked to regulating invasion through its ability to bind and inhibit E2F induced
transcriptional activation of the MMPs 9, 14, and 15 [67]. Knock-down of E2F1 and E2F3
inhibited migration and invasion of non-small cell lung cancer cells [67]. RGS16 may be
another mechanism employed to regulate cell migration and invasion by p53 and pRb.
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Future studies and conclusions
This is the first report of regulation of RGS16 pRb and RGS16-mediated inhibition of EGFinduced migration and invasion in normal and cancer cells. This study focused on examining
migration and invasion mediated by the EGF/EGFR pathway. However, a single RGS protein
can interact and regulate signaling of multiple pathways ([134, 172]). Future studies are needed
to determine if RGS16 can inhibit cell migration and invasion through other pathways such as
the SDF-1/CxCR4 pathway which is deregulated in pancreatic cancer ([222]).
By utilizing microarray expression profiling, we have 1) identified p53 and pRb regulated
candidates or genes involved in coordinating cancer suppression processes and determining cell
fate, 2) and identified a possible role for the cross-talk candidate RGS16 in inhibiting pancreatic
cancer cell migration and invasion. Our study suggests that the loss of RGS16 promotes
pancreatic cancer metastasis by removing the inhibitory function of RGS16 on cell migration and
invasion. Our study further supports the use of RGS16 as a prognostic marker for predicting
pancreatic cancer metastasis previously described by Kim et a.l that can be used to asses
eligibility of patient for surgery [149]. By investigating the p53 and pRb cross-talk and the role
of RGS16 in pancreatic cancer cell migration, we have uncovered a novel regulator of metastatic
processes that could be a future target in developing treatments for late stage pancreatic cancer.

Materials and Methods
Cell culture and virus transductions
The human lung fibroblast WI38 cell line, osteosarcoma cell line SAOS-2 (p53 null and
truncated RB1), and the pancreatic cancer cell lines, BxPC-3, AsPC-1, MIA PaCa-2, and PANC1 were purchased from the American Type Culture Collection (Manassas, VA, USA). WI38
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cells were grown in Hyclone MEM/EBSS (ThermoFisher Scientific, Waltham, MA) media
supplemented with 10% research grade fetal bovine serum (FBS) (PAA Laboratories,
Dartmouth, MA) and 1% Penicillin Streptomycin (Corning, Corning, NY) and SAOS-2, MIA
PaCa-2, and PANC-1 cells were grown in Hyclone High Glucose DMEM (ThermoFisher
Scientific, Waltham, MA) supplemented with 10% FBS and 1% Penicillin Streptomycin. BxPC3 and AsPC-1 were cultured in RPMI supplemented with 10% or 15% FBS (respectively) and
1% Penicillin Streptomycin. Cells were cultured at 37°C in a humidified 5% CO2 incubator.
Ad.CMV (adenovirus with CMV promoter) and Ad.CMV.p53 (Adenovirus containing wildtype p53 gene under control of CMV promoter) viral vectors were generated using the AdEasy
system (Carlsbad, CA). The Ad.CMV.pRb (Adenovirus containing RB1 gene cDNA under
control of CMV promoter) vector was provided by Dr. Juan Fueyo (M.D. Anderson Cancer
Center, The University of Texas). The Ad.GFP and Ad.GFP.RGS16 viruses were purchased
from Vector Biolabs (Philadelphia, PA). Viruses were amplified and tittered as previously
described [183-185].

Microarray expression profiling
For expression profiling, WI38 cells were transduced with each of the following vectors or
vector combination: (1) adenovirus vector with no insert (Adenoviral CMV-vector ctrl), (2)
Ad.CMV.p53, (3) Ad.CMV.pRb, and (4) both Ad.CMV.p53 and Ad.CMV.pRb. Vectors were
added at a multiplicity of infection (MOI) of 50 to 80% confluent WI38 cells in MEM/EBSS
supplemented with 2% heat-inactivated FBS. Culture media were replaced with 10% FBS and
1% Penicillin/Streptomycin supplemented MEM/EBSS medium 16 hours after vector addition;
cells were collected after 48 hours. Four biological replicates were performed for each of the
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four expression studies. Immunoblots were used to verify increased expression of p53 and/or
pRb in the WI38 samples prior to microarray analysis.
Total RNA was isolated from transduced WI38 cells using TRIzol reagent (Invitrogen,
Carlsbad, CA) according the manufacturer’s protocol. Using a universal reference design, two
RNAs (transduced WI38 cells + Agilent (Santa Clara, CA) human universal reference RNA)
were hybridized to Agilent 44K whole human genome expression arrays. Total RNAs were
labeled with either cyanine (Cy)-3-CTP and Cy5-CTP (Perkin Elmer, Waltham, MA) using
Agilent QuickAmp cRNA labeling kits. Following purification, Cy3- and Cy5-labeled cRNAs
were combined and hybridized for 17 hours at 65ºC in an Agilent hybridization oven.
Microarrays were then washed and scanned using Agilent DNA Microarray Scanner.

Statistical Analysis of Expression Profiling Data
Lowess-normalized feature intensities were extracted from the scanned image using Feature
Extraction (Agilent). These data were exported as tab-delimited files (one file per sample) to
Microsoft Excel for filtering. For each feature, data were removed if both channels reported
values not well-above background according to default Feature Extraction Criteria. For each
comparison, log base-2 ratios of each sample to universal reference RNA were collated into a
single table. Features for which fewer than 50% of all samples had a present value were
removed from further analysis.
The resulting tables were imported into Multiple Experiment Viewer (MEV) v4.3. Log base
2 ratios were compared between each of three sample sets (p53 expressed samples.

RB1

expressed samples and p53 and RB1 coexpressed samples) and the adenovirus vector control
samples by Significance Analysis of Microarrays [186]. We used a conservative threshold
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whereby only genes for which MEV reported a false discovery rate of 0% were considered
significantly differentially expressed.
Data extracted using Feature Extraction was uploaded to the NCBI’s Gene Expression
Omnibus (GEO) public database and is available via access number GSE59660.
Real-time PCR analysis
Total RNA was isolated from cells using TRIzol reagent (Invitrogen, Carlsbad, CA)
according to the manufacturer’s protocol. Total RNA was reverse transcribed into cDNA using
the High Capacity cDNA Reverse Transcription kit from Applied Biosystems (Foster City, CA)
according to the manufacturer’s protocol.

Real-Time PCR was performed using the Applied

Biosystems TaqMan Gene Expression Assays in the ABI 7000 detection system. TaqMan probes
were purchased from Applied Biosystems (Foster City, CA) IL-6 (HS00197982_m1), BCL2L11
(BCL2L11) (HS00197982_m1), RGS16 (HS00892674_m1), BTG2 (HS00198887), STAT4
(HS00231372_ml) and GAPDH (HS02758991). Human pancreatic total RNA used for
comparing the expression of RGS16 mRNA was purchased from Agilent Technologies (Cedar
Creek, TX). The relative fold change for each marker was calculated using the 2-ΔΔCT analysis
according to Livak et.al and statistical significance was determined using a one way ANOVA
with a Dunnett’s or Tukey (pancreatic cancer cell lines) post-hoc test, using Prism V6.0c
(GraphPad Software, Inc., La Jolla, CA) [187].
Western blot analysis
WI38 or Saos-2 cells were lysed in whole cell lysis buffer containing 50mM TRIS (pH7.4),
5mM EDTA 250mM NACL, 50mM NaF, 0.1mM Na3VO4, 0.1% Triton X-100 and protease
inhibitors (Pierce Protease inhibitor Tablets 88661; Thermo Scientific, Rockford, IL). Protein
extracts (50ug) were loaded onto 8% polyacrylamide gels and proteins were separated using
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sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Blots were blocked 1
hour in 5% dry non-fat milk diluted in Tris-buffered saline solution containing 0.1% Tween-20
(TBS-T). Membranes were probed overnight at 4°C with mouse anti-p53 (SC-DO1, 1: 1000) or
mouse anti-pRb (SC-IF8, 1:500) antibodies from Santa Cruz Biotechnology (Dallas, TX).
Following primary antibody incubation the membranes were washed and probed with
Horseradish peroxidase (HRP)-conjugated goat anti-mouse (1:5000) secondary antibodies
(Rockland, Gilbertsville, PA) for 1 hour at room-temperature. Primary and Secondary antibodies
were diluted in TBS-T. Blots were washed 5 minutes in TBS-T three times and Amersham ECL
prime western blotting detection reagent was added in order visualize the protein bands (RPN
2232, GE Life Sciences, Pittsburgh, PA).

Western blot images were captured using

FOTODYNE FOTO/Analyst FX (Hartland, WI) imaging camera. Membranes were normalized
using mouse anti-actin (1:1000). Densitometry was performed using TotalLab Quant software
(TotalLab Ltd, UK).

Wound healing Assay
Pancreatic cancer cells (BxPC-3, AsPC-1 and PANC-1) were placed in a 6 well plate at
approximately 70% confluency. The following day, 50 Multiplicity of Infection (MOIs) of
Ad.GFP (control) or Ad.GFP.RGS16 were added to the cells in media containing 2% heatinactivated FBS for 24 hours. The media was changed to complete media (10% FBS for BxPC-3
and PANC-1 or 15% for AsPC-1) for 24hrs. 48 hours after the addition of the virus the media
was changed from complete media to media supplemented with 0.5% FBS and 1% P/S for
24hours. Three wounds or scratches were made per well using a p200 pipette tip in PBS. The
cells were washed three times with PBS and incubated for 16-24 hours in complete media or
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media supplemented with 100ng/ml of EGF. FBS or EGF was added to induce cell migration at
a concentration previously described in [228-230]. Wound widths were measured and images
taken at 0, 16, or 24 hrs after addition of media supplemented with FBS or EGF at 100x
magnification using an Olympus DP71 microscope (Center Valley, PA). Efficacy of virus
transduction was confirmed using fluorescent microscopy to examine GFP expression prior to
the start of the experiment. Percent wound healing was determined using the following equation;
% wound healing = ([initial scratch width

–

final scratch width]/ initial scratch width)*100.

Three replicates were performed for each cell line.

Invasion Assay
BD Bio Coat Matrigel Invasion chambers (Bedford, MA) containing membrane with 8um
pores were used to assess the role of RGS16 to inhibit pancreatic cancer cell migration and
invasion. BxPC-3 cells were plated into 6-well dish, 24 hours later 50 MOIs of Ad.GFP or
Ad.GFP.RGS16 virus were added to the cells followed by 24 hour incubation in complete media
and 24 hours in low-serum media as described in the wound healing section. Chambers were rehydrated in RPMI containing 1% P/S and 0.1 % BSA for 2 hours at 37°C. BxPC-3 and AsPC-1
cells were collected and 25 x 104 cells were added to the top of the chambers in RPMI
supplemented with 1% P/S and 0.1%BSA. RPMI supplemented with 100ng/ml EGF, 1% P/S,
0.1% BSA was added to lower portion and the chambers were incubated for 18 (AsPC-1) or 20
(BxPC-3) hours at 37֯C. The non-migrating cells were removed using a cotton swab and the
invaded cells were fixed using 100% methanol (MeOH) for 5 minutes and stained using 0.5%
crystal violet plus 20% MeOH (10-15 mins).

Invaded cells were counted using 200x

magnification with 12 different views. Percentage of invasion compared to GFP control was
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calculated for each cell line [(# of invaded cellstreated / # of invaded cellcontrol) *100]. Three
replicates were performed for each cell line.

Statistical Analysis
Statistical significance for the wound healing and invasion assays was calculated using
Student’s t-test using Prism V6.0c (GraphPad Software, Inc., La Jolla, CA). Statistical Analysis
tests used for expression profiling and qRT-PCR analyses are listed in their respective sections.

Abbreviations
qRT-PCR: quantitative real-time PCR; pRb: retinoblastoma protein; RB1: retinoblastoma
gene; CMV: Cytomegalovirus; MOI: multiplicity of infection; RGS16: regulator of G protein
signaling 16; EGF: epidermal growth factor; EGFR; epidermal growth factor receptor; GPCR: G
protein coupled receptor.
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Figure Legends
Figure 1: Identification of differentially expressed transcripts in WI38 cells
expressing p53 and/or pRb. WI38 cells were transduced with adenoviruses carrying the
transgenes p53, or RB1/p105; a MOI of 50 was used in each case. A) Western blot analysis was
used to test for p53 and pRb expression prior to microarray analysis. B) A Venn diagram shows
the differentially expressed transcripts and intersects identified during the microarray analysis.
The numbers in red denote transcripts that were up-regulated due to p53, pRb, or p53 and pRb
expression.
Figure 2: Validation of microarray data using qRT-PCR in WI38 cells. Five
transcripts RGS16, BCL2L11, BTG2, IL-6 and STAT4 from the p53 and pRb intersect were
chosen for validation by qRT-PCR in WI38 cells expressing p53, pRb, or both p53 and pRb.
The vector control (Ad.CMV) was used to calculate the fold change for each transcript. Oneway ANOVA with Dunnett’s test for multiple comparison were used to test for statistical
significance * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001, and **** p-value <
0.0001.
Figure 3: Validation of microarray data using qRT-PCR in SAOS-2 cells. Five
transcripts RGS16, BCL2L11, BTG2, IL-6 and STAT4 from the p53 and pRb intersect were
chosen for validation by qRT-PCR in SAOS-2 cells expressing p53, pRb, or both p53 and pRb.
The vector control (Ad.CMV) was used to calculate the fold change for each transcript. Oneway ANOVA with Dunnett’s test for multiple comparison were used to test for statistical
significance * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001, and **** p-value <
0.0001.
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Figure 4: Decreased expression of RGS16 mRNA relative to total RNA extracted
from normal human pancreatic tissue. Expression of RGS16 was measured using qRT-PCR
in BxPC-3, MIA PaCa-2, PANC-1, and AsPC-1 cells. Relative fold change was measured using
total RNA extracted from normal human pancreatic tissue as the control. One-way ANOVA
with Tukey’s test for multiple comparison were used to test for statistical significance between
the cell lines and control * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001, and **** pvalue < 0.0001.
Figure 5: Expression of RGS16 inhibited migration of BxPC-3 cells. BxPC-3 cells
were transduced with 50 MOI of Ad.GFP (CTRL) or Ad.GFP.RGS16. A) Virus transduction
was verified by fluorescent microscopy. B) Images (100x) and measurements of wounds were
taken prior and 16 hours after addition of media supplemented with FBS (10%) or EGF
(100ng/ml). The dashed lines represent size of scratch at time 0. C) Mean Percentage of wound
healing ± SEM of three separate experiments (three scratches / well) was determined. Student’s
t-test was used to determine statistical significance compared to control * p-value < 0.05, ** pvalue < 0.01.
Figure 6: Expression of RGS16 did not inhibit migration of PANC-1 cells. Wound
healing assays were performed as described in Figure 2. A) Fluorescent microscopy was used to
verify virus transductions: B&C Images (100X) were taken and percentages of wound healing
were calculated at 24hrs.
Figure 7: Expression of RGS16 inhibited migration of AsPC-1 cells. Wound healing
assays were performed as described in Figure 2. A) Fluorescent microscopy was used to verify
virus transductions: B&C Images (100X) were taken and percentages of wound healing were
calculated at 24hrs * p-value < 0.05.
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Figure 8: Expression of RGS16 inhibited invasion of BxPC-3 and AsPC-1 cells.
Matrigel invasion chambers were used to measure cell migration and invasion of GFP and/or
RGS16 expressing BxPC-3 (A & B) and AsPC-1 (C & D) cells using EGF as a chemoattractant.
Migrated cells were stained with Crystal Violet and counted at 200x magnification (A &C).
Percent invasion was calculated for each cell line (B & D) * p-value < 0.05.
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Table 1. Fold Change of p53 and pRb common gene set cross-talk candidates.
Gene Symbol
LOC387763
A_24_p775812
RGS16
AREG
CCL3
TNFSF15
IL-1B
OLFM2
NR4A1
POSTN
D4S234e
IL-6
DMN
EPPK1
IQSEC3
PLAC2
L3MBTL2
LHX6
AKR1B10
RRAD
c10orf58
BCL2L11
COL7A1
JUP
VCAN
CRISPLD2
STOX2
BTG-2
P2RY2
TSKU
C4B
RTN4R
STAT4
AK124344
KLHL20
NOTCH3
KSR1
GDF15
LOC654346

Name
hypothetical LOC387763
Unknown
Regulator of G-protein signaling 16
Amphiregulin
Chemokine (c-c motif ligand 3)
Tumor necrosis factor (ligand) superfamily, member 15
Interleukin-1 beta
Olfactomedin 2
Nuclear receptor subfamily 4 group A member 1
Periostin
D4S234e (NSG1; neuron specific gene family member 1)
Interleukin-6
Desmuslin
Epiplakin
IQ motif and Sec7 domain 3
Placenta specific 2
Lethal(3)malignant brain tumor-like protein 2
LIM homeobox 6
Aldo-keto reductase family 1 member B10
Ras associated with diabetes
chromosome 10 open reading frame 58
Bcl2-like 11 (apoptosis facilitator)
Collagen, type VII, alpha 1
Junction plakoglobin
Versican proteoglycan
Cystein-rich secretory protein 11
Storkhead-box 2
B-cell translocation gene 2
purinergic receptor P2Y, G-protein coupled, 2
Tsukusi,small leucine rich proteoglycan
Complement component 4B
Reticulon 4 receptor
Signal transducer and activator of transcription 4
cDNA FLJ42353 fis, clone UTERU2007520
Kelch like 20
Notch homolog 3
Kinase suppressor of RAS
Growth/differentiation factor 15
similar to galectin 9 short isoform (LOC654346)

FC-p53
30.62
15.65
18.84
8.15
3.78
10.68
4.82
10.60
11.56
2.91
21.20
6.04
4.57
32.06
7.29
21.60
18.33
10.11
11.61
5.98
4.86
9.58
5.97
7.60
5.61
10.11
14.48
3.85
2.38
5.28
3.38
8.01
5.98
5.21
4.88
4.68
3.86
3.24
2.81

FC-Rb
159.25
199.36
30.82
46.41
8.18
69.61
22.53
37.76
20.73
21.051
7.86
12.37
27.42
8.27
20.37
4.63
11.82
7.11
13.92
7.80
9.20
6.50
10.65
16.61
9.17
5.38
8.70
5.07
19.53
5.42
7.64
6.19
7.80
7.13
4.46
3.96
4.08
3.40
4.77

FC-p53+Rb
297.07
252.80
149.75
81.91
56.12
53.34
43.79
27.31
27.08
25.66
22.06
21.99
21.25
20.04
19.95
19.00
16.00
15.15
13.30
12.61
11.74
11.34
10.94
9.92
9.73
9.55
9.33
7.46
6.91
5.97
2.22
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

FC = Fold change
N/A= Fold change not available. Gene was not found to be significantly differentially expressed in WI38 cells coexpressing p53 and pRb.
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BxPC-3
PANC-1
AsPC-1
MiaPaCa-2

p53
mt
mt
mt
mt

p16
del
del
mt
del

Ras
wt
mt
mt
mt

EGFR Differentiation
high
moderate
high
poor
high
poor
low
poor
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Origin
primary
primary
metastatic (ascites)
primary

Metastasis
no
yes
yes
no
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